<SEC-DOCUMENT>0001801198-26-000014.txt : 20260512
<SEC-HEADER>0001801198-26-000014.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512070627
ACCESSION NUMBER:		0001801198-26-000014
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Legend Biotech Corp
		CENTRAL INDEX KEY:			0001801198
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39307
		FILM NUMBER:		26965837

	BUSINESS ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
		BUSINESS PHONE:		732-850-5598

	MAIL ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>legn-20260331.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece,d:193932000b814507a92321cbf11dec52-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:legn="http://legendbiotech.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>legn-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-3">0001801198</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-4">3/31/2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-5">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-6">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-8">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="legn-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>legn:country</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:RelatedPartySublicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:RelatedPartySublicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">legn:OutsideTheUnitedStatesOfAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">legn:OutsideTheUnitedStatesOfAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">legn:RevenueMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">legn:RevenueMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-9 f-10" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-25 f-26" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-108 f-109 f-110 f-111 f-113 f-115 f-117 f-118 f-120 f-121 f-123 f-124 f-126 f-129 f-130 f-131 f-132 f-135 f-136 f-137 f-138 f-140 f-142 f-144 f-145 f-147 f-148 f-150 f-151 f-153 f-156 f-157 f-158 f-159" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-191 f-192" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="4"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-179 f-180" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-5" order="5"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-191 f-192" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-6" order="6"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-195 f-196" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-7" order="7"/></ix:resources></ix:header></div><div id="i193932000b814507a92321cbf11dec52_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Rule 13a-16 or 15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report: May&#160;12, 2026</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Commission File Number: 001-39307</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">Legend Biotech Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2101 Cottontail Lane</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Somerset, New Jersey 08873</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Form 20-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> Form 40-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Legend Biotech Reports Financial Results for the Three Months Ended March&#160;31, 2026</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Legend Biotech Corporation (&#8220;Legend Biotech&#8221;) is furnishing this report on Form 6-K to provide its unaudited interim condensed consolidated financial statements as of March&#160;31, 2026 and for the three months ended March&#160;31, 2026 and 2025 and to provide Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements. In addition, Legend Biotech is updating its pipeline of product candidates, as set forth in Exhibit 99.4 to this Form 6-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">On May&#160;12, 2026, Legend Biotech issued a press release regarding its unaudited financial results for the three months ended March&#160;31, 2026 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1. The unaudited interim condensed consolidated financial statements as of March&#160;31, 2026 and for the three months ended March&#160;31, 2026 and 2025 are attached to this Form 6-K as Exhibit 99.2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is attached to this Form 6-K as Exhibit 99.3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">This report on Form 6-K, including Exhibits 99.1 (other than the information included under &#8220;Webcast/Conference Call Details&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">and &#8220;About Legend Biotech&#8221;), 99.2, 99.3 and 99.4,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">are</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">hereby incorporated by reference into Legend Biotech&#8217;s Registration Statements on Form F-3 (Registration Nos. 333-278050, 333-257625 and 333-272222) and Legend Biotech&#8217;s Registration Statement on Form S-8 (Registration Nos. 333-239478 and 333-283217).</span></div><div id="i193932000b814507a92321cbf11dec52_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="a991earningsreleaseq12026.htm">99.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Press Release, dated May&#160;12, 2026.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i193932000b814507a92321cbf11dec52_16">99.2</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements as of March&#160;31, 2026, and for the three months ended March&#160;31, 2026, and 2025.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#i193932000b814507a92321cbf11dec52_79">99.3</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="q126pipeline.htm">99.4</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pipeline</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The following materials from Legend Biotech&#8217;s Report on Form 6-K for the three months ended March&#160;31, 2026 formatted in XBRL (eXtensible Business Reporting Language): (i) the Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income, (ii) the Unaudited Interim Condensed Consolidated Statement of Financial Position, (iii) the Unaudited Interim Condensed Consolidated Statements of Changes in Equity, (iv) the Unaudited Interim Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Unaudited Interim Condensed Consolidated Financial Statements. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">May 12, 2026</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Ying Huang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Ying Huang, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_16"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE THREE MONTHS ENDED MARCH&#160;31, 2026 AND 2025</span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except per share data)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REVENUE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-9">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-10">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-11">298.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-12">185.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-13">305.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-14">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:CostOfSales" scale="6" id="f-15">175.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:CostOfSales" scale="6" id="f-16">69.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license and other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:CostOfLicenseAndOtherRevenue" scale="6" id="f-17">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:CostOfLicenseAndOtherRevenue" scale="6" id="f-18">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-19">85.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-20">101.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdministrativeExpense" scale="6" id="f-21">40.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdministrativeExpense" scale="6" id="f-22">31.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling and distribution expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:SellingAndDistributionExpenses" scale="6" id="f-23">50.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:SellingAndDistributionExpenses" scale="6" id="f-24">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses**</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherExpenseByFunction" scale="6" id="f-25">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherExpenseByFunction" scale="6" id="f-26">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="f-27">49.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="f-28">51.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-29">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-30">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-31">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-32">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherGainsLosses" scale="6" id="f-33">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:OtherGainsLosses" scale="6" id="f-34">54.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss before tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="f-35">53.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="f-36">99.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-37">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-38">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-39">54.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-40">101.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LOSS PER SHARE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-41">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-42">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-43">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-44">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OTHER COMPREHENSIVE LOSS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-45">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-46">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-47">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-48">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL COMPREHENSIVE LOSS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-49">53.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-50">40.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*<ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes. </ix:footnote></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">** <ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts have been reclassified to present loss on asset impairment into the other operating expenses line for comparative purposes.</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_19"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT MARCH&#160;31, 2026 AND UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT DECEMBER&#160;31, 2025 </span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">NON-CURRENT ASSETS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-51">121.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-52">116.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-53">331.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-54">285.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration prepaid leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:CollaborationPrepaidLeases" scale="6" id="f-55">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:CollaborationPrepaidLeases" scale="6" id="f-56">72.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-57">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-58">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:NoncurrentAssets" scale="6" id="f-59">514.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:NoncurrentAssets" scale="6" id="f-60">486.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CURRENT ASSETS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration inventories, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-61">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-62">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-63">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-64">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments, other receivables and other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="6" id="f-65">209.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="6" id="f-66">253.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:TimeDeposits" scale="6" id="f-67">188.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:TimeDeposits" scale="6" id="f-68">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-69">646.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-70">901.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-71">1,082.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-72">1,247.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL ASSETS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-73">1,596.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-74">1,733.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CURRENT LIABILITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="6" id="f-75">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="6" id="f-76">83.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Tax payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentTaxLiabilities" scale="6" id="f-77">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentTaxLiabilities" scale="6" id="f-78">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other payables and accruals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:OtherPayablesAndAccrualsCurrent" scale="6" id="f-79">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:OtherPayablesAndAccrualsCurrent" scale="6" id="f-80">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-81">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-82">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-83">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-84">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration interest-bearing advanced funding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-85">266.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-86">319.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherCurrentLiabilities" scale="6" id="f-87">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:OtherCurrentLiabilities" scale="6" id="f-88">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentLiabilities" scale="6" id="f-89">509.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CurrentLiabilities" scale="6" id="f-90">636.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">NON-CURRENT LIABILITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities long term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="f-91">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="f-92">87.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-93">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-94">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:NoncurrentLiabilities" scale="6" id="f-95">119.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:NoncurrentLiabilities" scale="6" id="f-96">95.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Liabilities" scale="6" id="f-97">629.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Liabilities" scale="6" id="f-98">731.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">EQUITY</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-99">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-100">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Reserves</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherReserves" scale="6" id="f-101">967.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="6" id="f-102">1,002.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-103">967.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-104">1,002.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-105">1,596.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-106">1,733.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2026 AND 2025 </span></div></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Share <br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Share <br/>premium*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Share-based <br/>compensation <br/>reserves*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Foreign <br/>currency <br/>translation <br/>reserve*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Retained <br/>accumulated <br/>losses*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total <br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As at January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-107">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-108">2,696.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-109">74.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-110">68.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-111">1,661.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-112">1,040.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-113">101.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-114">101.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-115">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-116">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-117">60.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-118">101.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-119">40.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-120">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-121">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-122">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification of vested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" scale="6" id="f-123">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" scale="6" id="f-124">14.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:fixed-zero" scale="6" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Equity-settled share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-126">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-127">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As at March 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-128">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-129">2,712.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-130">74.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-131">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-132">1,762.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-133">1,017.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As at January 1, 2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-134">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-135">2,750.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-136">88.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-137">122.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-138">1,958.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-139">1,002.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Loss for the period </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-140">54.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-141">54.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-142">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-143">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive income/(loss) for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-144">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-145">54.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-146">53.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-147">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-148">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-149">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification of vested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" scale="6" id="f-150">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" scale="6" id="f-151">30.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:fixed-zero" scale="6" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Equity-settled share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-153">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-154">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As at March 31, 2026</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-155">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-156">2,780.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-157">76.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-158">122.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-159">2,012.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-160">967.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt"><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote">These reserve accounts comprise the consolidated reserves of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherReserves" scale="6" id="f-161">967.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="6" id="f-162">1,017.6</ix:nonFraction> million in the consolidated statements of financial position as at March&#160;31, 2026 and 2025, respectively</ix:footnote>.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2026 AND 2025</span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss before tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="f-163">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="f-164">99.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForFinanceIncome" scale="6" id="f-165">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForFinanceIncome" scale="6" id="f-166">12.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForFinanceCosts" scale="6" id="f-167">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForFinanceCosts" scale="6" id="f-168">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provision for inventory reserve</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="legn:AdjustmentsForInventoryReserveProvision" scale="6" id="f-169">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="legn:AdjustmentsForInventoryReserveProvision" scale="6" id="f-170">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="6" id="f-171">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="6" id="f-172">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:AdjustmentsForDepreciationOfRightOfUseAssets" scale="6" id="f-173">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:AdjustmentsForDepreciationOfRightOfUseAssets" scale="6" id="f-174">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized foreign currency exchange loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="6" id="f-175">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="6" id="f-176">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-177">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-178">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net *</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-179">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-180">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" scale="6" id="f-181">17.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" scale="6" id="f-182">32.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in trade receivables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-183">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-184">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in prepayments, other receivables and other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" scale="6" id="f-185">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" scale="6" id="f-186">48.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in collaboration inventories</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-187">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-188">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease)/increase in trade payables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="6" id="f-189">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="6" id="f-190">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in other payables and accruals&#x5E;**</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="6" id="f-191">65.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="6" id="f-192">39.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" scale="6" id="f-193">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" scale="6" id="f-194">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets and liabilities, net***</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" scale="6" id="f-195">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" scale="6" id="f-196">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income received</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" scale="6" id="f-197">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" scale="6" id="f-198">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax paid</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="6" id="f-199">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="6" id="f-200">11.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="f-201">85.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="f-202">103.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#x5E;<ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts have been reclassified between increase in (decrease)/trade payables and decrease in other payables and accruals for comparative purposes.</ix:footnote></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*<ix:footnote id="fn-5" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts including loss on impairment, loss on disposal of PPE, amortization of intangible assets, and deferred government grant have been grouped into the other, net line item for comparative purposes.</ix:footnote></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">**<ix:footnote id="fn-6" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts including interest on lease payments have been grouped into decrease in other payables and accruals.</ix:footnote></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">***<ix:footnote id="fn-7" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts including decrease/(increase) in other non-current assets, government grant received, increase/(decrease) in other non-current liabilities, and increase in pledged deposits, net have been grouped into the other assets and liabilities, net line item for comparative purposes.</ix:footnote>  </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2026 AND 2025</span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:71.156%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Purchase of property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-203">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-204">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Prepayment to collaborator for collaboration assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets" scale="6" id="f-205">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets" scale="6" id="f-206">15.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Addition in time deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:AdditionInTimeDeposits" scale="6" id="f-207">327.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:AdditionInTimeDeposits" scale="6" id="f-208">100.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Decrease in time deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:DecreaseInTimeDeposits" scale="6" id="f-209">184.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:DecreaseInTimeDeposits" scale="6" id="f-210">374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="f-211">168.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="f-212">256.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from exercise of share options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="6" id="f-213">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="6" id="f-214">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Principal portion of lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-215">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-216">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net cash (used in)/provided by financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-217">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-218">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-219">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-220">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="6" id="f-221">255.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="6" id="f-222">155.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-223">901.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-224">286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CASH AND CASH EQUIVALENTS AT END OF PERIOD</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-225">646.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-226">441.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank balances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Cash" scale="6" id="f-227">834.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="6" id="f-228">1,005.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Pledged deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="6" id="f-230">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:TimesDepositsCurrentAndNoncurrent" scale="6" id="f-231">188.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="legn:TimesDepositsCurrentAndNoncurrent" scale="6" id="f-232">563.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents as stated in the statement of financial position</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" scale="6" id="f-233">646.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" scale="6" id="f-234">441.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SUPPLEMENTAL CASH FLOW INFORMATION</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash repayment of collaboration interest-bearing advanced funding</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" scale="6" id="f-235">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" format="ixt:fixed-zero" scale="6" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED INTERIM CONDENSED </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="i193932000b814507a92321cbf11dec52_31"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="f-237" continuedAt="f-237-1" escape="true">CORPORATE INFORMATION </ix:nonNumeric></span></div><ix:continuation id="f-237-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Legend Biotech Corporation ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Legend is an investment holding company. The Company's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.</span></div></ix:continuation><div id="i193932000b814507a92321cbf11dec52_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.1. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-238" continuedAt="f-238-1" escape="true">BASIS OF PREPARATION </ix:nonNumeric></span></div><ix:continuation id="f-238-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#8220;Company&#8221;) for the three months ended March&#160;31, 2026 have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS34&#8221;) issued by the International Accounting Standards Board (the &#8220;IASB&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2025. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#8217;s annual consolidated financial statements as at December&#160;31, 2025.</span></div></ix:continuation><div id="i193932000b814507a92321cbf11dec52_37"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-239" continuedAt="f-239-1" escape="true">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</ix:nonNumeric></span></div><ix:continuation id="f-239-1" continuedAt="f-239-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no new International Financial Reporting Standards (&#8220;IFRS&#8221;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2026 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-239-2">The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_40"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-240" continuedAt="f-240-1" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="f-240-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-241" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualProperty" scale="6" id="f-242">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualProperty" scale="6" id="f-243">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Related party sublicense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualProperty" scale="6" id="f-244">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:fixed-zero" scale="6" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:OtherRevenue" scale="6" id="f-247">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue - total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-248">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-249">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-250">298.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-251">185.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-252">305.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-253">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-254" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-255">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-256">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-257">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-258">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total license and other revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-259">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:RevenueFromLicensingOfIntellectualPropertyAndOther" scale="6" id="f-260">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-261">216.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-262">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-263">82.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-264">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-265">298.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:CollaborationRevenue" scale="6" id="f-266">185.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-267">305.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-268">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" id="f-269" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-270">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-271">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-272">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-273">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-274">305.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:Revenue" scale="6" id="f-275">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_43"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfOtherIncomeExpenseNetTextBlock" id="f-276" continuedAt="f-276-1" escape="true">OTHER (EXPENSE)/INCOME, NET </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" id="f-277" escape="true"><ix:continuation id="f-276-1"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange loss, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="6" id="f-278">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="6" id="f-279">55.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense)/income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:OtherMiscellaneousIncomeExpense" scale="6" id="f-280">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="legn:OtherMiscellaneousIncomeExpense" scale="6" id="f-281">0.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherGainsLosses" scale="6" id="f-282">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:OtherGainsLosses" scale="6" id="f-283">54.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Foreign currency exchange loss is primarily remeasurement losses.</span></div></ix:continuation></ix:nonNumeric><div id="i193932000b814507a92321cbf11dec52_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-284" continuedAt="f-284-1" escape="true">LOSS PER SHARE </ix:nonNumeric></span></div><ix:continuation id="f-284-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2026 and 2025, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-285" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-286">54.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" scale="6" id="f-287">101.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" scale="6" id="f-288">370.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="-5" name="ifrs-full:WeightedAverageShares" scale="6" id="f-289">367.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" scale="6" id="f-290">370.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" scale="6" id="f-291">367.5</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-292">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-293">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-294">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-295">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i193932000b814507a92321cbf11dec52_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-296" continuedAt="f-296-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-296-1" continuedAt="f-296-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company as a lessee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between <ix:nonNumeric contextRef="c-49" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-297">3</ix:nonNumeric> and <ix:nonNumeric contextRef="c-50" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-298">29</ix:nonNumeric> years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of <ix:nonNumeric contextRef="c-51" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-299">50</ix:nonNumeric> years, and <ix:nonFraction unitRef="usd" contextRef="c-51" decimals="INF" name="legn:OngoingLeasePaymentsUnderTheLandLease" format="ixt:fixed-zero" scale="0" id="f-300">no</ix:nonFraction> ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#8217;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-296-2"><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Right-of-use assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-301" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2026 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-302">285.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:AdditionsToRightofuseAssets" scale="6" id="f-303">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" scale="6" id="f-304">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-305">13.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-306">331.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lease liabilities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of a lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. <ix:nonNumeric contextRef="c-1" name="legn:LesseeLeaseLiabilitiesTextBlock" id="f-307" continuedAt="f-307-1" escape="true">The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2026 are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-307-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-308">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="legn:IncreaseInLeaseLiabilities" scale="6" id="f-309">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="legn:IncreaseOfLeaseLiabilitiesBalance" scale="6" id="f-310">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="ifrs-full:CashOutflowForLeases" scale="6" id="f-311">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-312">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-313">123.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-314">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="f-315">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-316">123.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           The Company has a lease that commenced in February 2026, with Janssen located in Raritan, New Jersey. The Company expects to receive <ix:nonFraction unitRef="number" contextRef="c-55" decimals="2" name="legn:LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" scale="-2" id="f-317">50</ix:nonFraction>% of the future lease payments from Janssen from profit sharing under the Janssen Agreement. The Company recognizes the full lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-318">30.6</ix:nonFraction> million, rather than its share because the Company has the primary responsibility for making the lease payments. A finance sublease receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="ifrs-full:FinanceLeaseReceivables" scale="6" id="f-319">15.3</ix:nonFraction>&#160;million is subsequently recognized when the related right-of-use asset is subleased to the collaboration. The total sublease receivable of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="6" id="f-320">15.3</ix:nonFraction>&#160;million has been classified in prepayments, other receivables and other assets of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="ifrs-full:CurrentFinanceLeaseReceivables" scale="6" id="f-321">1.8</ix:nonFraction>&#160;million, and other non-current assets of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="ifrs-full:NoncurrentFinanceLeaseReceivables" scale="6" id="f-322">13.5</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="f-323" continuedAt="f-323-1" escape="true">COLLABORATION INVENTORIES, NET</ix:nonNumeric></span></div><ix:continuation id="f-323-1"><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" id="f-324" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:RawMaterials" scale="6" id="f-325">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:RawMaterials" scale="6" id="f-326">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:WorkInProgress" scale="6" id="f-327">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:WorkInProgress" scale="6" id="f-328">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:FinishedGoods" scale="6" id="f-329">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:FinishedGoods" scale="6" id="f-330">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-331">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-332">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:InventoryReserve" scale="6" id="f-333">12.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:InventoryReserve" scale="6" id="f-334">18.7</ix:nonFraction> million as of March&#160;31, 2026 and December&#160;31, 2025, respectively. The Company&#8217;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.</span></div></ix:continuation><div id="i193932000b814507a92321cbf11dec52_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" id="f-335" continuedAt="f-335-1" escape="true">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" id="f-336" escape="true"><ix:continuation id="f-335-1" continuedAt="f-335-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="legn:OtherCollaborationReceivables" scale="6" id="f-337">174.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="legn:OtherCollaborationReceivables" scale="6" id="f-338">227.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="ifrs-full:ValueAddedTaxReceivables" scale="6" id="f-339">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="ifrs-full:ValueAddedTaxReceivables" scale="6" id="f-340">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="ifrs-full:Prepayments" scale="6" id="f-341">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="ifrs-full:Prepayments" scale="6" id="f-342">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="ifrs-full:OtherCurrentAssets" scale="6" id="f-343">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="ifrs-full:OtherCurrentAssets" scale="6" id="f-344">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="legn:PrepaymentsOtherReceivablesAndOtherAssets" scale="6" id="f-345">209.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="legn:PrepaymentsOtherReceivablesAndOtherAssets" scale="6" id="f-346">253.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-335-2">None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2026 and December&#160;31, 2025 is insignificant.</ix:continuation> </span></div><div id="i193932000b814507a92321cbf11dec52_67"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBorrowingsExplanatory" id="f-347" continuedAt="f-347-1" escape="true">COLLABORATION INTEREST-BEARING ADVANCED FUNDING </ix:nonNumeric></span></div><ix:continuation id="f-347-1" continuedAt="f-347-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="f-348" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-349">6.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-350">266.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the Janssen Agreement, the Company received advances from Janssen over time ("Funding Advances"). These Funding Advances are accounted for as interest-bearing borrowings funded by Janssen, constituted by a principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="legn:InterestBearingBorrowingsFundingAdvances" scale="6" id="f-351">250.0</ix:nonFraction>&#160;million and applicable interests accrued amounting to $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="legn:InterestBearingBorrowingsFundedInterestsAccrued" scale="6" id="f-352">73.3</ix:nonFraction>&#160;million upon such principal as of March&#160;31, 2026. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding Funding Advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-353">2.5</ix:nonFraction>%.  <br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">There is no specific maturity date for the Funding Advances. However, pursuant to the terms of the Janssen Agreement, Janssen may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#8217;s share of pre-tax profits starting from the first calendar quarter following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the quarter ended March&#160;31, 2026, the Company reduced its collaboration advanced funding principal balance by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" scale="6" id="f-354">57.3</ix:nonFraction>&#160;million by offsetting it with the pre-tax profit receivable for the quarter, which resulted in an outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" scale="6" id="f-355">192.7</ix:nonFraction>&#160;million and outstanding accrued interest balance of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="legn:InterestBearingBorrowingsFundedInterestsAccrued" scale="6" id="f-356">73.3</ix:nonFraction>&#160;million, in each case as of March&#160;31, 2026. As of March&#160;31, 2026, the Company estimated that the entire balance of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-357">266.0</ix:nonFraction>&#160;million (inclusive of both principal and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-347-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">interest) would be recouped by Janssen within the next 12 months, and therefore such amount was classified as a current liability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interest for the Funding Advances was $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-358">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-359">4.6</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively. These amounts are included in Finance Costs on the consolidated statement of profit or loss and other comprehensive income/(loss).</span></div></ix:continuation><div id="i193932000b814507a92321cbf11dec52_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-360" continuedAt="f-360-1" escape="true">SHARE CAPITAL AND SHARE PREMIUM </ix:nonNumeric></span></div><ix:continuation id="f-360-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-361" escape="true"><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="ifrs-full:NumberOfSharesAuthorised" format="ixt:num-dot-decimal" scale="0" id="f-362"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="ifrs-full:NumberOfSharesAuthorised" format="ixt:num-dot-decimal" scale="0" id="f-363">2,000,000,000</ix:nonFraction></ix:nonFraction> ordinary shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-364"><ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-365">0.0001</ix:nonFraction></ix:nonFraction> each</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="legn:AuthorizedShareCapital" scale="6" id="f-366">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="legn:AuthorizedShareCapital" scale="6" id="f-367">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-368">371,479,583</ix:nonFraction> and (2025: <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-369">369,886,369</ix:nonFraction>) ordinary shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-370"><ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-371">0.0001</ix:nonFraction></ix:nonFraction> each</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-372">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-373">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" id="f-374" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025 and January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-375">369,886,369</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="legn:ShareCapitalAndSharePremium" scale="6" id="f-376">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="6" id="f-377">2,750.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="6" id="f-378">2,750.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="legn:ExerciseOfShareOptionNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-379">271,380</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="legn:ExerciseOfShareOption" format="ixt:fixed-zero" scale="6" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="legn:ExerciseOfShareOption" scale="6" id="f-381">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:ExerciseOfShareOption" scale="6" id="f-382">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-383">1,321,834</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" format="ixt:fixed-zero" scale="6" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" scale="6" id="f-385">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" scale="6" id="f-386">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-387">371,479,583</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="legn:ShareCapitalAndSharePremium" scale="6" id="f-388">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="6" id="f-389">2,780.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="6" id="f-390">2,781.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i193932000b814507a92321cbf11dec52_73"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory" id="f-391" continuedAt="f-391-1" escape="true">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-391-1">The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2026.</ix:continuation> </span></div><div id="i193932000b814507a92321cbf11dec52_549755814229"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-392" continuedAt="f-392-1" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><ix:continuation id="f-392-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2026, milestones payable to Legend were triggered due to the successful completion of milestones related to the receipt of commercialization approvals in <ix:nonFraction unitRef="country" contextRef="c-67" decimals="INF" name="legn:NumberOfCountriesToReceiveCommericalApproval" format="ixt-sec:numwordsen" scale="0" id="f-393">three</ix:nonFraction> major European countries. The milestone payments of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="legn:ProceedsFromMilestonePayments" scale="6" id="f-394">55.0</ix:nonFraction>&#160;million attributable to these milestones will be recognized as License and other revenue in the three months ended June 30, 2026.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), unless otherwise indicated or the context otherwise requires, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;Legend Biotech&#8221; refer to Legend Biotech Corporation and its consolidated subsidiaries. &#8220;Legend Biotech,&#8221; the Legend logo and other trademarks or service marks of the Company appearing in this MD&amp;A are the property of the Company. Solely for convenience, the trademarks, service marks and trade names referred to in this MD&amp;A are without the &#174;, &#8482; and other similar symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. CARVYKTI is a registered trademark in the United States of Johnson &amp; Johnson. Other trade names, trademarks and service marks of other companies appearing in this MD&amp;A are the property of their respective holders. We do not intend our use or display of other companies&#8217; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other person.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and the accompanying notes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This MD&amp;A contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of present and historical facts and conditions are forward-looking statements. Forward-looking statements can often be identified by words or phrases, such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. Such forward-looking statements reflect our current expectations and views of future events, but are not assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our financial needs, our operational results and other future conditions. These forward-looking statements involve various risks and uncertainties. Many important factors may adversely affect such forward-looking statements and cause actual results to differ from those in any forward-looking statement, including, without limitation, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech&#8217;s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; the impact of U.S. or foreign laws and regulations on our operations, including the impact of tariffs; competition in general; government, industry, and general product pricing and other political pressures; commercialization factors, including regulatory approval and pricing determinations; disruptions to access to raw materials; delays or disruptions at manufacturing facilities; proliferation and continuous evolution of new technologies; dislocations in the capital markets; and other important factors described under &#8220;Risk Factors&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 10, 2026 (the &#8220;Annual Report&#8221;) and under &#8220;Risk Factors&#8221; in any other reports that we file with the Securities and Exchange Commission. As a result of these factors, we cannot assure you that the forward-looking statements in this interim report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, even if our results of operations, financial condition and liquidity are consistent with the forward-looking statements contained in this report, those results or developments may not be indicative of results or developments in subsequent periods.</span></div><div id="i193932000b814507a92321cbf11dec52_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 3,100 employees in the United States, China and Europe, our differentiated technology, as well as our global development and manufacturing expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Our lead product candidate, ciltacabtagene autoleucel, ("cilta-cel") (referred to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as LCAR-B38M for purposes of our LEGEND-2 trial), is a CAR-T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), for the treatment of multiple myeloma (&#8220;MM&#8221;). Clinical trial results achieved to date demonstrate that cilta-cel is the first CAR-T cell therapy to demonstrate overall survival benefit when compared to standard therapies in patients with relapsed and refractory multiple myeloma ("RRMM") with a manageable safety profile.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2022, cilta-cel was approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) under the trademark CARVYKTI for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, the FDA approved CARVYKTI for the treatment of patients with RRMM who have received at least one prior line of therapy, including proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide. CARVYKTI is our first and only product approved by a health authority.</span></div><div id="i193932000b814507a92321cbf11dec52_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Recent Business Developments</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic and Australia</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $834.6&#160;million, as of March&#160;31, 2026.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i193932000b814507a92321cbf11dec52_88"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Global Economic Conditions</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Worldwide economic conditions remain uncertain and we continue to monitor the impact of macroeconomic conditions, including those related to the public health crises, international tension and conflicts, the failure and instability of financial institutions and rising inflation rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  Changes in tariffs, supply chain constraints, logistics challenges, labor shortages, international tension and conflicts and steps taken by governments and central banks, have led to fluctuating inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including fluctuating interest rates. Our manufacturing activities in the United States, Europe and China have continued. Currently, we have not experienced any material impact to our supply chain as a result of inflation and fluctuating interest rates. Increased quantities of certain raw materials and consumables have been stocked as an appropriate safety measure. We believe we have established robust sourcing strategies for all necessary materials and do not expect any significant impact.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Specifically with respect to the current tariffs imposed by the Trump administration, we do not currently believe such tariffs will have a material impact on our financial condition, as pharmaceuticals were exempted from these tariffs. However, the Trump administration has announced an intention to implement tariffs for pharmaceuticals at a future date. While the impact of any such pharmaceutical tariffs on Legend may be mitigated by the fact that the US CARVYKTI&#174; supply is domestically produced at the Raritan site in New Jersey and at the Novartis CMO facility in Morris Plains, New Jersey, we may face tariff exposure from certain pharmaceutical ingredients and processing materials that are imported from outside the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If these changes in economic conditions continue or if they increase in severity, it could result in further economic uncertainty and volatility in the capital markets in the near term and could negatively affect our operations. Although we do not believe that these macroeconomic conditions have had a material impact on our financial position or results of operations to date, we may experience impacts in the near future (especially if inflation rates begin to rise again or significant tariffs are imposed on pharmaceutical ingredients) on our operating costs, including our cost of goods sold, labor costs and research and development costs, due to tariffs, supply chain constraints, consequences associated with public health crises, international tension and conflicts, and employee availability and wage increases, which may result in additional stress on our working capital resources. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Three Months Ended March&#160;31, 2026 and 2025 </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2026 and 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other  revenue</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">298.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(175.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(69.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(105.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(85.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(101.9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(40.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(31.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling and distribution expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41.0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(51.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finance income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(99.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(101.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $298.4 million for the three months ended March&#160;31, 2026, compared to $185.6 million for the three months ended March&#160;31, 2025. The increase of $112.8 million was due to an increase in revenue generated from sales of CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in connection with the Janssen collaboration and license agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Other Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License revenue was $6.7 million for the three months ended March&#160;31, 2026, compared to $9.4 million for the three months ended March&#160;31, 2025. The decrease of $2.7 million was primarily attributed to revenue recognized under the license agreement with Novartis Pharma AG, which was recognized over time as Legend Biotech conducts a Phase 1 clinical trial for LB2102.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Cost of collaboration revenue was $175.4 million for the three months ended March&#160;31, 2026, compared to $69.5 million for the three months ended March&#160;31, 2025. The increase of $105.9 million was primarily due to Legend Biotech&#8217;s share of the cost of sales in connection with CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> sales under the Janssen Agreement, as well as one-time additional costs incurred for capacity expansion and depreciation charges. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $85.7 million for the three months ended March&#160;31, 2026 compared to $101.9 million for the three months ended March&#160;31, 2025. The decrease of $16.2 millionwas primarily driven by lower </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenditures in the cilta-cel clinical program as the patient dosing phases of major trials concluded, partially offset by higher pipeline related research and development activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Administrative Expenses </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses were $40.0 million for the three months ended March 31, 2026, compared to $31.5 million for the three months ended March&#160;31, 2025. The increase of $8.5 million was primarily driven by higher professional fees.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Selling and Distribution Expenses</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;Selling and distribution expenses were $50.1 million for the three months ended March&#160;31, 2026, compared to $41.0&#160;million for the three months ended March&#160;31, 2025. The increase of $9.1 million was primarily due to higher commercial costs, including sales force expansion and Janssen-related marketing and market access activities, which rose with collaboration revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Expense, net for the three months ended March&#160;31, 2026, was $5.1&#160;million, compared to Other Expense, net of $54.5&#160;million for the three months ended March&#160;31, 2025. The decrease of $49.4&#160;million was primarily driven by lower unrealized foreign currency exchange losses compared to the prior period.</span></div><div id="i193932000b814507a92321cbf11dec52_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We believe that our cash and cash equivalent</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s, and time deposits of $834.6&#160;million, as of March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and cash that we expect to generate from our operations will provide sufficient resources to meet our operational needs and loan repayment needs for at least the next 12 months. We also believe that we have ability to access capital markets as sources of liquidity if needed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of our first product, CARVYKTI, which was initially approved by the FDA on February 28, 2022, we do not currently have any approved products and we have not generated any revenue from product sales for other products. From inception through March&#160;31, 2026, we have funded our operations primarily through revenue from sales of CARVYKTI, equity financings, payments, and advancements from Janssen and Novartis pursuant to collaboration and license agreements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had approximately $646.4 million in cash and cash equivalents, approximately $188.2 million of time deposits, and accumulated losses of $2.0 billion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries, including those registered as wholly foreign-owned enterprises in the People's Republic of China (the "PRC"), are required to set aside at least 10.0% of their after-tax profits to their general reserves until such reserves reach 50.0% of their registered capital. Under PRC regulations, foreign-invested enterprises may pay dividends only out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and regulations. A PRC company is not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year. Although we do not currently require any such dividends from our PRC subsidiaries to fund our operations, should we require additional sources of liquidity in the future, such restrictions may have a material adverse effect on our liquidity and capital resources. For more information, see &#8220;Item 4.B-Business Overview - Government Regulation - PRC Regulation - Other PRC National- and Provincial-Level Laws and Regulations - Regulations Relating to Dividend Distributions&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2025.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i193932000b814507a92321cbf11dec52_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flow:</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(85.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(103.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in)/provided by investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(168.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">256.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in)/provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effect of foreign exchange rate changes, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease)/increase in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(255.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i193932000b814507a92321cbf11dec52_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2026 was $85.1 million, primarily as a result of net loss before tax of $53.1 million, after adjusting for non-cash items, and changes in operating assets and liabilities. The year-over-year change was primarily due to a decrease in operating losses and a decrease in income taxes paid, partially offset by a decrease in working capital and a decrease in interest income received.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2025 was $103.6 million, primarily as a result of net loss before tax of approximately $99.2 million after adjusting for non-cash items, and changes in operating assets and liabilities. Adjustments mainly included $12.1 million of finance income, offset by $55.2 million of foreign exchange loss and $15.9 million of equity-settled share-based compensation expenses. Changes in operating assets and liabilities mainly include an increase in prepayment, other receivable and other assets of $48.6 million, a decrease in other payables and accruals of $39.1 million, and a decrease in contract liabilities, net of $9.0 million. This was partially offset by an increase in trade payables of $19.5 million. Cash items primarily include interest income received of $15.0 million. This was partially offset by income tax payment of $11.9 million. </span></div><div id="i193932000b814507a92321cbf11dec52_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2026 was $168.0 million. This change mainly reflects the timing of time deposit investments and maturities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2025 was $256.6 million, consisting primarily of a redemption of time deposits of $374.0 million. This was partially offset by a $100.0 million addition of time deposits, and a $15.4 million prepayment to Janssen for collaboration assets.</span></div><div id="i193932000b814507a92321cbf11dec52_106"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March&#160;31, 2026 was $1.2 million. The year-over-year change is primarily attributable to the decrease in proceeds from exercise of stock options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2025 was $0.6 million, consisting primarily of proceeds from exercise of share options of $1.4 million, partially offset by the principal portion of lease payments of $0.8 million.</span></div><div id="i193932000b814507a92321cbf11dec52_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur expenses in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, following the FDA&#8217;s approval of CARVYKTI, we continue to incur significant commercialization expenses related to program sales, marketing, manufacturing and distribution. For example, in addition to investing in our own facilities, we have supplemented our manufacturing capabilities and infrastructure by entering into agreements with a CMO </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and may enter into additional CMO agreements in the future. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we may need to obtain additional funding in connection with our continuing operations. If we are unable to raise capital if and when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Although consequences of the macroeconomic conditions, including global conflicts and inflation, and resulting economic uncertainty could adversely affect our liquidity and capital resources in the future, and cash requirements may fluctuate based on the timing and extent of many factors such as those discussed below, we currently expect our existing cash and cash equivalents, and time deposits as well as revenue that we expect to generate from our operations will provide sufficient resources to meet our operational needs and loan repayment needs for at least the next 12 months. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenue we receive from commercial sales of CARVYKTI under the Janssen Agreement;</span></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of product discovery, preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, prioritization and number of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under the Janssen Agreement and any other collaboration agreements we enter into;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of securing manufacturing arrangements for commercial production; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our commercial product CARVYKTI, we have a broad portfolio of earlier-stage product candidates. Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for such product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues from earlier-stage product candidates, if any, will be derived from sales of product candidates that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our cash proceeds from the product revenue, we might need to finance our cash through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, holders of our ADSs will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Janssen Agreement, Janssen may recoup the aggregate amount of Funding Advances, together with interest thereon, from our share of pre-tax profits starting from the first calendar quarter following the first profitable year </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of the collaboration program and, subject to some limitations, from milestone payments due to us under the Janssen Agreement.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we estimated that the entire balance of $266.0&#160;million of Funding Advances would be recouped by Janssen within the next 12 months, and therefore such amount was classified as a current liability. </span></div><div id="i193932000b814507a92321cbf11dec52_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Certain Supplemental Non-IFRS Metrics</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our management uses various financial metrics, including certain metrics that are not prepared in accordance with IFRS, to measure and assess the performance of our business, to make critical business decisions, and to assess our compliance with certain financial obligations. We therefore believe that presentation of certain of these non-IFRS metrics alongside the IFRS measures will aid investors in understanding our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The non-IFRS metrics should be considered in addition to, and not as a substitute for, or as superior to, measures of financial performance, financial position or cash flows reported in accordance with IFRS. We strongly encourage investors to review our historical financial statements in their entirety and to use the measures presented in accordance with IFRS as the primary means of evaluating our performance. Moreover, we encourage investors to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures. In addition, non-IFRS metrics are not uniformly defined by all companies, including those in our industry. Accordingly, non-IFRS metrics may not be comparable with similarly titled measures and disclosures by other companies, and we therefore encourage investors to review the discussions of these non-IFRS financial measures particularly the limitations on their usefulness and to understand how such measures differ from similarly titled measures that may be presented by other companies in the pharmaceutical industry or in general.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adjusted Net Loss and Adjusted Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as &#8220;Adjusted EPS&#8221; or &#8220;ANL per Share&#8221;, respectively) as performance metrics. Adjusted Net Loss and ANL per share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Loss has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Loss does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss excludes unrealized foreign exchange gain or loss.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss does not reflect changes in, or cash requirements for, our working capital needs.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, Adjusted Net Loss excludes share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Also, our definition of Adjusted Net Loss and ANL per Share may not be the same as similarly titled measures used by other companies.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">However, we believe that providing information concerning Adjusted Net Loss and ANL per Share enhances an investor&#8217;s understanding of our financial performance. We use Adjusted Net Loss as a performance metric that guides management in its operation of and planning for the future of the business. We believe that Adjusted Net Loss provides a useful measure of our operating performance from period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Loss as net loss adjusted for (1) non-cash items such as depreciation and amortization, share based compensation, and loss on impairment asset, and (2) unrealized foreign exchange gain or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ANL per Share is computed by dividing Adjusted Net Loss by the weighted average shares outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Reconciliation between Adjusted Net Loss and Net Loss, the most directly comparable measure under IFRS, has been provided in the table below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(101.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment charges </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized foreign exchange loss/(gain) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted net loss (ANL)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ANL per share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ANL per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ANL per share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Included in Other operating expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in Other income/(expense), net</span></div><div id="i193932000b814507a92321cbf11dec52_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash is held in readily available operating accounts and short to medium term deposits and securities. These securities are principal secured and not adversely impacted by interest rate fluctuations. As a result, a change in market interest rates would not have any significant impact on our cash balance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The interest rate pursuant to the Janssen Agreement, has transitioned in accordance with the LIBOR Act. Thus, outstanding Funding Advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%. Accordingly, changes in SOFR could result in fluctuations in our cash flow. For example, based on the $192.7 million aggregate principal amount of Funding Advances outstanding from Janssen as of March&#160;31, 2026, a 0.5% (fifty basis point) per annum increase in SOFR would result in an additional $1.0 million per year in interest payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three months ended March&#160;31, 2026 and 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Our financial results are subject to fluctuations due to foreign exchange rate movements. We conduct business in multiple currencies, and as a result, we are exposed to exchange rate fluctuations that may impact our financial statements. Unrealized foreign exchange gains and losses arise from the revaluation of monetary assets and liabilities denominated in foreign currencies, as well as from translation adjustments related to our international operations. These unrealized gains and losses can significantly impact our net income and financial position, even when there is no underlying economic impact on our cash flows. If exchange rates move unfavorably, we may experience substantial unrealized losses, which could negatively affect our reported earnings and create volatility in our financial performance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In addition, the value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China&#8217;s foreign exchange policies. In recent years, the RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. Significant revaluation of the RMB may have a negative effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">As of the date thereof, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991earningsreleaseq12026.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i38a4bc577f644810a858db5c4edc1571_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><img alt="legendlogo.jpg" src="legendlogo.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legend Biotech Reports First Quarter 2026 Results and Recent Highlights</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> (ciltacabtagene autoleucel&#59; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic and Australia</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:14.5pt">Advanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $834.6&#160;million, as of March&#160;31, 2026.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SOMERSET, N.J.&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May&#160;12, 2026&#8212; Legend Biotech Corporation (NASDAQ&#58; LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highlights. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;We believe CARVYKTI&#8217;s continued adoption and strong year&#8209;over&#8209;year growth reinforce our leadership in BCMA CAR&#8209;T and the strength of our underlying operating model,&#8221; said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. &#8220;As scale continues to build, we are seeing operating leverage translate into improving margins, supporting our path toward sustainable profitability. This continued progress is enabling us to advance our broad pipeline of cell therapy programs and extend the impact of our platform to address unmet needs for patients across multiple indications.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Key Business Developments</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Compared to the first quarter of 2025, CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> net trade sales increased 62% in the first quarter of 2026 to approximately $597 million, with U.S. net trade sales growth of 36% and ex-U.S. net trade sales growth of 222%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Launched CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Italy, Poland, the Czech Republic, and Australia, bringing availability to more than 300 global sites and 18 global markets.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Continued to optimize CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacturing capabilities, including increasing manufacturing success rate to 99%, decreasing turnaround time, and delivering over 95% on-time order releases for final product delivery date during the first quarter of 2026. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In April 2026, achieved milestones totaling $55 million in connection with the Janssen Agreement (as defined below).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $834.6&#160;million as of March&#160;31, 2026, which Legend Biotech believes will provide financial runway beyond 2026, when Legend Biotech believes it will achieve a company-wide profit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">First Quarter 2026 Financial Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Cash Position</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Cash and cash equivalents, and time deposits were $834.6&#160;million as of March&#160;31, 2026.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Collaboration Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Collaboration revenue was $298.4 million for the three months ended March&#160;31, 2026, compared to $185.6 million for the three months ended March&#160;31, 2025. The increase of $112.8 million was due to an increase in revenue generated from sales of CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in connection with the Janssen collaboration and license agreement (the &#8220;Janssen Agreement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">License and Other Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; License revenue was $6.7 million for the three months ended March&#160;31, 2026, compared to $9.4 million for the three months ended March&#160;31, 2025. The decrease of $2.7 million was primarily attributed to revenue recognized under the license agreement with Novartis Pharma AG, which was recognized over time as Legend Biotech conducts a Phase 1 clinical trial for LB2102.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Cost of Collaboration Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Cost of collaboration revenue was $175.4 million for the three months ended March&#160;31, 2026, compared to $69.5 million for the three months ended March&#160;31, 2025. The increase of $105.9 million was primarily due to Legend Biotech&#8217;s share of the cost of sales in connection with CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales under the Janssen Agreement, as well as one-time additional costs incurred for capacity expansion and depreciation charges. </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company-wide profit defined as Adjusted Net Income</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Research and Development Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Research and development expenses were $85.7 million for the three months ended March&#160;31, 2026, compared to $101.9 million for the three months ended March&#160;31, 2025. The decrease of $16.2 million was primarily driven by lower expenditures in the cilta-cel clinical program as the patient dosing phases of major trials concluded, partially offset by higher pipeline related research and development activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Administrative Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Administrative expenses were $40.0 million for the three months ended March 31, 2026, compared to $31.5 million for the three months ended March&#160;31, 2025. The increase of $8.5 million was primarily driven by higher professional fees.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Selling and Distribution Expe</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">nses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Selling and distribution expenses were $50.1 million for the three months ended March&#160;31, 2026, compared to $41.0&#160;million for the three months ended March&#160;31, 2025. The increase of $9.1 million was primarily due to higher commercial costs, including sales force expansion and Janssen-related marketing and market access activities, which rose with collaboration revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Operating loss&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss for the three months ended March&#160;31, 2026 was $49.8 million compared to $51.7 million for the three months ended March&#160;31, 2025. The year-over-year improvement of $1.9 million was primarily due to higher gross profit from CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Net Loss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Net loss was $54.3 million for the three months ended March&#160;31, 2026, compared to a net loss of $101.0 million for the three months ended March&#160;31, 2025. The year-over-year improvement of $46.7 million was primarily driven by lower unrealized foreign currency exchange losses compared to the prior period, as well as improved operating performance reflecting higher gross profit from CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Adjusted Net Loss&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Adjusted net loss was $10.5 million for the three months ended March&#160;31, 2026, compared to an adjusted net loss of $27.0 million for the three months ended March&#160;31, 2025. The year-over-year improvement of $16.5 million was primarily driven by improved operating performance, reflecting higher gross profit from CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#47;Conference Call Details&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legend Biotech will host its quarterly earnings call and webcast today at 8&#58;00 am ET. To access the webcast, please visit this weblink. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A replay of the webcast will be available on Legend Biotech&#8217;s website at https&#58;&#47;&#47;investors.legendbiotech.com&#47;events-and-presentations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Legend Biotech </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI&#174;, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &#38; Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI&#8217;s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Learn more at https&#58;&#47;&#47;legendbiotech.com and follow us on LinkedIn. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech&#8217;s strategies and objectives&#59; statements relating to the expected timing of initiation, completion, and results and data of Legend Biotech&#8217;s early-stage cell therapy portfolio&#59; statements relating to the expected timing of initiation, completion, and results and data of Legend Biotech&#8217;s early-stage cell therapy portfolio&#59;  statements relating to CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, including Legend Biotech&#8217;s expectations for CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and its therapeutic potential&#59; statements related to Legend Biotech&#8217;s ability to fund its operations beyond 2026 and to achieve profitability in 2026&#59; and the potential benefits of Legend Biotech&#8217;s product candidates. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech&#8217;s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products&#59; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data&#59; unexpected regulatory actions or delays, including requests for </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">additional safety and&#47;or efficacy data or analysis of data, or government regulation generally&#59; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners&#59; uncertainties arising from challenges to Legend Biotech&#8217;s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process&#59; government, industry, and general product pricing and other political pressures&#59; as well as the other factors discussed in the &#8220;Risk Factors&#8221; section of Legend Biotech&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 10, 2026 and Legend Biotech&#8217;s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INVESTOR CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jessie Yeung</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; (732) 956-8271</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jessie.yeung&#64;legendbiotech.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PRESS CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kim Fox</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; (848) 388-8445</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;legendbiotech.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i38a4bc577f644810a858db5c4edc1571_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED, DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REVENUE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license and other revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and distribution expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses**</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.8)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.7)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.2)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.0)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LOSS PER SHARE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.2&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.5&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">** Certain prior year amounts have been reclassified to present loss on asset impairment into the other operating expenses line for comparative purposes.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i38a4bc577f644810a858db5c4edc1571_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(DOLLARS IN MILLIONS)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NON-CURRENT ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration prepaid leases</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.6&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CURRENT ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration inventories, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments, other receivables and other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247.1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596.7&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733.7&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CURRENT LIABILITIES</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payables and accruals</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration interest-bearing advanced funding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.4&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NON-CURRENT LIABILITIES</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities long term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.6&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002.1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596.7&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733.7&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i38a4bc577f644810a858db5c4edc1571_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED&#59; DOLLARS IN MILLIONS)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.2)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in operating activities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by financing activities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and bank balances</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Pledged deposits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents as stated in the statement of financial position</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.7&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i38a4bc577f644810a858db5c4edc1571_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF IFRS TO NON-IFRS MEASURES</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as &#8220;Adjusted EPS&#8221; &#8220;ANL per Share&#8221;) as performance metrics. Adjusted Net Loss and ANL per share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Loss has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Loss does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss excludes unrealized foreign exchange gain or loss.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss does not reflect changes in, or cash requirements for, our working capital needs.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, Adjusted Net Loss excludes such as share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, our definition of Adjusted Net Loss and ANL per Share may not be the same as similarly titled measures used by other companies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, we believe that providing information concerning Adjusted Net Loss and ANL per Share enhances an investor&#8217;s understanding of our financial performance. We use Adjusted Net Loss as a performance metric that guides management in its operation of and planning for the future of the business. We believe that Adjusted Net Loss provides a useful measure of our operating performance from period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Loss as net loss adjusted for (1) non-cash items such as depreciation and amortization, share based compensation, impairment loss, and (2) unrealized foreign exchange gain or loss.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANL per Share is computed by dividing Adjusted Net Loss by the weighted average shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation between Adjusted Net Loss and Net Loss, the most directly comparable measure under IFRS, has been provided in the table below.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECONCILIATION OF IFRS TO NON-IFRS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED&#59; DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.0)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss&#47;(gain) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net loss (ANL)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANL per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANL per share - basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANL per share - diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Included in Other operating expenses</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Other income&#47;(expense), net</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>3
<FILENAME>q126pipeline.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>q126pipeline</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- q126pipeline001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="q126pipeline001.jpg" title="slide1" width="1365" height="1055">
<DIV><FONT size="1" style="font-size:1pt;color:white">8 Advancing a Robust, Differentiated Cell Therapy Pipeline This presentation is for investor relations purposes only - Not for product promotional purposes Notes&#65306; 1. In collaboration with Janssen, Pharmaceutical Companies of Johnson &amp; Johnson. NDMM = Newly Diagnosed Multiple Myeloma. 2. Phase 1 investigator-initiated trial in China 3. IND applications have been cleared by the United States FDA 4. Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in  any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list PartnerCurrent StatusNDAPhase IIIPhase IIPhase IPre-ClinicalIndicationTargetProgram CARVYKTI&reg;: BCMA-directed Autologous Therapy Patient follow-upNDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)(1) BCMACARVYKTI&reg; Patient follow-upNDMM (Front-line, Transplant Eligible) (CARTITUDE-6)(1) EnrollingNDMM (Front-line, Transplant Not Intended) (CARTITUDE-10)(1) Autologous Therapies Met primary endpoint, patient follow-upRelapsed/Refractory Gastric &amp; Pancreatic Cancers(3)Claudin 18.2LB1908 Met primary endpoint, patient follow-up2L+ Small Cell Lung Cancer and Large Cell Neuroendocrine  Carcinoma (3)(4)DLL3LB2102 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)GPRC5DLB2401 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)CD19 x GPRC5DLB2402 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)GPRC5D (FAST CAR)LB2403 EnrollingRelapsed/Refractory Multiple Myeloma(2)FcRH5 (FAST CAR)LB2502 Allogeneic Therapies EnrollingRelapsed/Refractory Autoimmune Diseases(2)CD19 x CD70 (CAR-&#947;&#948; T)LB2404D EnrollingRelapsed/Refractory Autoimmune Diseases(2)CD19 x BCMA (CAR-NK)LB2405 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD20 (CAR-&#945;&#946; T)LB2302 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20 (CAR-&#947;&#948; T)LB2303 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20  (CAR-&#947;&#948; T)LB2406 In Vivo Therapies EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20LB2501 EnrollingRelapsed/Refractory Multiple Myeloma(2)GPRC5DLB2503 InitiatingRelapsed/Refractory Autoimmune Diseases(2)BCMALB2505 Multi-Regional Clinical Trial   Multi-Regional Clinical Trial  US IND US IND Multi-Region Single Arm Trial </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>legn-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:legn="http://legendbiotech.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://legendbiotech.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://legendbiotech.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATEINFORMATION" roleURI="http://legendbiotech.com/role/CORPORATEINFORMATION">
        <link:definition>9952155 - Disclosure - CORPORATE INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPREPARATION" roleURI="http://legendbiotech.com/role/BASISOFPREPARATION">
        <link:definition>9952156 - Disclosure - BASIS OF PREPARATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" roleURI="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY">
        <link:definition>9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://legendbiotech.com/role/REVENUE">
        <link:definition>9952158 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENET" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET">
        <link:definition>9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://legendbiotech.com/role/LOSSPERSHARE">
        <link:definition>9952160 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://legendbiotech.com/role/LEASES">
        <link:definition>9952161 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNET" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET">
        <link:definition>9952162 - Disclosure - COLLABORATION INVENTORIES, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS">
        <link:definition>9952163 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING">
        <link:definition>9952164 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUM" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM">
        <link:definition>9952165 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" roleURI="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS">
        <link:definition>9952166 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://legendbiotech.com/role/SUBSEQUENTEVENT">
        <link:definition>9952167 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://legendbiotech.com/role/REVENUETables">
        <link:definition>9955511 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETTables" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables">
        <link:definition>9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://legendbiotech.com/role/LOSSPERSHARETables">
        <link:definition>9955513 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://legendbiotech.com/role/LEASESTables">
        <link:definition>9955514 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETTables" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables">
        <link:definition>9955515 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables">
        <link:definition>9955516 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables">
        <link:definition>9955517 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMTables" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables">
        <link:definition>9955518 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofAnalysisofRevenueDetails" roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails">
        <link:definition>9955519 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofRevenueDetails" roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails">
        <link:definition>9955520 - Disclosure - REVENUE - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails">
        <link:definition>9955521 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETDetails" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails">
        <link:definition>9955522 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails" roleURI="http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails">
        <link:definition>9955523 - Disclosure - LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails">
        <link:definition>9955524 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" roleURI="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails">
        <link:definition>9955525 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails">
        <link:definition>9955526 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails">
        <link:definition>9955527 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails">
        <link:definition>9955528 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails">
        <link:definition>9955529 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails">
        <link:definition>9955530 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails">
        <link:definition>9955531 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails">
        <link:definition>9955532 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails">
        <link:definition>9955533 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTDetails" roleURI="http://legendbiotech.com/role/SUBSEQUENTEVENTDetails">
        <link:definition>9955534 - Disclosure - SUBSEQUENT EVENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="legn_RevenueFromLicensingOfIntellectualPropertyAndOther" abstract="false" name="RevenueFromLicensingOfIntellectualPropertyAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CollaborationRevenue" abstract="false" name="CollaborationRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CostOfLicenseAndOtherRevenue" abstract="false" name="CostOfLicenseAndOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_SellingAndDistributionExpenses" abstract="false" name="SellingAndDistributionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CollaborationPrepaidLeases" abstract="false" name="CollaborationPrepaidLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_TimeDeposits" abstract="false" name="TimeDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_OtherPayablesAndAccrualsCurrent" abstract="false" name="OtherPayablesAndAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" abstract="false" name="IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForInventoryReserveProvision" abstract="false" name="AdjustmentsForInventoryReserveProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForDepreciationOfRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" abstract="false" name="AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" abstract="false" name="AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" abstract="false" name="PrepaymentToCollaboratorForCollaborationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdditionInTimeDeposits" abstract="false" name="AdditionInTimeDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DecreaseInTimeDeposits" abstract="false" name="DecreaseInTimeDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_TimesDepositsCurrentAndNoncurrent" abstract="false" name="TimesDepositsCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" abstract="false" name="CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_SupplementalCashFlowInformationAbstract" abstract="true" name="SupplementalCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" abstract="false" name="NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" abstract="false" name="DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_BasisOfPreparationAbstract" abstract="true" name="BasisOfPreparationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfOtherIncomeAndExpenseAbstract" abstract="true" name="DisclosureOfOtherIncomeAndExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfOtherIncomeExpenseNetTextBlock" abstract="false" name="DisclosureOfOtherIncomeExpenseNetTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_LeaseAbstract" abstract="true" name="LeaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" abstract="false" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" abstract="false" name="DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_LesseeLeaseLiabilitiesTextBlock" abstract="false" name="LesseeLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_RelatedPartySublicenseMember" abstract="true" name="RelatedPartySublicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_RevenueFromLicensingOfIntellectualProperty" abstract="false" name="RevenueFromLicensingOfIntellectualProperty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_OutsideTheUnitedStatesOfAmericaMember" abstract="true" name="OutsideTheUnitedStatesOfAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_OtherMiscellaneousIncomeExpense" abstract="false" name="OtherMiscellaneousIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_LeasesTable" abstract="true" name="LeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_LesseeLeasingArrangementsLeasesTerm" abstract="false" name="LesseeLeasingArrangementsLeasesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="legn_OngoingLeasePaymentsUnderTheLandLease" abstract="false" name="OngoingLeasePaymentsUnderTheLandLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" abstract="false" name="LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" abstract="false" name="IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_IncreaseInLeaseLiabilities" abstract="false" name="IncreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_IncreaseOfLeaseLiabilitiesBalance" abstract="false" name="IncreaseOfLeaseLiabilitiesBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InventoryReserve" abstract="false" name="InventoryReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" abstract="true" name="PrepaymentsOtherReceivablesAndOtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_OtherCollaborationReceivables" abstract="false" name="OtherCollaborationReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PrepaymentsOtherReceivablesAndOtherAssets" abstract="false" name="PrepaymentsOtherReceivablesAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InterestBearingBorrowingsFundingAdvances" abstract="false" name="InterestBearingBorrowingsFundingAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InterestBearingBorrowingsFundedInterestsAccrued" abstract="false" name="InterestBearingBorrowingsFundedInterestsAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" abstract="false" name="InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" abstract="false" name="InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AuthorisedAbstract" abstract="true" name="AuthorisedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_AuthorizedShareCapital" abstract="false" name="AuthorizedShareCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ShareCapitalMember" abstract="true" name="ShareCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_ShareCapitalRollForward" abstract="true" name="ShareCapitalRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" abstract="false" name="ShareCapitalAndSharePremiumNumberOfSharesInIssue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ShareCapitalAndSharePremium" abstract="false" name="ShareCapitalAndSharePremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ExerciseOfShareOptionNumberOfSharesInIssue" abstract="false" name="ExerciseOfShareOptionNumberOfSharesInIssue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ExerciseOfShareOption" abstract="false" name="ExerciseOfShareOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" abstract="false" name="ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" abstract="false" name="ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_RevenueMilestonePaymentMember" abstract="true" name="RevenueMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_NumberOfCountriesToReceiveCommericalApproval" abstract="false" name="NumberOfCountriesToReceiveCommericalApproval" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="legn_ProceedsFromMilestonePayments" abstract="false" name="ProceedsFromMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>legn-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d99b2-e50b-7214-8bea-eeea8674762b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d99b2-e50b-7fbf-af95-ea8e3e824b0e" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers_019d99b2-e50b-7214-8bea-eeea8674762b" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d99b2-e50b-7fbf-af95-ea8e3e824b0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d99b2-e50b-7a73-b31f-09a166d1a106" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers_019d99b2-e50b-7214-8bea-eeea8674762b" xlink:to="loc_legn_CollaborationRevenue_019d99b2-e50b-7a73-b31f-09a166d1a106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_019d99b4-f4a1-7f9d-b100-19646201af38" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d99b4-f4a1-75cc-8d28-0691194560ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_019d99b4-f4a1-7f9d-b100-19646201af38" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d99b4-f4a1-75cc-8d28-0691194560ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_019d99b2-1a06-769d-ba30-fc85ee666eeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-1a06-79b8-b5fa-52c718b8a8ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_019d99b2-1a06-769d-ba30-fc85ee666eeb" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-1a06-79b8-b5fa-52c718b8a8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019d99b2-1a06-7ea5-b579-0481864b476f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_019d99b2-1a06-769d-ba30-fc85ee666eeb" xlink:to="loc_ifrs-full_FinanceCosts_019d99b2-1a06-7ea5-b579-0481864b476f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019d99b2-1a06-7621-89ab-66300be56fad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_019d99b2-1a06-769d-ba30-fc85ee666eeb" xlink:to="loc_ifrs-full_FinanceIncome_019d99b2-1a06-7621-89ab-66300be56fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_019d99b2-1a06-7913-901e-52391be0c420" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_019d99b2-1a06-769d-ba30-fc85ee666eeb" xlink:to="loc_ifrs-full_OtherGainsLosses_019d99b2-1a06-7913-901e-52391be0c420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d99b1-bddb-7fe2-9b5f-77c2ce9fd8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_019d99b1-bddb-73ef-95bd-c4044239f00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019d99b1-bddb-7fe2-9b5f-77c2ce9fd8f5" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_019d99b1-bddb-73ef-95bd-c4044239f00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019d99b1-bddb-7c05-9a50-28382f930ee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019d99b1-bddb-7fe2-9b5f-77c2ce9fd8f5" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019d99b1-bddb-7c05-9a50-28382f930ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d99b2-a048-7ad5-8104-03afed7a5eaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d99b2-a048-7ad5-8104-03afed7a5eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019d99b2-a048-7c69-953f-b6274c6e664c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_ifrs-full_CostOfSales_019d99b2-a048-7c69-953f-b6274c6e664c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue_019d99b2-a048-776e-81bb-594ee3429083" xlink:href="legn-20260331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_legn_CostOfLicenseAndOtherRevenue_019d99b2-a048-776e-81bb-594ee3429083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019d99b2-a048-7fa0-9c12-546a3746b597" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019d99b2-a048-7fa0-9c12-546a3746b597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_019d99b2-a048-7676-923f-98c502d7849d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_ifrs-full_AdministrativeExpense_019d99b2-a048-7676-923f-98c502d7849d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses_019d99b2-a048-7808-8aeb-2568e9a9c5c2" xlink:href="legn-20260331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_legn_SellingAndDistributionExpenses_019d99b2-a048-7808-8aeb-2568e9a9c5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByFunction_019d99b2-a048-7c02-b561-aacfdb111943" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99b2-a048-7339-838e-68b49ad3f206" xlink:to="loc_ifrs-full_OtherExpenseByFunction_019d99b2-a048-7c02-b561-aacfdb111943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019d20ae-21e8-74e8-aeec-899a869fa4d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d20ae-21e8-7539-9e18-485e2bae6709" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019d20ae-21e8-74e8-aeec-899a869fa4d4" xlink:to="loc_ifrs-full_ProfitLoss_019d20ae-21e8-7539-9e18-485e2bae6709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_019d20ae-21e8-71bf-b24f-03f7f11f6a54" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019d20ae-21e8-74e8-aeec-899a869fa4d4" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_019d20ae-21e8-71bf-b24f-03f7f11f6a54" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_019d20ae-22c4-7259-8446-48235ab84997" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_019d20ae-22c4-7259-8446-48235ab84997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_019d20ae-22c4-7d0b-a272-3b97596cb9e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_019d20ae-22c4-7d0b-a272-3b97596cb9e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_019d20ae-22c4-78f2-ab2d-b1d906e1b030" xlink:href="legn-20260331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_legn_OtherPayablesAndAccrualsCurrent_019d20ae-22c4-78f2-ab2d-b1d906e1b030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-723a-9d9a-0d33f0d93cca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-723a-9d9a-0d33f0d93cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_019d20ae-22c4-7306-8bf6-b7890014f695" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_CurrentContractLiabilities_019d20ae-22c4-7306-8bf6-b7890014f695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019d20ae-22c4-715e-a55e-5f55b8d5268a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019d20ae-22c4-715e-a55e-5f55b8d5268a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_019d99c5-7c69-79e9-8fbb-50b1b8d14925" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-7c72-b9f2-077b5d551790" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_019d99c5-7c69-79e9-8fbb-50b1b8d14925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d99cd-d74b-7f61-ac51-fbf74ec0d9ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019d99cd-d74b-7660-9631-33c9a490f86a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_019d99cd-d74b-7f61-ac51-fbf74ec0d9ce" xlink:to="loc_ifrs-full_IssuedCapital_019d99cd-d74b-7660-9631-33c9a490f86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_019d99cd-d74b-7f74-b02d-769b5cdb1048" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_019d99cd-d74b-7f61-ac51-fbf74ec0d9ce" xlink:to="loc_ifrs-full_OtherReserves_019d99cd-d74b-7f74-b02d-769b5cdb1048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019d20ae-22c4-7435-8aff-c851b06e01bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:to="loc_ifrs-full_Inventories_019d20ae-22c4-7435-8aff-c851b06e01bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019d20ae-22c4-7e20-9b5e-a9004717e5ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019d20ae-22c4-7e20-9b5e-a9004717e5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019d20ae-22c4-78b9-9e7a-7104662c443d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019d20ae-22c4-78b9-9e7a-7104662c443d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimeDeposits_019d20ae-22c4-7228-93f7-483d7c8c900f" xlink:href="legn-20260331.xsd#legn_TimeDeposits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:to="loc_legn_TimeDeposits_019d20ae-22c4-7228-93f7-483d7c8c900f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-74a3-830b-6a4622f67a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019d20ae-22c4-7e94-bd95-cd7a7255d740" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-74a3-830b-6a4622f67a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7ae9-bcf5-b93efb4e816b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019d20ae-22c3-7740-9d94-69c8f436a89e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7ae9-bcf5-b93efb4e816b" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019d20ae-22c3-7740-9d94-69c8f436a89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019d20ae-22c3-7edf-a433-ce8291818979" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7ae9-bcf5-b93efb4e816b" xlink:to="loc_ifrs-full_RightofuseAssets_019d20ae-22c3-7edf-a433-ce8291818979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases_019d20ae-22c3-7374-8af7-12efa623afc5" xlink:href="legn-20260331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7ae9-bcf5-b93efb4e816b" xlink:to="loc_legn_CollaborationPrepaidLeases_019d20ae-22c3-7374-8af7-12efa623afc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019d20ae-22c3-7b80-8b58-04724690faa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7ae9-bcf5-b93efb4e816b" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019d20ae-22c3-7b80-8b58-04724690faa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019d20ae-22c3-7ea7-a773-543486006a10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7c29-ab32-42f3e6420fbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_019d20ae-22c3-7ea7-a773-543486006a10" xlink:to="loc_ifrs-full_NoncurrentAssets_019d20ae-22c3-7c29-ab32-42f3e6420fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019d20ae-22c3-76e2-be92-5d3b95571c69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_019d20ae-22c3-7ea7-a773-543486006a10" xlink:to="loc_ifrs-full_CurrentAssets_019d20ae-22c3-76e2-be92-5d3b95571c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_019d20ae-22c4-7641-89d4-dd1f84a3c6a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-70d0-8e91-c689d04218d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_019d20ae-22c4-7641-89d4-dd1f84a3c6a7" xlink:to="loc_ifrs-full_CurrentLiabilities_019d20ae-22c4-70d0-8e91-c689d04218d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c4-75da-b5ec-16bcc583e851" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_019d20ae-22c4-7641-89d4-dd1f84a3c6a7" xlink:to="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c4-75da-b5ec-16bcc583e851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c3-799f-b0eb-c503a5af4bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c3-7313-bfac-2a7efd87cdbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c3-799f-b0eb-c503a5af4bc4" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c3-7313-bfac-2a7efd87cdbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_019d20ae-22c4-762f-9189-3ad0f4743ac4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c3-799f-b0eb-c503a5af4bc4" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_019d20ae-22c4-762f-9189-3ad0f4743ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_019d20ae-22c4-79a5-9ea4-d5fc146a2bb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c4-74a5-97ca-1f6b89591e4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_019d20ae-22c4-79a5-9ea4-d5fc146a2bb0" xlink:to="loc_ifrs-full_Equity_019d20ae-22c4-74a5-97ca-1f6b89591e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_019d20ae-22c4-7a40-aa43-8790d98debe3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_019d20ae-22c4-79a5-9ea4-d5fc146a2bb0" xlink:to="loc_ifrs-full_Liabilities_019d20ae-22c4-7a40-aa43-8790d98debe3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7bab-a529-811293a0c6c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d20ae-22c4-75fc-9d38-45e8accece36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7bab-a529-811293a0c6c1" xlink:to="loc_ifrs-full_ProfitLoss_019d20ae-22c4-75fc-9d38-45e8accece36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7c32-90b9-723bd4320a8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7bab-a529-811293a0c6c1" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7c32-90b9-723bd4320a8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-7d9b-b8b5-04e472c12ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-75b5-881f-e3e3fcda149c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-7d9b-b8b5-04e472c12ece" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-75b5-881f-e3e3fcda149c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7eeb-ae1e-f4a45973428d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-7d9b-b8b5-04e472c12ece" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7eeb-ae1e-f4a45973428d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7540-93f4-8bdc36b69e7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-7d9b-b8b5-04e472c12ece" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7540-93f4-8bdc36b69e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019d9a00-27f3-76c7-a47f-bf2ce3826682" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-7d9b-b8b5-04e472c12ece" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019d9a00-27f3-76c7-a47f-bf2ce3826682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-7418-8cc1-4306ab83a01a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019d20ae-22c4-7a50-b8ea-7430dfb01d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-7418-8cc1-4306ab83a01a" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019d20ae-22c4-7a50-b8ea-7430dfb01d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_019d20ae-22c4-7f5d-ad68-e9383704108e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-7418-8cc1-4306ab83a01a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_019d20ae-22c4-7f5d-ad68-e9383704108e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_019d99fb-36db-746a-be7c-b0e8e8664e9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_019d99fb-36db-7eb6-abe6-77a826af99b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Cash_019d99fb-36db-746a-be7c-b0e8e8664e9d" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_019d99fb-36db-7eb6-abe6-77a826af99b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsCurrentAndNoncurrent_019d99fb-36db-718c-8224-84a4cd949046" xlink:href="legn-20260331.xsd#legn_TimesDepositsCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Cash_019d99fb-36db-746a-be7c-b0e8e8664e9d" xlink:to="loc_legn_TimesDepositsCurrentAndNoncurrent_019d99fb-36db-718c-8224-84a4cd949046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_019d99fb-36db-79cb-b781-f941121ccf02" xlink:href="legn-20260331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Cash_019d99fb-36db-746a-be7c-b0e8e8664e9d" xlink:to="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_019d99fb-36db-79cb-b781-f941121ccf02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7531-bf37-9bad69f4f27b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019d20ae-22c4-744a-a0dc-8b1986b5c6e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7531-bf37-9bad69f4f27b" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019d20ae-22c4-744a-a0dc-8b1986b5c6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_019d20ae-22c4-75c3-998c-7be91860c45d" xlink:href="legn-20260331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7531-bf37-9bad69f4f27b" xlink:to="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_019d20ae-22c4-75c3-998c-7be91860c45d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits_019d20ae-22c4-70b6-8125-656f175b812d" xlink:href="legn-20260331.xsd#legn_AdditionInTimeDeposits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7531-bf37-9bad69f4f27b" xlink:to="loc_legn_AdditionInTimeDeposits_019d20ae-22c4-70b6-8125-656f175b812d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits_019d20ae-22c4-7f8f-95bb-76bfd44f603f" xlink:href="legn-20260331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-7531-bf37-9bad69f4f27b" xlink:to="loc_legn_DecreaseInTimeDeposits_019d20ae-22c4-7f8f-95bb-76bfd44f603f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7cac-98a7-db7de8ff67c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7cac-98a7-db7de8ff67c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019d20ae-22c4-7e67-ba69-66069064b857" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019d20ae-22c4-7e67-ba69-66069064b857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_019d20ae-22c4-7d38-936b-a6215a5f075e" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_019d20ae-22c4-7d38-936b-a6215a5f075e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019d20ae-22c4-7639-a455-a5e8883e4a42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019d20ae-22c4-7639-a455-a5e8883e4a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_019d99ef-8579-7e9c-b7ab-843232519462" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_019d99ef-8579-7e9c-b7ab-843232519462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_019d99ef-8579-7fe4-a37f-3828c2f84896" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_019d99ef-8579-7fe4-a37f-3828c2f84896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_019d99ef-8579-75a4-9dad-74bd0bdf3f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_019d99ef-8579-75a4-9dad-74bd0bdf3f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_019d99ef-8579-7091-ae3b-a0f148e333c0" xlink:href="legn-20260331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_019d99ef-8579-7091-ae3b-a0f148e333c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_019d99ef-8579-747b-b754-783961b16f24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_019d99ef-8579-747b-b754-783961b16f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_019d99ef-8579-7375-9a4c-6ec3757f7d80" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-22c4-7dd4-acd3-2d5697b46116" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_019d99ef-8579-7375-9a4c-6ec3757f7d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-22c4-7808-8bc5-bc58a1a86eb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-22c4-7808-8bc5-bc58a1a86eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_019d20ae-22c4-7d6c-9e92-c5b455ce961b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_019d20ae-22c4-7d6c-9e92-c5b455ce961b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_019d20ae-22c4-7b1d-8b7f-c0bc9298741f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_019d20ae-22c4-7b1d-8b7f-c0bc9298741f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision_019d20ae-22c4-78a5-b843-8b9a79b6c04b" xlink:href="legn-20260331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_legn_AdjustmentsForInventoryReserveProvision_019d20ae-22c4-78a5-b843-8b9a79b6c04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_019d20ae-22c4-7374-8b72-9da1269d7db8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_019d20ae-22c4-7374-8b72-9da1269d7db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_019d20ae-22c4-7e91-8eb7-5c6f6aa0fdce" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_019d20ae-22c4-7e91-8eb7-5c6f6aa0fdce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_019d20ae-22c4-7da8-8e02-362f68a1bf95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_019d20ae-22c4-7da8-8e02-362f68a1bf95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_019d20ae-22c4-7d58-b802-f2817fcd254e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_019d20ae-22c4-7d58-b802-f2817fcd254e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019d20ae-22c4-709c-bcb4-5dbd6a74cb8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b56-b2ce-3bac5e7b652c" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019d20ae-22c4-709c-bcb4-5dbd6a74cb8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUESummaryofAnalysisofRevenueDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0f-7be9-729f-8798-63dc18f2966a" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0f-7be9-731e-9e19-b98ecca7510a" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0f-7be9-729f-8798-63dc18f2966a" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0f-7be9-731e-9e19-b98ecca7510a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019d9a0f-7be9-7a60-8521-64e5c22c9bce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0f-7be9-729f-8798-63dc18f2966a" xlink:to="loc_ifrs-full_OtherRevenue_019d9a0f-7be9-7a60-8521-64e5c22c9bce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#OTHEREXPENSEINCOMENETDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_019d20ae-22c4-7ad7-b705-382b2a14412c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_019d20ae-22c4-7044-a27d-9ea8ec14cde0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_019d20ae-22c4-7ad7-b705-382b2a14412c" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_019d20ae-22c4-7044-a27d-9ea8ec14cde0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense_019d20ae-22c4-7a6c-b9e8-f1963740cfba" xlink:href="legn-20260331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_019d20ae-22c4-7ad7-b705-382b2a14412c" xlink:to="loc_legn_OtherMiscellaneousIncomeExpense_019d20ae-22c4-7a6c-b9e8-f1963740cfba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-75fc-b454-71decf41f664" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-7cdf-8e38-f7e6083e867a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-75fc-b454-71decf41f664" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-7cdf-8e38-f7e6083e867a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-700d-ba15-6d39e63ce7cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-75fc-b454-71decf41f664" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-700d-ba15-6d39e63ce7cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019d20ae-22c5-7731-a15f-f195daa538f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_019d20ae-22c5-770c-aa52-70f2232866d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_019d20ae-22c5-7731-a15f-f195daa538f0" xlink:to="loc_ifrs-full_WorkInProgress_019d20ae-22c5-770c-aa52-70f2232866d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_019d20ae-22c5-7f2d-b026-58f545732121" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_019d20ae-22c5-7731-a15f-f195daa538f0" xlink:to="loc_ifrs-full_RawMaterials_019d20ae-22c5-7f2d-b026-58f545732121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_019d20ae-22c5-73a6-b6c0-728ebedda7fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_019d20ae-22c5-7731-a15f-f195daa538f0" xlink:to="loc_ifrs-full_FinishedGoods_019d20ae-22c5-73a6-b6c0-728ebedda7fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-22c5-750c-acc4-965ac09a977e" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_019d20ae-22c5-7ae7-bd5d-bd1f90ff0331" xlink:href="legn-20260331.xsd#legn_OtherCollaborationReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-22c5-750c-acc4-965ac09a977e" xlink:to="loc_legn_OtherCollaborationReceivables_019d20ae-22c5-7ae7-bd5d-bd1f90ff0331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_019d20ae-22c5-7ac0-a8fe-cb18bb67b3be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-22c5-750c-acc4-965ac09a977e" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_019d20ae-22c5-7ac0-a8fe-cb18bb67b3be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_019d20ae-22c5-7d60-84ab-71cebde218af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-22c5-750c-acc4-965ac09a977e" xlink:to="loc_ifrs-full_Prepayments_019d20ae-22c5-7d60-84ab-71cebde218af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_019de24d-64e1-7942-b8a4-c2b3bbe3bf39" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-22c5-750c-acc4-965ac09a977e" xlink:to="loc_ifrs-full_OtherCurrentAssets_019de24d-64e1-7942-b8a4-c2b3bbe3bf39" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>legn-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-7494-959f-1991613d8005_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-7494-959f-1991613d8005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c4-7a61-b5da-dbadd1e062e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c4-7a61-b5da-dbadd1e062e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019d20ae-22c4-7e62-8561-afe71f2fa848" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_SharePremiumMember_019d20ae-22c4-7e62-8561-afe71f2fa848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019d20ae-22c4-77fd-808e-ad26419fce3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019d20ae-22c4-77fd-808e-ad26419fce3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_019d20ae-22c4-7c8a-9955-422105cffd10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_019d20ae-22c4-7c8a-9955-422105cffd10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_019d20ae-22c4-7e64-87f8-0f914157b14a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_RetainedEarningsMember_019d20ae-22c4-7e64-87f8-0f914157b14a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c4-79df-8781-baff693be861" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_Equity_019d20ae-22c4-79df-8781-baff693be861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d20ae-22c4-7325-9b6e-1b270ec1b4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_ProfitLoss_019d20ae-22c4-7325-9b6e-1b270ec1b4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7a77-9882-2cd88ac45f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7a77-9882-2cd88ac45f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7de0-904d-86cfb800ce7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7de0-904d-86cfb800ce7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019d20ae-22c4-7af3-b9c8-c280ab4700f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019d20ae-22c4-7af3-b9c8-c280ab4700f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_019d20ae-22c4-7836-9223-2c380c8ca8f3" xlink:href="legn-20260331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_019d20ae-22c4-7836-9223-2c380c8ca8f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_019d20ae-22c4-7d7e-bc0a-409529ed8a4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_019d20ae-22c4-7d7e-bc0a-409529ed8a4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c4-73f9-ad42-cfc8cfd00e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_019d20ae-22c4-7186-ad44-6fcd970f2903" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_OtherReserves_019d20ae-22c4-7186-ad44-6fcd970f2903" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUESummaryofAnalysisofRevenueDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:to="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember_019d20ae-22c4-7320-8904-42c55b3df2ac" xlink:href="legn-20260331.xsd#legn_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:to="loc_legn_NovartisMember_019d20ae-22c4-7320-8904-42c55b3df2ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RelatedPartySublicenseMember_019ddd83-8e79-7360-8b60-01ec981f8bf3" xlink:href="legn-20260331.xsd#legn_RelatedPartySublicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:to="loc_legn_RelatedPartySublicenseMember_019ddd83-8e79-7360-8b60-01ec981f8bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0d-71c7-7e0d-998c-3bdb40ce0ade" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0d-71c7-7e0d-998c-3bdb40ce0ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019d9a0d-71c7-7088-8828-80a8b2455b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_ifrs-full_OtherRevenue_019d9a0d-71c7-7088-8828-80a8b2455b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0d-71c7-7e6d-8853-da326ffa30b3" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0d-71c7-7e6d-8853-da326ffa30b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d9a0d-71c7-736b-b44d-10fadd209943" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_CollaborationRevenue_019d9a0d-71c7-736b-b44d-10fadd209943" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d9a0d-71c7-798d-a4f0-f1bf16b36599" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d9a0d-71c7-798d-a4f0-f1bf16b36599" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUESummaryofRevenueDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:to="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72bd-b930-417483a6e3b1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:to="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72bd-b930-417483a6e3b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:to="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019d20ae-22c4-72ba-9a80-717f2ab1b09a" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_country_US_019d20ae-22c4-72ba-9a80-717f2ab1b09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019d20ae-22c4-7346-a082-4d5e27445f31" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_country_CN_019d20ae-22c4-7346-a082-4d5e27445f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OutsideTheUnitedStatesOfAmericaMember_019e0064-95f1-7a8a-814d-af28766f8a64" xlink:href="legn-20260331.xsd#legn_OutsideTheUnitedStatesOfAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_legn_OutsideTheUnitedStatesOfAmericaMember_019e0064-95f1-7a8a-814d-af28766f8a64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019daea1-0aa3-7c74-a51e-3db03a8d3464" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019daea1-0aa3-7c74-a51e-3db03a8d3464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d20ae-22c4-7c4c-a300-8932c5208260" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_legn_CollaborationRevenue_019d20ae-22c4-7c4c-a300-8932c5208260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d20ae-22c4-76bb-a990-58d02b553474" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d20ae-22c4-76bb-a990-58d02b553474" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-7ffd-a890-f927447272a6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-7ffd-a890-f927447272a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_019d20ae-22c4-7f62-a16e-26e3dc8dd653" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_019d20ae-22c4-7f62-a16e-26e3dc8dd653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_019d20ae-22c4-7b32-af40-32338811df30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_019d20ae-22c4-7b32-af40-32338811df30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_019d20ae-22c4-78e7-910e-0e713d1fb1df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:to="loc_ifrs-full_Revenue_019d20ae-22c4-78e7-910e-0e713d1fb1df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:href="legn-20260331.xsd#legn_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:href="legn-20260331.xsd#legn_LeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019e0548-240d-7161-8ca6-a329bf737e05_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:to="loc_ifrs-full_RangeDomain_019e0548-240d-7161-8ca6-a329bf737e05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:to="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019e0548-240d-728e-a7be-08bbe37f6c20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:to="loc_ifrs-full_BottomOfRangeMember_019e0548-240d-728e-a7be-08bbe37f6c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019e0548-240d-7d16-9a62-a96f1aebdb0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:to="loc_ifrs-full_TopOfRangeMember_019e0548-240d-7d16-9a62-a96f1aebdb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7c5b-8217-e0ee091d3458_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7c5b-8217-e0ee091d3458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_019e0548-240d-7da8-9f0d-75b0c624fb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:to="loc_ifrs-full_LandMember_019e0548-240d-7da8-9f0d-75b0c624fb13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-73b8-bad4-0bfe90c5a8ac_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:to="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-73b8-bad4-0bfe90c5a8ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:to="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019e0549-180f-78d7-a97e-695ff31b8ad3" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:to="loc_legn_JanssenMember_019e0549-180f-78d7-a97e-695ff31b8ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm_019e0548-240d-768f-84c7-04975de5f6a1" xlink:href="legn-20260331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_LesseeLeasingArrangementsLeasesTerm_019e0548-240d-768f-84c7-04975de5f6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease_019e0548-240d-7a4e-8471-d8e4f8755cc4" xlink:href="legn-20260331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_OngoingLeasePaymentsUnderTheLandLease_019e0548-240d-7a4e-8471-d8e4f8755cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_019e0549-180f-7ce0-8e78-01b588a5726a" xlink:href="legn-20260331.xsd#legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_019e0549-180f-7ce0-8e78-01b588a5726a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019e0549-180f-7016-a2d5-2509c4119ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_LeaseLiabilities_019e0549-180f-7016-a2d5-2509c4119ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables_019e0549-180f-78ed-8739-9cdc6bb0b73a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_FinanceLeaseReceivables_019e0549-180f-78ed-8739-9cdc6bb0b73a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019e0549-180f-7752-b9d9-65b6ffc6c29f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019e0549-180f-7752-b9d9-65b6ffc6c29f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinanceLeaseReceivables_019e0549-180f-7b8f-a0d6-fde298692dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinanceLeaseReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_CurrentFinanceLeaseReceivables_019e0549-180f-7b8f-a0d6-fde298692dc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_019e0549-180f-7285-a98c-d7f7f4dba6dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_019e0549-180f-7285-a98c-d7f7f4dba6dd" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7f2b-8816-299cc056fc8a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7f2b-8816-299cc056fc8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_019d20ae-22c4-70ac-baec-c1d6f242f08c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_019d20ae-22c4-70ac-baec-c1d6f242f08c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:to="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7ce6-a90e-169723625746_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:to="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7ce6-a90e-169723625746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:to="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019dfb93-ac42-7a9e-aec4-b9fbd84e13d9" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:to="loc_legn_JanssenMember_019dfb93-ac42-7a9e-aec4-b9fbd84e13d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-77c4-bba4-a8ba6fba4d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-77c4-bba4-a8ba6fba4d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities_019d20ae-22c4-739f-b801-855264d5fa12" xlink:href="legn-20260331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_legn_IncreaseInLeaseLiabilities_019d20ae-22c4-739f-b801-855264d5fa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance_019d20ae-22c4-7538-8dd6-b0ada65fe8b5" xlink:href="legn-20260331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_legn_IncreaseOfLeaseLiabilitiesBalance_019d20ae-22c4-7538-8dd6-b0ada65fe8b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_019d20ae-22c4-74dc-9d8d-f0c51f1566b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_CashOutflowForLeases_019d20ae-22c4-74dc-9d8d-f0c51f1566b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_019d20ae-22c4-7604-8198-057b3998e05d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_019d20ae-22c4-7604-8198-057b3998e05d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-726d-8189-69fa410be928" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-743d-a432-193c1294a763" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-743d-a432-193c1294a763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-79f4-b2d4-e3cf6c1ce5ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-79f4-b2d4-e3cf6c1ce5ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-7501-9d2c-e1df528603c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-79cd-b89b-d0a5ee037250_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-79cd-b89b-d0a5ee037250_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_019d20ae-22c5-7b6c-bc3e-057146932afd" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_019d20ae-22c5-7b6c-bc3e-057146932afd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_019d9a2e-8e96-7c04-b3f4-2f7770620ec1" xlink:href="legn-20260331.xsd#legn_OtherCollaborationReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_legn_OtherCollaborationReceivables_019d9a2e-8e96-7c04-b3f4-2f7770620ec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_019d9a2e-8e96-7d46-88ed-ffd8517c4c76" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_019d9a2e-8e96-7d46-88ed-ffd8517c4c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_019d9a2e-8e96-7d31-948c-756c2b2f8fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_Prepayments_019d9a2e-8e96-7d31-948c-756c2b2f8fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_019d9a2e-8e96-72a7-992a-504ba35edcd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_OtherCurrentAssets_019d9a2e-8e96-72a7-992a-504ba35edcd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d9a2e-8e96-74bf-978c-8f817d615da2" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d9a2e-8e96-74bf-978c-8f817d615da2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:to="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-76ab-8b1b-dc70f85ba04e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-76ab-8b1b-dc70f85ba04e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019d9a4c-7181-7108-a1b8-2b31f9700c86" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:to="loc_legn_JanssenMember_019d9a4c-7181-7108-a1b8-2b31f9700c86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvances_019d9a4c-7181-7415-9a48-3861be138c5c" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvances_019d9a4c-7181-7415-9a48-3861be138c5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_019d9a4c-7181-78ee-8aec-09c4f7ba7622" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundedInterestsAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_019d9a4c-7181-78ee-8aec-09c4f7ba7622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019d9a4c-7181-7a0e-b45e-065203ff0469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019d9a4c-7181-7a0e-b45e-065203ff0469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_019e0556-693f-7c3b-858d-220cd2b2165e" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_019e0556-693f-7c3b-858d-220cd2b2165e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_019e055a-ee99-7772-8d5b-df606db1f131" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_019e055a-ee99-7772-8d5b-df606db1f131" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daeb2-a723-7231-8925-5eadd20cdafe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daeb2-a723-7231-8925-5eadd20cdafe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019d9a4c-7181-7cff-b60e-0c609207b3d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019d9a4c-7181-7cff-b60e-0c609207b3d8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019d20ae-22c5-75a3-a271-9945bcbcd977" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:to="loc_ifrs-full_OrdinarySharesMember_019d20ae-22c5-75a3-a271-9945bcbcd977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:href="legn-20260331.xsd#legn_AuthorisedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:to="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_019d20ae-22c5-7b80-a19b-90be6c2d6dce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_019d20ae-22c5-7b80-a19b-90be6c2d6dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-71a5-9a02-e6873d8d41e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-71a5-9a02-e6873d8d41e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital_019d20ae-22c5-77ed-a667-6730764e8a64" xlink:href="legn-20260331.xsd#legn_AuthorizedShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_legn_AuthorizedShareCapital_019d20ae-22c5-77ed-a667-6730764e8a64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_019d20ae-22c5-70ce-81df-4c9b57c66df1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_019d20ae-22c5-70ce-81df-4c9b57c66df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-7659-8b34-8bf9a40536ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019d20ae-22c5-7ed9-91c3-ce278351bf34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:to="loc_ifrs-full_IssuedCapital_019d20ae-22c5-7ed9-91c3-ce278351bf34" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7d18-9c38-525cd912a8d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7d18-9c38-525cd912a8d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c5-7f35-b9ce-e305167c682e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c5-7f35-b9ce-e305167c682e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember_019d20ae-22c5-7d02-81ef-8d9ec102e47e" xlink:href="legn-20260331.xsd#legn_ShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_legn_ShareCapitalMember_019d20ae-22c5-7d02-81ef-8d9ec102e47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019d20ae-22c5-71cf-aa0a-2529dff0f4b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_ifrs-full_SharePremiumMember_019d20ae-22c5-71cf-aa0a-2529dff0f4b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:href="legn-20260331.xsd#legn_ShareCapitalRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:to="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7f46-ab21-f8ad8bce5244" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7f46-ab21-f8ad8bce5244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-79b5-83db-465f0c1d56ea" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-79b5-83db-465f0c1d56ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_019d20ae-22c5-7366-95a3-c894be849421" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_019d20ae-22c5-7366-95a3-c894be849421" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption_019d20ae-22c5-7d77-a1f1-ca1d70ff7b97" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ExerciseOfShareOption_019d20ae-22c5-7d77-a1f1-ca1d70ff7b97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_019d20ae-22c5-7b71-8a00-e5852e4376ba" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_019d20ae-22c5-7b71-8a00-e5852e4376ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_019d20ae-22c5-7cef-8d14-0e76083fea0e" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_019d20ae-22c5-7cef-8d14-0e76083fea0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7351-b415-65a0a4b6debe" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-7515-aafc-052971527daf" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremium"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7cb3-a289-08de42b5a521_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7cb3-a289-08de42b5a521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueMilestonePaymentMember_019df0be-6d6c-772d-bf71-f558bfa58cf9" xlink:href="legn-20260331.xsd#legn_RevenueMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:to="loc_legn_RevenueMilestonePaymentMember_019df0be-6d6c-772d-bf71-f558bfa58cf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:to="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-753b-a5e8-50be01018828_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-753b-a5e8-50be01018828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019df898-677e-7361-b5de-d69b8227fc03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:to="loc_srt_ScenarioForecastMember_019df898-677e-7361-b5de-d69b8227fc03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NumberOfCountriesToReceiveCommericalApproval_019e031f-c275-75ab-904b-e8c4151782ea" xlink:href="legn-20260331.xsd#legn_NumberOfCountriesToReceiveCommericalApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:to="loc_legn_NumberOfCountriesToReceiveCommericalApproval_019e031f-c275-75ab-904b-e8c4151782ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromMilestonePayments_019df60c-b78a-75b1-91ba-cf73ea9d7ec5" xlink:href="legn-20260331.xsd#legn_ProceedsFromMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:to="loc_legn_ProceedsFromMilestonePayments_019df60c-b78a-75b1-91ba-cf73ea9d7ec5" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>legn-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019d20ae-2422-7a16-8b70-66769da594cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenue by Geographic Area</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_019d99ad-1812-7543-b433-ea457954c7f6_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_019d20ae-2381-7a38-8893-65b5b8bc2188_terseLabel_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense)/income, net</link:label>
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_label_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expense)</link:label>
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_documentation_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense" xlink:href="legn-20260331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherMiscellaneousIncomeExpense" xlink:to="lab_legn_OtherMiscellaneousIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019d20ae-2381-7ebb-9d40-75b99cb4b2ee_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_019d20ae-2381-75c1-bf23-b664cafa0b2c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in other payables and accruals</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_NovartisMember_019d20ae-2381-7f2e-a619-db8ae8657374_terseLabel_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_legn_NovartisMember_label_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_legn_NovartisMember_documentation_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember" xlink:href="legn-20260331.xsd#legn_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_NovartisMember" xlink:to="lab_legn_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_019d20ae-2381-73a0-8b3d-7f18c9bed59a_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-2381-7de1-8bfc-ead7ee41f786_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-2381-7cca-9b32-e4c627a37775_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-2423-7f8a-9d28-78a8caae5569_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_019dfbc3-86f1-72e5-8c4b-4779eb0f68e3_terseLabel_en-US" xlink:label="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease commitment, percentage of future lease payments expected under profit Sharing agreement</link:label>
    <link:label id="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_label_en-US" xlink:label="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement</link:label>
    <link:label id="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_documentation_en-US" xlink:label="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:href="legn-20260331.xsd#legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:to="lab_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-2423-7d57-8647-d7971bcd6880_periodStartLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-2423-78d4-8b84-dbaca495fedd_periodEndLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital And Share Premium Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital and share premium, number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:to="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_019d20ae-2381-72e8-b19e-3ffcc9d8086c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares authorised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_019d20ae-2381-7833-9d7a-4e25903d4cdf_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-2423-76d4-82f3-2d8740aa49f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-2423-72bb-aa6d-d532184138bc_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_019d20ae-2381-7dc6-b12e-5b157d6c7edb_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_019d20ae-2381-76b0-9a6d-bd8f2e29afbf_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_019d20ae-2381-7581-900e-a17f73dd4209_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeasesTable_019d20ae-2381-744e-893b-450c6e424722_terseLabel_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_legn_LeasesTable_label_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_legn_LeasesTable_documentation_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable" xlink:href="legn-20260331.xsd#legn_LeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeasesTable" xlink:to="lab_legn_LeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvances_019d633f-568c-7789-83a7-2487366ccc8f_terseLabel_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest bearing borrowings, funding advances</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvances_label_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvances_documentation_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvances" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestBearingBorrowingsFundingAdvances" xlink:to="lab_legn_InterestBearingBorrowingsFundingAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-2381-7497-a91b-8b41aa1fc028_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_019d20ae-2381-78aa-911f-cd2ceb44c364_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of authorisation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_019d20ae-2381-7760-8ee0-7fc3be4cb8f0_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-2381-7f17-a16b-c14003de4891_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_019d20ae-2381-753b-be5f-d1716dbcf76b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_019d20ae-2381-7f6a-baf4-70811434f452_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Carrying Amounts of The Right-of-use Assets and Movements</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-2381-77de-a562-bf317decf453_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_019d20ae-2381-702c-973a-b2b39c4247ba_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-2381-765d-9319-9a77fe4f2049_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Prepayments_019d9a2e-8e96-7e57-bd2d-39f7b3de9bdf_terseLabel_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_ifrs-full_Prepayments_label_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Prepayments" xlink:to="lab_ifrs-full_Prepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_019d99c3-f354-7460-aa6a-0dbf45e1cbf5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_BasisOfPreparationAbstract_label_en-US" xlink:label="lab_legn_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Preparation [Abstract]</link:label>
    <link:label id="lab_legn_BasisOfPreparationAbstract_documentation_en-US" xlink:label="lab_legn_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Preparation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_BasisOfPreparationAbstract" xlink:href="legn-20260331.xsd#legn_BasisOfPreparationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_BasisOfPreparationAbstract" xlink:to="lab_legn_BasisOfPreparationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_019d20ae-2381-7a4f-ac10-d3f386e8ea41_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019d20ae-2423-7188-8d4e-aa39d0314065_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate margin percentage</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, adjustment to interest rate basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:to="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_019d20ae-2381-781f-a1ed-8249bc737623_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_019d20ae-2381-7350-a2c3-9783251d969f_terseLabel_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted share units</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_label_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Through Reclassification Of Vested Restricted Stock Equity</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_documentation_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through reclassification of vested restricted stock, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:href="legn-20260331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:to="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_019d20ae-2381-7667-b861-6d0f44bc720a_terseLabel_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of interest recognized during the period</link:label>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_label_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Of Lease Liabilities Balance</link:label>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_documentation_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase of lease liabilities balance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:href="legn-20260331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:to="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019d20ae-2381-7331-9d07-e1b499db7d08_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in trade receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_019d20ae-2423-7ede-8066-12b11946cb20_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in the Company's Share Capital and Share Premium</link:label>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Movements In Company Share Capital And Share Premium Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of movements in the company's share capital and share premium explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_019d99e5-3c35-79af-9de8-248b649390e5_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Increase (Decrease) In Other Assets and liabilities, Net</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for Increase (Decrease) In Other Assets and liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:href="legn-20260331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:to="lab_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_019df0be-d262-7ff7-8da6-6d60cb42c3c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherCollaborationReceivables_019d20ae-2381-7b4c-ac46-831ea197b9e5_terseLabel_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration receivables</link:label>
    <link:label id="lab_legn_OtherCollaborationReceivables_label_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration Receivables</link:label>
    <link:label id="lab_legn_OtherCollaborationReceivables_documentation_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables" xlink:href="legn-20260331.xsd#legn_OtherCollaborationReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherCollaborationReceivables" xlink:to="lab_legn_OtherCollaborationReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_019d20ae-2422-7678-b7ec-b660058a578d_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_019d20ae-2423-73df-a298-b434eee7899b_terseLabel_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term</link:label>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee lease liabilities text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeaseLiabilitiesTextBlock" xlink:href="legn-20260331.xsd#legn_LesseeLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LesseeLeaseLiabilitiesTextBlock" xlink:to="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-2381-7fab-9ee7-07cedb9c5daa_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_019e0548-74bf-7ddd-ad33-154c3da6c0c2_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_019d20ae-2381-75bc-b8e5-6e5915a18f09_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Carrying amount at January 1, 2026</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_019d20ae-2381-7569-a3fd-d515809c5019_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Carrying amount at March 31, 2026</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_019d20ae-2381-7710-93dd-7c04e5d8e83c_totalLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Carrying amount at March 31, 2026</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_NumberOfCountriesToReceiveCommericalApproval_019e031f-c275-75a4-b487-7201026fd661_terseLabel_en-US" xlink:label="lab_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of countries to receive commerical approval</link:label>
    <link:label id="lab_legn_NumberOfCountriesToReceiveCommericalApproval_label_en-US" xlink:label="lab_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Countries To Receive Commerical Approval</link:label>
    <link:label id="lab_legn_NumberOfCountriesToReceiveCommericalApproval_documentation_en-US" xlink:label="lab_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Countries To Receive Commerical Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:href="legn-20260331.xsd#legn_NumberOfCountriesToReceiveCommericalApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:to="lab_legn_NumberOfCountriesToReceiveCommericalApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_019d20ae-2381-7781-8335-c198dc82f64a_terseLabel_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange realignment</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_label_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_documentation_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of exchange realignment in foreign exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:href="legn-20260331.xsd#legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:to="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_019d20ae-2422-7cc3-9358-1ff2fdbcc6b6_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_019d62d5-caf1-75f7-856c-8934aa410c57_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in contract liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019d20ae-2381-7d40-bb86-ff5b5c2d1843_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis of Revenue</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-2423-76d4-a4b4-612e09019722_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019d20ae-2381-7ca5-8264-e45800c40c28_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments, other receivables and other assets</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepayments and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-2381-7c7b-8db8-d4cd8f1c008f_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RevenueMilestonePaymentMember_019dddcc-5293-779d-8012-8612c1f321f8_terseLabel_en-US" xlink:label="lab_legn_RevenueMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Milestone Payment</link:label>
    <link:label id="lab_legn_RevenueMilestonePaymentMember_label_en-US" xlink:label="lab_legn_RevenueMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone Payment [Member]</link:label>
    <link:label id="lab_legn_RevenueMilestonePaymentMember_documentation_en-US" xlink:label="lab_legn_RevenueMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueMilestonePaymentMember" xlink:href="legn-20260331.xsd#legn_RevenueMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RevenueMilestonePaymentMember" xlink:to="lab_legn_RevenueMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_019d20ae-2381-7d43-8a58-ee5a194e413f_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_019d20ae-2381-7d92-8d84-63ff8ef067a8_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CollaborationPrepaidLeases_019d20ae-2381-7c16-80e2-54e49377136e_terseLabel_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration prepaid leases</link:label>
    <link:label id="lab_legn_CollaborationPrepaidLeases_label_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Prepaid Leases</link:label>
    <link:label id="lab_legn_CollaborationPrepaidLeases_documentation_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Prepaid Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases" xlink:href="legn-20260331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CollaborationPrepaidLeases" xlink:to="lab_legn_CollaborationPrepaidLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_019d20ae-2381-7ccb-b2d6-4c9bac6046aa_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_019d20ae-2381-7d5a-86cd-f45e3a1f02f0_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019d20ae-2381-727a-ad76-d343710a4e4b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_019d20ae-2381-7654-a82a-8005c31c90b0_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration inventories, net</link:label>
    <link:label id="lab_ifrs-full_Inventories_019d20ae-2381-742d-a3a8-420190541dc2_totalLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total collaboration inventories, net</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_019e0559-3c1f-72ab-a45f-0a553420e015_terseLabel_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced funding principal balance increase (decrease)</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_label_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances, Increase (Decrease)</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_documentation_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:to="lab_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_019d20ae-2423-7860-b7b4-24e81a1254b4_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in prepayments, other receivables and other assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_label_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_documentation_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease increase in prepayments other receivable other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:to="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-2381-7a0e-a7cd-a1eabf52b279_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-2423-744c-86fc-beb5f69d0ede_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherExpenseByFunction_019d99a2-7fdf-7d8c-8c2f-4919bbdd3aa2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherExpenseByFunction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_OtherExpenseByFunction_label_en-US" xlink:label="lab_ifrs-full_OtherExpenseByFunction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense, by function</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByFunction" xlink:to="lab_ifrs-full_OtherExpenseByFunction" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OutsideTheUnitedStatesOfAmericaMember_019e0064-95f1-7ce5-a055-237d831dc1ad_terseLabel_en-US" xlink:label="lab_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside the United States of America</link:label>
    <link:label id="lab_legn_OutsideTheUnitedStatesOfAmericaMember_label_en-US" xlink:label="lab_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside the United States of America [Member]</link:label>
    <link:label id="lab_legn_OutsideTheUnitedStatesOfAmericaMember_documentation_en-US" xlink:label="lab_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outside the United States of America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:href="legn-20260331.xsd#legn_OutsideTheUnitedStatesOfAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:to="lab_legn_OutsideTheUnitedStatesOfAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_019d20ae-2422-7edb-9855-0d32b7773cbb_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_019d20ae-2381-7e7c-a340-bcb75649b92d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_019d20ae-2381-771b-9fa9-49d0685561c9_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Other (Expense) / Income</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense) [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_019d20ae-2381-770f-ad0f-f0e90959f4c0_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_019d20ae-2381-7c7b-be7b-a41f37a961a2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_019d20ae-2423-7c03-8a49-675df6f45ba7_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019d20ae-2381-73ba-bb47-d5972db84fb7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PREPARATION</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-2381-75f5-82c2-2cbc1c50a1c8_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019d20ae-2381-7f8a-9cce-4a1337c785fa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_019d20ae-2381-709f-a7ce-a811997f5e0c_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019d20ae-2381-7d82-9ead-b313db0b9434_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdministrativeExpense_019d20ae-2381-7036-9444-2ccb01829afb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
    <link:label id="lab_ifrs-full_AdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrativeExpense" xlink:to="lab_ifrs-full_AdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019dddc0-fabe-7c4f-918c-effec6c0e8d7_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019dddc0-fabe-74b8-b7ce-37f4df7162c9_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-2381-7a12-ad3a-46a4778390c1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_019d20ae-2381-72bf-b1a0-79fc296e481c_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of Range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-2381-7ae5-9f0d-341601ca035d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_019d20ae-2381-7527-acf3-f1eb7852096f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_019d20ae-2423-7cf3-9764-dceaac023cf3_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_019d20ae-2381-7956-b750-6de3022c56ce_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue at a point in time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred at point in time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_019d20ae-2423-7e79-84f4-7fb708f055db_terseLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019d20ae-2381-7c67-b5e9-a3d06ef7dec4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019d20ae-2422-7b96-b019-a3929156c24a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_019d20ae-2423-78a4-8dd3-13918b0e899b_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_019d20ae-2381-7637-a31d-2f5202efd42c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION INTEREST-BEARING ADVANCED FUNDING</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinanceLeaseReceivables_019e0548-74bf-7b52-9b39-67e2b3145dcd_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current finance lease receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentFinanceLeaseReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current finance lease receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinanceLeaseReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinanceLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinanceLeaseReceivables" xlink:to="lab_ifrs-full_CurrentFinanceLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_019d20ae-2381-793b-bb60-92a8c30c7738_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_019d20ae-2381-79c8-b130-dd3213e04da0_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares in issue</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_019d20ae-2381-7f33-8da3-fbddb0ebd4a6_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_019d20ae-2381-7feb-ad9d-1d5ff0595891_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_019d20ae-2381-73e2-8ac0-a9b9e7c71645_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued and fully paid (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_019d20ae-2381-77c6-9ae3-3268607f435c_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CORPORATE INFORMATION</link:label>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_label_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of notes and other explanatory information [text block]</link:label>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_documentation_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of notes and other explanatory information as part of a complete set of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:href="legn-20260331.xsd#legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-2381-7c91-aa6a-5b701e927c7f_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities long term</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-2381-75cf-980d-7bf885fdd75e_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_019d20ae-2381-752a-a0b7-e5f853d5d450_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandMember_019d20ae-2381-7d43-afdd-f379c8125558_terseLabel_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Freehold land</link:label>
    <link:label id="lab_ifrs-full_LandMember_label_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandMember" xlink:to="lab_ifrs-full_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0c-28d7-7971-a9a4-da65f61dc299_terseLabel_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and other revenue</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_label_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Licensing Of Intellectual Property</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_documentation_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Licensing Of Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RevenueFromLicensingOfIntellectualProperty" xlink:to="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalRollForward_019d20ae-2423-7c39-ab32-bcf8a4dbd92f_terseLabel_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital [Roll Forward]</link:label>
    <link:label id="lab_legn_ShareCapitalRollForward_label_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital [Roll Forward]</link:label>
    <link:label id="lab_legn_ShareCapitalRollForward_documentation_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward" xlink:href="legn-20260331.xsd#legn_ShareCapitalRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalRollForward" xlink:to="lab_legn_ShareCapitalRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_019d20ae-2381-7dbe-b4f0-b807ad1f8f68_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_019d626c-df82-7c87-a20c-d894994e93fa_totalLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_019d20ae-2381-7b0a-bdb5-e9df830e6085_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_019d20ae-2381-7843-bcfa-bc8e47765553_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_019d9a1d-bd56-7634-9ae4-08489f6ec3aa_verboseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_019d20ae-2381-7064-9e10-24f678614086_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding_019df649-340e-7565-98c0-ae3bf67cf78e_terseLabel_en-US" xlink:label="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash repayment of collaboration interest-bearing advanced funding</link:label>
    <link:label id="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding_label_en-US" xlink:label="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Repayment Of Collaboration Interest-Bearing Advanced Funding</link:label>
    <link:label id="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding_documentation_en-US" xlink:label="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Repayment Of Collaboration Interest-Bearing Advanced Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:href="legn-20260331.xsd#legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:to="lab_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_019d20ae-2381-767a-9043-8b198fb9b6c5_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_019d20ae-2381-7f04-98fe-c56cd4c7c264_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_019d20ae-2381-73b6-9345-e2ec5d19301f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_019d20ae-2381-7ca3-bca0-c5eea9fadb53_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_019d20ae-2381-7507-bc5b-6ee8f1c556f8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_019d20ae-2423-7a2f-a61c-131a97b41ca5_terseLabel_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vesting of restricted share units (in shares)</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted stock units, number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:to="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_TimeDeposits_019d20ae-2423-7113-9119-b778a24bd5cf_terseLabel_en-US" xlink:label="lab_legn_TimeDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_TimeDeposits_label_en-US" xlink:label="lab_legn_TimeDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_legn_TimeDeposits_documentation_en-US" xlink:label="lab_legn_TimeDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Times deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimeDeposits" xlink:href="legn-20260331.xsd#legn_TimeDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_TimeDeposits" xlink:to="lab_legn_TimeDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019d20ae-2381-76d7-bab0-128c9553d629_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019dddb4-99a8-76a3-b2a3-809dd897e4b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_019d20ae-2423-72ad-bada-5e034e86bc8e_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_019d20ae-2423-7b89-a137-f7a495cd566f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_019d20ae-2381-7c7e-9e24-0d53408d2341_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RelatedPartySublicenseMember_019ddd83-8e79-7386-9570-e2053a6eb637_terseLabel_en-US" xlink:label="lab_legn_RelatedPartySublicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Sublicense</link:label>
    <link:label id="lab_legn_RelatedPartySublicenseMember_label_en-US" xlink:label="lab_legn_RelatedPartySublicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Sublicense [Member]</link:label>
    <link:label id="lab_legn_RelatedPartySublicenseMember_documentation_en-US" xlink:label="lab_legn_RelatedPartySublicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Sublicense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RelatedPartySublicenseMember" xlink:href="legn-20260331.xsd#legn_RelatedPartySublicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RelatedPartySublicenseMember" xlink:to="lab_legn_RelatedPartySublicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_019d20ae-2381-797a-a7f4-06b12a5ead2f_terseLabel_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share option (in shares)</link:label>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Share Option Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of share option number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:to="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeasesLineItems_019d20ae-2381-776e-8635-2c61563acc66_terseLabel_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_legn_LeasesLineItems_label_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_legn_LeasesLineItems_documentation_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems" xlink:href="legn-20260331.xsd#legn_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeasesLineItems" xlink:to="lab_legn_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_019d20ae-2381-72d5-ae33-9a1e35ef9226_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesDomain" xlink:to="lab_ifrs-full_CounterpartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_019d20ae-2381-7e2e-b00f-9e124343385c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest-Bearing Loans and Borrowings</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_019d20ae-2381-7eca-9361-4525b94ace5a_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019d20ae-2381-7847-a846-c0c5281de0e0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_019d20ae-2381-7447-85f2-ec05d00a17b3_terseLabel_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables and accruals</link:label>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_label_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payables And Accruals Current</link:label>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_documentation_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other payables and accruals, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent" xlink:href="legn-20260331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent" xlink:to="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019d20ae-2381-766c-91da-b5abfbcf8f70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Shares</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_019d20ae-2381-7306-80ae-bcf68e0d97d8_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_019d9a4c-dd30-74b4-a151-dc9fceb9538d_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_019d20ae-2423-7a0e-86df-f0282dc49345_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_019d9a2b-105e-762f-93fb-c1c32fdc017e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_019d20ae-2422-7ff3-8725-893174ea4f5c_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_019d20ae-2423-7e24-88c8-a09206a676cc_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT ASSETS</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-2423-72e1-bd31-d26ddcf40925_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-2381-7ab2-be7a-eeb6b55df36c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationExpense_019d20ae-2381-72d5-96e0-d4f2c6ba9a02_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_SupplementalCashFlowInformationAbstract_019df61a-23ae-75a5-bd52-b9e9139a5744_terseLabel_en-US" xlink:label="lab_legn_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_legn_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_legn_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_legn_SupplementalCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_legn_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SupplementalCashFlowInformationAbstract" xlink:href="legn-20260331.xsd#legn_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_SupplementalCashFlowInformationAbstract" xlink:to="lab_legn_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_019d20ae-2381-7642-9beb-6679e34837ed_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of detailed information about inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_019d20ae-2381-71a7-94da-5226fef98918_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange realignment</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_019d20ae-2423-7561-ab70-d7233eba5cd9_terseLabel_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ongoing lease payments</link:label>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_label_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ongoing Lease Payments Under The Land Lease</link:label>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_documentation_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ongoing lease payments under the land lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:href="legn-20260331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:to="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_019d20ae-2381-751f-b3fe-6d06387756de_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CollaborationRevenue_019d20ae-2381-7ea1-8b99-e683dbd301ef_terseLabel_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_legn_CollaborationRevenue_label_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_legn_CollaborationRevenue_documentation_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CollaborationRevenue" xlink:to="lab_legn_CollaborationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019d20ae-2381-7850-acd8-9126c8793a93_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE CAPITAL AND SHARE PREMIUM</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_019d99fb-36db-7c66-98f6-908cce18de93_totalLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash and bank balances</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_019d20ae-2381-7add-a578-28c8712a2b12_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_019d20ae-2423-7e93-9e8a-09aa0a3c5c04_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation reserves</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-2381-7f05-911e-f5138a5ddb95_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-2423-712e-adf2-d7833b85c793_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceLeaseReceivables_019d20ae-2381-7b44-b094-69500ccbede1_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
    <link:label id="lab_ifrs-full_FinanceLeaseReceivables_label_en-US" xlink:label="lab_ifrs-full_FinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceLeaseReceivables" xlink:to="lab_ifrs-full_FinanceLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_019d20ae-2381-728d-8773-909f66f6b244_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_label_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation Of Right Of Use Assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_documentation_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation of right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:to="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalMember_019d20ae-2381-730e-899d-a7dd84b9e129_terseLabel_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_legn_ShareCapitalMember_label_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital [Member]</link:label>
    <link:label id="lab_legn_ShareCapitalMember_documentation_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember" xlink:href="legn-20260331.xsd#legn_ShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalMember" xlink:to="lab_legn_ShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_019d20ae-2381-7e4f-9fbb-11663bf1287e_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (%)</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-2422-778c-925b-61212d030ede_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019df895-fd13-73f5-afd7-8d821f126d11_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinanceLeaseReceivables_019e0548-74bf-70f4-b623-6e116125e33b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinanceLeaseReceivables_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:to="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock_019d6309-d9a8-7060-846f-07d77b7f13d7_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER (EXPENSE)/INCOME, NET</link:label>
    <link:label id="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income (Expense), Net [Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeExpenseNetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:to="lab_legn_DisclosureOfOtherIncomeExpenseNetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InventoryReserve_019d20ae-2423-7dc5-923e-61e80d62aab0_terseLabel_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_legn_InventoryReserve_label_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_legn_InventoryReserve_documentation_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InventoryReserve" xlink:href="legn-20260331.xsd#legn_InventoryReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InventoryReserve" xlink:to="lab_legn_InventoryReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_019d20ae-2381-7bcf-821f-6195c00cf551_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-2381-7f5c-b2da-54311b9385fa_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in)/provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-2381-7088-b38d-ffcfa0cba4fc_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analyzed into:</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_019d20ae-2423-7c65-b46c-6858a55434a1_negatedTerseLabel_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of license and other revenue</link:label>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_label_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of License And Other Revenue</link:label>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_documentation_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Of License And Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue" xlink:href="legn-20260331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CostOfLicenseAndOtherRevenue" xlink:to="lab_legn_CostOfLicenseAndOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-2423-77c5-be03-81d7ce154236_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_019d20ae-2381-7305-a81f-9e45417098d0_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_019d20ae-2381-7d66-9466-186aa25778c5_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-2381-724f-ad1f-21ca6df8c8b9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-2381-7e0a-bbc8-13153ca7d6c0_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AuthorizedShareCapital_019d20ae-2381-767e-9844-2973df212c63_terseLabel_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2,000,000,000 ordinary shares of $0.0001 each</link:label>
    <link:label id="lab_legn_AuthorizedShareCapital_label_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorized Share Capital</link:label>
    <link:label id="lab_legn_AuthorizedShareCapital_documentation_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorized share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital" xlink:href="legn-20260331.xsd#legn_AuthorizedShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AuthorizedShareCapital" xlink:to="lab_legn_AuthorizedShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_019d20ae-2422-777e-a25b-92706ef45f01_terseLabel_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_label_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Lease Liabilities</link:label>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities" xlink:href="legn-20260331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseInLeaseLiabilities" xlink:to="lab_legn_IncreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_019d20ae-2381-78dd-8b6f-fe5d1768d347_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019d20ae-2423-7d83-9a54-7775f29e40ef_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_019d20ae-2381-704d-9dd6-350082959591_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss, net</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-2381-78b5-a1b1-4859d05bebb4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019d20ae-2381-70f1-94bf-25c47e45fa39_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-2381-78aa-801d-b9052e0a98b9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_019d20ae-2381-7d0c-af14-cd27663bcc3f_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherGainsLosses_019d20ae-2381-711b-b145-ea419e6ec2b9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_ifrs-full_OtherGainsLosses_019d20ae-2381-772d-8d58-124ab6e0a811_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_ifrs-full_OtherGainsLosses_label_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other gains (losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherGainsLosses" xlink:to="lab_ifrs-full_OtherGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_019d20ae-2381-7d3b-b456-3492127436ca_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue over time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred over time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DecreaseInTimeDeposits_019d20ae-2422-7330-8218-cdae2452919a_terseLabel_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in time deposits</link:label>
    <link:label id="lab_legn_DecreaseInTimeDeposits_label_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Time Deposits</link:label>
    <link:label id="lab_legn_DecreaseInTimeDeposits_documentation_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease in time deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits" xlink:href="legn-20260331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DecreaseInTimeDeposits" xlink:to="lab_legn_DecreaseInTimeDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-2422-729c-99b2-a77011aae237_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operations before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_019d20ae-2381-704e-9a24-de91b2dbe7e4_terseLabel_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in the statement of financial position</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_label_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents As Stated In Statement Of Financial Position</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_documentation_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in statement of financial position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:href="legn-20260331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:to="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019d20ae-2422-76e5-934c-289fe14082c6_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes, net</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019d99c3-7a4a-7f80-a4ec-244adb191765_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration interest-bearing advanced funding</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daeb1-e173-79ca-bfbf-d115b00b26ea_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Interest-bearing Advanced Funding</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_019d20ae-2381-7e15-91b0-38c282826d08_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of collaboration revenue</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d20ae-2381-72be-99ed-faf7dab03aae_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019d20ae-2381-755d-a88b-45b79b296ce9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d20ae-2381-795f-b175-22da509f7bb8_totalLabel_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_label_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivables And Other Assets</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_documentation_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:to="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_019d20ae-2381-79e9-a493-a0e6f448ec72_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_019d20ae-2381-70bc-b027-9ccb0ca1cf72_negatedTerseLabel_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepayment to collaborator for collaboration assets</link:label>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_label_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment To Collaborator For Collaboration Right Of Use Assets</link:label>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_documentation_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment To Collaborator For Collaboration Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:href="legn-20260331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:to="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-2422-78c8-912d-e6cdfd88a2b4_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_019d20ae-2381-76fd-974a-e04c4983459b_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of Range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_019d20ae-2423-78a4-95f1-4fddde5449ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019d20ae-2381-70cf-8f3f-5097040920b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-2422-75bf-b6fe-7d41bf2fbe7f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019dddb4-99a8-708d-979c-d0330771eab6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_019d20ae-2381-722d-9603-3abc0e2d6154_netLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Authorized, price per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_019d20ae-2381-7de7-9648-b9c0b83f2a30_verboseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued and fully paid, price per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_019d20ae-2381-7e30-b3ab-9640750c5397_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_019d20ae-2381-7017-82b4-4bf02662cb60_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_019d9a1d-bd56-77cf-808b-7903dd80eb9f_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_019d20ae-2381-7f40-be67-27c0541c4a52_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_SellingAndDistributionExpenses_019d20ae-2381-7857-beba-86bb3063fe66_negatedTerseLabel_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling and distribution expenses</link:label>
    <link:label id="lab_legn_SellingAndDistributionExpenses_label_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling And Distribution Expenses</link:label>
    <link:label id="lab_legn_SellingAndDistributionExpenses_documentation_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling and distribution expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses" xlink:href="legn-20260331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_SellingAndDistributionExpenses" xlink:to="lab_legn_SellingAndDistributionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_019d20ae-2381-7091-b1e3-2cc8342e278a_periodStartLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_019d20ae-2381-7a7f-8fb6-c404408bbd30_periodEndLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_label_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital And Share Premium</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_documentation_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalAndSharePremium" xlink:to="lab_legn_ShareCapitalAndSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_019d99f0-b283-7d52-b50f-a1ebed162624_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019d20ae-2422-7eee-b276-3b3ca04982fe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_019d20ae-2381-73b0-8af8-16f05ced34b9_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_019d20ae-2422-749d-b9c9-43dea469ba93_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_019e055a-ee99-79b9-b773-e5cfe52731b4_terseLabel_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding principal balance</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_label_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_documentation_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:to="lab_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_019d20ae-2381-7987-b984-fd90a576b867_negatedNetLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7c96-b804-03b9d0711128_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of continuing involvement in derecognised financial assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of continuing involvement in derecognised financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019d20ae-2381-7389-8284-87ecebf3ffac_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_019d20ae-2381-7ef9-b6dc-55a1cf2279e9_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for inventory reserve</link:label>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_label_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Inventory Reserve Provision</link:label>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_documentation_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Inventory Reserve Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision" xlink:href="legn-20260331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForInventoryReserveProvision" xlink:to="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_019d20ae-2381-71dd-b1a8-a7cbda487fcd_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_019d20ae-2381-7d5e-bffe-068bc5d92366_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Prepayments, Other Receivables and Other Assets</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_019d20ae-2422-7bf8-a5a8-cd58c98b3336_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_019d20ae-2381-7ed4-aeec-02a55ed838c8_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained accumulated losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ProceedsFromMilestonePayments_019d20ae-2381-7c0b-a88b-f82099beaa70_terseLabel_en-US" xlink:label="lab_legn_ProceedsFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments recognized as revenue</link:label>
    <link:label id="lab_legn_ProceedsFromMilestonePayments_label_en-US" xlink:label="lab_legn_ProceedsFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Milestone Payments</link:label>
    <link:label id="lab_legn_ProceedsFromMilestonePayments_documentation_en-US" xlink:label="lab_legn_ProceedsFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromMilestonePayments" xlink:href="legn-20260331.xsd#legn_ProceedsFromMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ProceedsFromMilestonePayments" xlink:to="lab_legn_ProceedsFromMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_019d20ae-2381-7093-9f63-1c32166dfb8a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease)/increase in trade payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-2381-7c20-b20f-256cd7760b55_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued and fully paid:</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-2381-785f-b904-00508c692d22_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValueAddedTaxReceivables_019d9a2e-8e96-7b76-b061-69e5635dc952_terseLabel_en-US" xlink:label="lab_ifrs-full_ValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT recoverable</link:label>
    <link:label id="lab_ifrs-full_ValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_ValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValueAddedTaxReceivables" xlink:to="lab_ifrs-full_ValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019d20ae-2423-7e11-88e1-19f819e1ab09_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-2381-78b5-8c30-979128d04042_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_label_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_019d20ae-2381-71ef-9ec8-757f9b13c54c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_019d20ae-2381-7bdf-a324-5449827d2303_terseLabel_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, lease terms</link:label>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_label_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements Leases Term</link:label>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_documentation_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee leasing arrangements leases term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm" xlink:href="legn-20260331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LesseeLeasingArrangementsLeasesTerm" xlink:to="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_019d20ae-2381-7834-9f1e-8aabc5894869_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_019d20ae-2381-7cef-9feb-1f5cdeac2b32_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_019d20ae-2381-7c70-af23-f30d39931398_terseLabel_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vesting of restricted share units</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_label_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_documentation_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted stock units, share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:to="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7976-add5-b2060ad67c28_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of continuing involvement in derecognised financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of continuing involvement in derecognised financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019d20ae-2381-7539-9174-0024447a413f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_019d20ae-2381-7565-ba2d-742d566c8768_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:to="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income and Expense [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income and Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:to="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_019d20ae-2423-7112-bd77-8f059dd0724d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION INVENTORIES, NET</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_019d20ae-2381-7bd7-afda-e254cca2d15f_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Disclosure of Timing of transfer of Goods or Services</link:label>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Timing Of Transfer Of Goods Or Services [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Timing Of Transfer Of Goods Or Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:to="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_019d20ae-2381-7aa3-9d26-0b76f501c458_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income received</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_019d20ae-2381-7e32-801f-cd8229045535_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_019d20ae-2381-78d6-a8e7-8f036a4f70ae_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilities_019d20ae-2381-70b4-84f5-f1e21d3c94c1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax payable</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilities" xlink:to="lab_ifrs-full_CurrentTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_019d20ae-2381-78f1-97e1-a663bd1e286b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_019d20ae-2381-7886-9e3d-42d3b07524f0_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_019d99aa-c24d-7d6d-80a3-9b722a8e71c6_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_019d20ae-2381-7141-93e6-cd003a02b3d0_terseLabel_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest accrued on funding advances</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_label_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings Funded Interests Accrued</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_documentation_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest bearing borrowings funded interests accrued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundedInterestsAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:to="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_019d20ae-2423-7986-a3e9-13473143c1a7_terseLabel_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivable and Other Assets</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_label_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivables And Other Assets [Member]</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_documentation_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments other receivables and other assets.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:to="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-2381-759d-bb86-8c8eb6a9c9bb_terseLabel_en-US" xlink:label="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract_label_en-US" xlink:label="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange differences on translation [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExchangeDifferencesOnTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:to="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019d20ae-2422-79d7-b6b5-d7353eb283a1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in collaboration inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_019d20ae-2381-70bb-8bb8-3e8618b9e0a2_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_019d20ae-2422-7f1f-ac2c-8fdd49b1d364_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019d20ae-2381-74d6-971e-433e841ad022_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal portion of lease payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_019d20ae-2381-7471-91be-005ca44b0d89_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_019d20ae-2381-7f8d-bf29-32b3ce6d074a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_019d20ae-2381-72d3-aaa5-f57bdc94381f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeaseAbstract_label_en-US" xlink:label="lab_legn_LeaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease [Abstract]</link:label>
    <link:label id="lab_legn_LeaseAbstract_documentation_en-US" xlink:label="lab_legn_LeaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract" xlink:href="legn-20260331.xsd#legn_LeaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeaseAbstract" xlink:to="lab_legn_LeaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019d99dd-8204-742e-ad39-7cc0266bc889_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_019d20ae-2381-771a-be62-91baffdb72e6_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Pledged deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_019d20ae-2381-748a-adad-d1ccdd3a17df_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Calculations of Basic and Diluted Loss per Share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_JanssenMember_019d20ae-2381-7314-99be-2a67d1727a4d_terseLabel_en-US" xlink:label="lab_legn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_legn_JanssenMember_label_en-US" xlink:label="lab_legn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_legn_JanssenMember_documentation_en-US" xlink:label="lab_legn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_JanssenMember" xlink:to="lab_legn_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019d20ae-2381-787a-bf56-545f7032598c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterials_019d20ae-2381-79bd-a536-ef6a6edbf47f_terseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_ifrs-full_RawMaterials_label_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current raw materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterials" xlink:to="lab_ifrs-full_RawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_019d20ae-2423-7ddb-b6fa-be31d0776405_terseLabel_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_label_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Times Deposits Current And Noncurrent</link:label>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Times deposits current and noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsCurrentAndNoncurrent" xlink:href="legn-20260331.xsd#legn_TimesDepositsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_TimesDepositsCurrentAndNoncurrent" xlink:to="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_019d20ae-2423-75ce-af18-9ee79a17f7e5_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_019d20ae-2423-7357-a433-1a5384987cd0_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency exchange loss</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ExerciseOfShareOption_019d20ae-2423-717d-a864-191d2a7e34d7_terseLabel_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_legn_ExerciseOfShareOption_label_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Share Option</link:label>
    <link:label id="lab_legn_ExerciseOfShareOption_documentation_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of share option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ExerciseOfShareOption" xlink:to="lab_legn_ExerciseOfShareOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_019d9a1d-bd56-70e2-a9a6-567ec65f0a2e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="lab_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AuthorisedAbstract_019d20ae-2422-7cda-a924-7eb02d6475a2_terseLabel_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized:</link:label>
    <link:label id="lab_legn_AuthorisedAbstract_label_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorised [Abstract]</link:label>
    <link:label id="lab_legn_AuthorisedAbstract_documentation_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract" xlink:href="legn-20260331.xsd#legn_AuthorisedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AuthorisedAbstract" xlink:to="lab_legn_AuthorisedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_019d9a1d-bd56-71c7-ad0d-c6cef3867e34_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d20ae-2381-793a-b201-b2389311ba08_terseLabel_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and other revenue - total</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0f-7be9-7468-8770-7afa7d60bf69_totalLabel_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">License and other revenue - total</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_label_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Licensing Of Intellectual Property and Other</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_documentation_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from licensing of intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:to="lab_legn_RevenueFromLicensingOfIntellectualPropertyAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdditionInTimeDeposits_019d20ae-2423-7ab6-b9ec-8f5f0b4e3e07_negatedTerseLabel_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Addition in time deposits</link:label>
    <link:label id="lab_legn_AdditionInTimeDeposits_label_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Addition In Time Deposits</link:label>
    <link:label id="lab_legn_AdditionInTimeDeposits_documentation_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Addition in time deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits" xlink:href="legn-20260331.xsd#legn_AdditionInTimeDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdditionInTimeDeposits" xlink:to="lab_legn_AdditionInTimeDeposits" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>legn-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d20ae-21e6-738a-906e-3a7605564728,g:650532a9-3221-4d13-8849-474e49aa0ece-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://legendbiotech.com/role/COVER" xlink:type="simple" xlink:href="legn-20260331.xsd#COVER"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019d20ae-21e8-73ea-8014-d6850b820999" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_DocumentType_019d20ae-21e8-73ea-8014-d6850b820999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019d20ae-21e8-7d87-aaf9-e7484c17696b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_EntityRegistrantName_019d20ae-21e8-7d87-aaf9-e7484c17696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019d20ae-21e8-75ae-8910-22424d20c3dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_EntityCentralIndexKey_019d20ae-21e8-75ae-8910-22424d20c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019d20ae-21e8-73fc-8e85-7b0a58046777" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_DocumentPeriodEndDate_019d20ae-21e8-73fc-8e85-7b0a58046777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019d20ae-21e8-7469-b1c2-b624f2adfc56" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_DocumentFiscalYearFocus_019d20ae-21e8-7469-b1c2-b624f2adfc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019d20ae-21e8-79ae-8dd4-73a9de87dfb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019d20ae-21e8-79ae-8dd4-73a9de87dfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019d20ae-21e8-73d7-bcf2-fb85a745fa63" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_CurrentFiscalYearEndDate_019d20ae-21e8-73d7-bcf2-fb85a745fa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019d20ae-21e8-73f9-905d-490bd168c13f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d20ae-21e8-76a8-bebb-2fcdc9f7bc40" xlink:to="loc_dei_AmendmentFlag_019d20ae-21e8-73f9-905d-490bd168c13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_019d20ae-21e8-7286-a311-8825b99544c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_RevenueAbstract_019d20ae-21e8-7286-a311-8825b99544c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d20ae-21e8-7543-94db-2d54929085d5" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019d20ae-21e8-7286-a311-8825b99544c3" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d20ae-21e8-7543-94db-2d54929085d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d20ae-21e8-7f52-982f-868a1b94de5d" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019d20ae-21e8-7286-a311-8825b99544c3" xlink:to="loc_legn_CollaborationRevenue_019d20ae-21e8-7f52-982f-868a1b94de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d626b-44e7-7a84-904c-458ecf272ef6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019d20ae-21e8-7286-a311-8825b99544c3" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d626b-44e7-7a84-904c-458ecf272ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019d20ae-21e8-7268-bb4c-82413c2dfcea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_CostOfSales_019d20ae-21e8-7268-bb4c-82413c2dfcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue_019d20ae-21e8-7978-853d-89073a060832" xlink:href="legn-20260331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_legn_CostOfLicenseAndOtherRevenue_019d20ae-21e8-7978-853d-89073a060832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019d20ae-21e8-7a94-b57b-fcbbdad3be8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019d20ae-21e8-7a94-b57b-fcbbdad3be8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_019d20ae-21e8-7cb9-aff8-4631e4464d05" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_AdministrativeExpense_019d20ae-21e8-7cb9-aff8-4631e4464d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses_019d20ae-21e8-7218-87e3-4fa4308f7929" xlink:href="legn-20260331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_legn_SellingAndDistributionExpenses_019d20ae-21e8-7218-87e3-4fa4308f7929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByFunction_019d99a0-ef22-7b29-8c5a-cbd9bfd3a92d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_OtherExpenseByFunction_019d99a0-ef22-7b29-8c5a-cbd9bfd3a92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99a2-0308-7997-ba71-ccd59a2c041d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019d99a2-0308-7997-ba71-ccd59a2c041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019d20ae-21e8-73a1-96ab-2f98e30365ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_FinanceCosts_019d20ae-21e8-73a1-96ab-2f98e30365ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019d20ae-21e8-76cb-a443-4f0434d48a14" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_FinanceIncome_019d20ae-21e8-76cb-a443-4f0434d48a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_019d20ae-21e8-7c37-83cf-fba3ce6569c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_OtherGainsLosses_019d20ae-21e8-7c37-83cf-fba3ce6569c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-21e8-78d2-b708-0f749971cb31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-21e8-78d2-b708-0f749971cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019d20ae-21e8-7930-b731-2f42142b4fbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019d20ae-21e8-7930-b731-2f42142b4fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d20ae-21e8-767c-84ca-68fa56837690" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_ProfitLoss_019d20ae-21e8-767c-84ca-68fa56837690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_019d20ae-21e8-7d8e-b1f3-ae3114927348" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_019d20ae-21e8-7d8e-b1f3-ae3114927348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_019d20ae-21e8-7197-90d8-4f4332c49f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_019d20ae-21e8-7d8e-b1f3-ae3114927348" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_019d20ae-21e8-7197-90d8-4f4332c49f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_019d20ae-21e8-7cce-8b67-374e383621b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_019d20ae-21e8-7d8e-b1f3-ae3114927348" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_019d20ae-21e8-7cce-8b67-374e383621b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-21e8-7773-b13c-be5d72226897" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExchangeDifferencesOnTranslationAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_019d20ae-21e8-7702-944d-d23fdea18cc1" xlink:to="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-21e8-7773-b13c-be5d72226897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_019d99ad-1812-7497-a230-63fa9035a388" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-21e8-7773-b13c-be5d72226897" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_019d99ad-1812-7497-a230-63fa9035a388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d99ae-6de8-7890-933a-7a96bfb6fa7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_019d99ad-1812-7497-a230-63fa9035a388" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d99ae-6de8-7890-933a-7a96bfb6fa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_019d99ad-a3e8-7162-af42-7253ab2d630b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-21e8-7773-b13c-be5d72226897" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_019d99ad-a3e8-7162-af42-7253ab2d630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019d99ad-a3e8-714e-a0d7-7bcf3e59ce8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_019d20ae-21e8-7773-b13c-be5d72226897" xlink:to="loc_ifrs-full_ComprehensiveIncome_019d99ad-a3e8-714e-a0d7-7bcf3e59ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019d20ae-21e8-7516-8b65-0cba57df3e3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019d20ae-21e8-7516-8b65-0cba57df3e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019d20ae-21e8-77f4-ab76-d6280d5c17b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:to="loc_ifrs-full_RightofuseAssets_019d20ae-21e8-77f4-ab76-d6280d5c17b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases_019d20ae-21e8-7b99-8f72-2fa0bc16f428" xlink:href="legn-20260331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:to="loc_legn_CollaborationPrepaidLeases_019d20ae-21e8-7b99-8f72-2fa0bc16f428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019d20ae-21e8-7b44-8021-5521073697e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_019d20ae-21e8-7b44-8021-5521073697e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019d20ae-21e8-7fc2-b3f7-09ab7878f1b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019d20ae-21e8-76e3-aa09-387ae7ad6ac6" xlink:to="loc_ifrs-full_NoncurrentAssets_019d20ae-21e8-7fc2-b3f7-09ab7878f1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019d20ae-21e8-7ace-891e-fba02398ca67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_ifrs-full_Inventories_019d20ae-21e8-7ace-891e-fba02398ca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019d20ae-21e8-7e80-a436-9c0f7490fae6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019d20ae-21e8-7e80-a436-9c0f7490fae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019d20ae-21e8-7530-8340-195de2ee6693" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019d20ae-21e8-7530-8340-195de2ee6693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimeDeposits_019d20ae-21e8-718e-8c23-5845b10a84b0" xlink:href="legn-20260331.xsd#legn_TimeDeposits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_legn_TimeDeposits_019d20ae-21e8-718e-8c23-5845b10a84b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019d20ae-21e8-72d0-9d98-fcd2fa46c1ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019d20ae-21e8-72d0-9d98-fcd2fa46c1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019d20ae-21e8-797c-93db-690c5b69098e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_019d20ae-21e8-78bf-bb0f-c239b2f635df" xlink:to="loc_ifrs-full_CurrentAssets_019d20ae-21e8-797c-93db-690c5b69098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019d20ae-21e8-7146-a0af-17e8a5155a49" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_Assets_019d20ae-21e8-7146-a0af-17e8a5155a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_019d20ae-21e8-746e-9948-4d5c016ecc8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_019d20ae-21e8-746e-9948-4d5c016ecc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_019d20ae-22c3-7d2a-907b-cf6b076c22a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_019d20ae-22c3-7d2a-907b-cf6b076c22a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_019d20ae-21e8-700b-850c-05344700bff6" xlink:href="legn-20260331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_legn_OtherPayablesAndAccrualsCurrent_019d20ae-21e8-700b-850c-05344700bff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c3-746a-b1be-e687f7f53acc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c3-746a-b1be-e687f7f53acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_019d20ae-22c3-7d43-91bc-d31cbc363cff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_CurrentContractLiabilities_019d20ae-22c3-7d43-91bc-d31cbc363cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019d99c3-7a4a-7358-b09b-2aa98c6e7e23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019d99c3-7a4a-7358-b09b-2aa98c6e7e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_019d99c3-f354-74f6-a59b-35eb145214b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_019d99c3-f354-74f6-a59b-35eb145214b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019d20ae-22c3-7aa4-8dcf-5307ab76294e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_019d20ae-21e8-7ff6-b7a8-99c44b0b388d" xlink:to="loc_ifrs-full_CurrentLiabilities_019d20ae-22c3-7aa4-8dcf-5307ab76294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-22c3-72e3-bb2d-fc70c73f761e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-22c3-72e3-bb2d-fc70c73f761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c3-7231-8b7b-34b150e718c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-22c3-72e3-bb2d-fc70c73f761e" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c3-7231-8b7b-34b150e718c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_019d99c6-808d-72b3-911c-c95c316b1af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-22c3-72e3-bb2d-fc70c73f761e" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_019d99c6-808d-72b3-911c-c95c316b1af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c3-7035-a0b9-d7423d7175e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_019d20ae-22c3-72e3-bb2d-fc70c73f761e" xlink:to="loc_ifrs-full_NoncurrentLiabilities_019d20ae-22c3-7035-a0b9-d7423d7175e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_019d20ae-22c3-75b0-899d-87939e4337ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_Liabilities_019d20ae-22c3-75b0-899d-87939e4337ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_019d20ae-22c3-75d9-94eb-b9ce588ea075" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_EquityAbstract_019d20ae-22c3-75d9-94eb-b9ce588ea075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019d20ae-22c3-7214-afff-eb6370a694ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_019d20ae-22c3-75d9-94eb-b9ce588ea075" xlink:to="loc_ifrs-full_IssuedCapital_019d20ae-22c3-7214-afff-eb6370a694ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_019d20ae-22c3-7017-b1d6-86c9b8ad7a65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_019d20ae-22c3-75d9-94eb-b9ce588ea075" xlink:to="loc_ifrs-full_OtherReserves_019d20ae-22c3-7017-b1d6-86c9b8ad7a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c3-7386-ab76-b19073691b20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_019d20ae-22c3-75d9-94eb-b9ce588ea075" xlink:to="loc_ifrs-full_Equity_019d20ae-22c3-7386-ab76-b19073691b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_019d20ae-22c3-7a1c-8055-0b14f5351785" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-21e8-7e0c-9b01-f02ff119e731" xlink:to="loc_ifrs-full_EquityAndLiabilities_019d20ae-22c3-7a1c-8055-0b14f5351785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_019d20ae-22c4-7ac8-8453-10b6c76e4ec3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_019d20ae-22c4-7ac8-8453-10b6c76e4ec3" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c4-7494-959f-1991613d8005" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c4-7a61-b5da-dbadd1e062e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c4-7a61-b5da-dbadd1e062e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019d20ae-22c4-7e62-8561-afe71f2fa848" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_SharePremiumMember_019d20ae-22c4-7e62-8561-afe71f2fa848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019d20ae-22c4-77fd-808e-ad26419fce3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019d20ae-22c4-77fd-808e-ad26419fce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_019d20ae-22c4-7c8a-9955-422105cffd10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_019d20ae-22c4-7c8a-9955-422105cffd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_019d20ae-22c4-7e64-87f8-0f914157b14a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c4-798e-a395-79e458f9f878" xlink:to="loc_ifrs-full_RetainedEarningsMember_019d20ae-22c4-7e64-87f8-0f914157b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019d20ae-22c4-7979-a543-d9c4d1bf7381" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c4-79df-8781-baff693be861" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_Equity_019d20ae-22c4-79df-8781-baff693be861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d20ae-22c4-7325-9b6e-1b270ec1b4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_ProfitLoss_019d20ae-22c4-7325-9b6e-1b270ec1b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7a77-9882-2cd88ac45f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019d20ae-22c4-7fc6-8812-d6c93f8037db" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_019d20ae-22c4-7a77-9882-2cd88ac45f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7de0-904d-86cfb800ce7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_ComprehensiveIncome_019d20ae-22c4-7de0-904d-86cfb800ce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019d20ae-22c4-7af3-b9c8-c280ab4700f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019d20ae-22c4-7af3-b9c8-c280ab4700f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_019d20ae-22c4-7836-9223-2c380c8ca8f3" xlink:href="legn-20260331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_019d20ae-22c4-7836-9223-2c380c8ca8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_019d20ae-22c4-7d7e-bc0a-409529ed8a4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_019d20ae-22c4-7d7e-bc0a-409529ed8a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019d20ae-22c4-73f9-ad42-cfc8cfd00e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_Equity_019d20ae-22c4-73f9-ad42-cfc8cfd00e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_019d20ae-22c4-7186-ad44-6fcd970f2903" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019d20ae-22c4-7ae6-a1a1-18e321a5d828" xlink:to="loc_ifrs-full_OtherReserves_019d20ae-22c4-7186-ad44-6fcd970f2903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="legn-20260331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-22c4-7405-8b0d-ddce7e8d3a1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-22c4-7405-8b0d-ddce7e8d3a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-22c4-7dcb-956f-3b096df6bea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-22c4-7405-8b0d-ddce7e8d3a1e" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_019d20ae-22c4-7dcb-956f-3b096df6bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-22c4-7405-8b0d-ddce7e8d3a1e" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_019d20ae-22c4-7c8d-a725-baf975eb0693" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_019d20ae-22c4-7c8d-a725-baf975eb0693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_019d20ae-22c4-7d5d-96f5-ce9ebad6792f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_019d20ae-22c4-7d5d-96f5-ce9ebad6792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision_019d20ae-22c4-79f6-8741-c75be9409bb6" xlink:href="legn-20260331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_legn_AdjustmentsForInventoryReserveProvision_019d20ae-22c4-79f6-8741-c75be9409bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_019d20ae-22c4-79d6-90ce-df90690a5ffd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_019d20ae-22c4-79d6-90ce-df90690a5ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_019d20ae-22c4-7c00-8b44-2d9bff0798cd" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_019d20ae-22c4-7c00-8b44-2d9bff0798cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_019d20ae-22c4-78ea-8e57-439419181ac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_019d20ae-22c4-78ea-8e57-439419181ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_019d20ae-22c4-737f-92c6-6b360b9e7f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_019d20ae-22c4-737f-92c6-6b360b9e7f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019d99dd-8204-7f0a-8d83-810bf505388d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019d99dd-8204-7f0a-8d83-810bf505388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b8b-9f8b-cfce5f46cabd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019d20ae-22c4-7b8b-9f8b-cfce5f46cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019d20ae-22c4-727e-b065-68364fa3ea25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019d20ae-22c4-727e-b065-68364fa3ea25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_019d20ae-22c4-715a-bb71-57a5d8b80ae8" xlink:href="legn-20260331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_019d20ae-22c4-715a-bb71-57a5d8b80ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019d20ae-22c4-70ab-836c-c9c63d1e57f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019d20ae-22c4-70ab-836c-c9c63d1e57f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_019d20ae-22c4-7bf6-9189-df04678cfb52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_019d20ae-22c4-7bf6-9189-df04678cfb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_019d20ae-22c4-7ea9-80f2-a80c90769f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_019d20ae-22c4-7ea9-80f2-a80c90769f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_019d62d5-caf1-7a96-9655-843d6dfa69a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_019d62d5-caf1-7a96-9655-843d6dfa69a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_019d99e5-3c35-78a6-87a4-8bb9d3b1c9a9" xlink:href="legn-20260331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet_019d99e5-3c35-78a6-87a4-8bb9d3b1c9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_019d20ae-22c4-729f-8518-12d5237f0648" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_019d20ae-22c4-729f-8518-12d5237f0648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_019d99f0-a72a-7782-93c9-299284bb8b92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_019d20ae-22c4-712b-9ca7-b16d83f08edc" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_019d99f0-a72a-7782-93c9-299284bb8b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d99ed-3b5f-756c-809d-55f9c8a36421" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019d20ae-22c4-7405-8b0d-ddce7e8d3a1e" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019d99ed-3b5f-756c-809d-55f9c8a36421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019d20ae-22c4-7fea-baeb-b698ff320354" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019d20ae-22c4-7fea-baeb-b698ff320354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_019d20ae-22c4-74ad-8d16-b54d977d62b2" xlink:href="legn-20260331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:to="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_019d20ae-22c4-74ad-8d16-b54d977d62b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits_019d20ae-22c4-7445-856d-3f1958617eda" xlink:href="legn-20260331.xsd#legn_AdditionInTimeDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:to="loc_legn_AdditionInTimeDeposits_019d20ae-22c4-7445-856d-3f1958617eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits_019d20ae-22c4-7eec-a21d-dd6d78767b38" xlink:href="legn-20260331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:to="loc_legn_DecreaseInTimeDeposits_019d20ae-22c4-7eec-a21d-dd6d78767b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-738b-a000-b0731d0ab7df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019d20ae-22c4-7b40-861f-747f635116cb" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019d20ae-22c4-738b-a000-b0731d0ab7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-22c4-78bb-9fb8-b8736343fa1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-22c4-78bb-9fb8-b8736343fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_019d20ae-22c4-76a8-9622-44f188222cf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-22c4-78bb-9fb8-b8736343fa1d" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_019d20ae-22c4-76a8-9622-44f188222cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019d20ae-22c4-75d6-a941-4ff1a083e293" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-22c4-78bb-9fb8-b8736343fa1d" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019d20ae-22c4-75d6-a941-4ff1a083e293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-701d-b3b5-beb30c35b034" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019d20ae-22c4-78bb-9fb8-b8736343fa1d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019d20ae-22c4-701d-b3b5-beb30c35b034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019d20ae-22c4-7f07-890f-a3b5f77b37a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019d20ae-22c4-7f07-890f-a3b5f77b37a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-75f6-b2e3-ef81ced76566" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019d20ae-22c4-75f6-b2e3-ef81ced76566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-7970-9202-e48030bddd36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-7970-9202-e48030bddd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-789f-939a-fd9285885e18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019d20ae-22c4-789f-939a-fd9285885e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_019d20ae-22c4-7aff-be6a-8798f91fe14e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:to="loc_ifrs-full_Cash_019d20ae-22c4-7aff-be6a-8798f91fe14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_019d20ae-22c4-745c-b90d-751cab863b0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_019d20ae-22c4-745c-b90d-751cab863b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsCurrentAndNoncurrent_019d20ae-22c4-761a-9aef-72f2acd41a2e" xlink:href="legn-20260331.xsd#legn_TimesDepositsCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:to="loc_legn_TimesDepositsCurrentAndNoncurrent_019d20ae-22c4-761a-9aef-72f2acd41a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_019d20ae-22c4-7b1a-a49a-e241260cb298" xlink:href="legn-20260331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019d20ae-22c4-779a-8e13-af556fbf7344" xlink:to="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_019d20ae-22c4-7b1a-a49a-e241260cb298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SupplementalCashFlowInformationAbstract_019df61a-23ae-7be7-8738-fd6adffaac39" xlink:href="legn-20260331.xsd#legn_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019d20ae-22c4-70f8-a0ef-8b21f1e5de43" xlink:to="loc_legn_SupplementalCashFlowInformationAbstract_019df61a-23ae-7be7-8738-fd6adffaac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding_019df649-340e-7f5f-891a-1dd88fbb8e38" xlink:href="legn-20260331.xsd#legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_SupplementalCashFlowInformationAbstract_019df61a-23ae-7be7-8738-fd6adffaac39" xlink:to="loc_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding_019df649-340e-7f5f-891a-1dd88fbb8e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CORPORATEINFORMATION" xlink:type="simple" xlink:href="legn-20260331.xsd#CORPORATEINFORMATION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CORPORATEINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_019d20ae-22c4-7f6f-9b66-7ddf40470afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_019d20ae-22c4-73c8-a45e-9185b8d6c260" xlink:href="legn-20260331.xsd#legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_019d20ae-22c4-7f6f-9b66-7ddf40470afd" xlink:to="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_019d20ae-22c4-73c8-a45e-9185b8d6c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/BASISOFPREPARATION" xlink:type="simple" xlink:href="legn-20260331.xsd#BASISOFPREPARATION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/BASISOFPREPARATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_BasisOfPreparationAbstract_019d20ae-22c4-76c6-84c6-7e77b02b7b5b" xlink:href="legn-20260331.xsd#legn_BasisOfPreparationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019d20ae-22c4-712b-8759-c78b352b5ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_BasisOfPreparationAbstract_019d20ae-22c4-76c6-84c6-7e77b02b7b5b" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019d20ae-22c4-712b-8759-c78b352b5ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" xlink:type="simple" xlink:href="legn-20260331.xsd#NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_019d20ae-22c4-7537-a348-3461ea9b513b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019d20ae-22c4-7119-96b6-d1af62d2b847" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_019d20ae-22c4-7537-a348-3461ea9b513b" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019d20ae-22c4-7119-96b6-d1af62d2b847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUE" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7f90-a483-9adcf0763e1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_019d20ae-22c4-7dcb-bdcd-2793d728ebf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7f90-a483-9adcf0763e1b" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_019d20ae-22c4-7dcb-bdcd-2793d728ebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET" xlink:type="simple" xlink:href="legn-20260331.xsd#OTHEREXPENSEINCOMENET"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-70a5-ad81-ac444501e300" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeExpenseNetTextBlock_019d6309-d9a8-735c-a29b-67be7771e7f5" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeExpenseNetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-70a5-ad81-ac444501e300" xlink:to="loc_legn_DisclosureOfOtherIncomeExpenseNetTextBlock_019d6309-d9a8-735c-a29b-67be7771e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="legn-20260331.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_019d20ae-22c4-7615-8e92-7738b675f7e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019d20ae-22c4-7f2d-8a4c-be7065ab51d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_019d20ae-22c4-7615-8e92-7738b675f7e7" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019d20ae-22c4-7f2d-8a4c-be7065ab51d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASES" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_019d20ae-22c4-7d13-a577-09e68d89519a" xlink:href="legn-20260331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_019d20ae-22c4-7bd6-a8eb-b2e2f780f482" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-7d13-a577-09e68d89519a" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_019d20ae-22c4-7bd6-a8eb-b2e2f780f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINVENTORIESNET"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7785-81c3-1368e1ab43a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_019d20ae-22c5-792a-88ec-73c8ed196b4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7785-81c3-1368e1ab43a0" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_019d20ae-22c5-792a-88ec-73c8ed196b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" xlink:type="simple" xlink:href="legn-20260331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-72ad-a3c2-1c54e9ea4fff" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_019d20ae-22c5-74a1-af44-8b26e614440a" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-72ad-a3c2-1c54e9ea4fff" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_019d20ae-22c5-74a1-af44-8b26e614440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDING"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-7a06-afed-db8d737e5611" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_019d20ae-22c5-7755-81ba-218001366f74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-7a06-afed-db8d737e5611" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_019d20ae-22c5-7755-81ba-218001366f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUM"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-740b-a45c-bc5fea5a1fc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019d20ae-22c5-7393-b518-4b31800fac87" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-740b-a45c-bc5fea5a1fc4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019d20ae-22c5-7393-b518-4b31800fac87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="legn-20260331.xsd#APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-22c5-7e35-bcbc-1aa7dd3b28f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_019d20ae-22c5-716c-bee6-193b77ba82ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019d20ae-22c5-7e35-bcbc-1aa7dd3b28f7" xlink:to="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_019d20ae-22c5-716c-bee6-193b77ba82ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="legn-20260331.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_019d20ae-22c5-772d-8d72-70bf5f606173" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_019d20ae-22c5-77e2-a732-fcf3d132ba84" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_019d20ae-22c5-772d-8d72-70bf5f606173" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_019d20ae-22c5-77e2-a732-fcf3d132ba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUETables" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7870-98d5-f3c7ae8fe1c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019d20ae-22c4-7142-a278-4dd57d70cb5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7870-98d5-f3c7ae8fe1c1" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019d20ae-22c4-7142-a278-4dd57d70cb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019d20ae-22c4-73fa-9f4f-9629b0ce4ef1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7870-98d5-f3c7ae8fe1c1" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019d20ae-22c4-73fa-9f4f-9629b0ce4ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_019d20ae-22c4-7ffe-b077-943b5ada4f9d" xlink:href="legn-20260331.xsd#legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7870-98d5-f3c7ae8fe1c1" xlink:to="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_019d20ae-22c4-7ffe-b077-943b5ada4f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="simple" xlink:href="legn-20260331.xsd#OTHEREXPENSEINCOMENETTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-784b-b5be-dac8813bf4e7" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_019d20ae-22c4-7cd3-8008-75b33f1fcbf9" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-784b-b5be-dac8813bf4e7" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_019d20ae-22c4-7cd3-8008-75b33f1fcbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="legn-20260331.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_019d20ae-22c4-737e-bde7-19e323c6d0ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_019d20ae-22c4-7e67-bc8f-b72317995bde" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_019d20ae-22c4-737e-bde7-19e323c6d0ca" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_019d20ae-22c4-7e67-bc8f-b72317995bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESTables" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_019d20ae-22c4-777d-b929-c2c02c61bfc5" xlink:href="legn-20260331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_019d20ae-22c4-796e-bd83-debc4b7b2515" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-777d-b929-c2c02c61bfc5" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_019d20ae-22c4-796e-bd83-debc4b7b2515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeaseLiabilitiesTextBlock_019d20ae-22c4-77f6-84eb-55f8e56a7cec" xlink:href="legn-20260331.xsd#legn_LesseeLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-777d-b929-c2c02c61bfc5" xlink:to="loc_legn_LesseeLeaseLiabilitiesTextBlock_019d20ae-22c4-77f6-84eb-55f8e56a7cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINVENTORIESNETTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7575-86d7-d79360771bac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_019d20ae-22c5-7dbc-8d2e-4da25f8e2527" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7575-86d7-d79360771bac" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_019d20ae-22c5-7dbc-8d2e-4da25f8e2527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" xlink:type="simple" xlink:href="legn-20260331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-7fa8-b00d-3ccb8f26c500" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_019d20ae-22c5-704e-92e3-abddaddce971" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-7fa8-b00d-3ccb8f26c500" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_019d20ae-22c5-704e-92e3-abddaddce971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-71c9-b586-b02558193647" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_019d20ae-22c5-793c-ab89-356366c7cd02" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-71c9-b586-b02558193647" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_019d20ae-22c5-793c-ab89-356366c7cd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUMTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-7657-8c1b-69d5c4759318" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019d20ae-22c5-7a79-b48e-722e5712e5a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-7657-8c1b-69d5c4759318" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019d20ae-22c5-7a79-b48e-722e5712e5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_019d20ae-22c5-7612-9980-1652a0d813a7" xlink:href="legn-20260331.xsd#legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-7657-8c1b-69d5c4759318" xlink:to="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_019d20ae-22c5-7612-9980-1652a0d813a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUESummaryofAnalysisofRevenueDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7058-a4de-5327cad2fd6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7058-a4de-5327cad2fd6e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:to="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d20ae-22c4-7c8b-9cc8-ac89ff9d292f" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember_019d20ae-22c4-7320-8904-42c55b3df2ac" xlink:href="legn-20260331.xsd#legn_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:to="loc_legn_NovartisMember_019d20ae-22c4-7320-8904-42c55b3df2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RelatedPartySublicenseMember_019ddd83-8e79-7360-8b60-01ec981f8bf3" xlink:href="legn-20260331.xsd#legn_RelatedPartySublicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d20ae-22c4-788d-bc99-248c8ca0c4dc" xlink:to="loc_legn_RelatedPartySublicenseMember_019ddd83-8e79-7360-8b60-01ec981f8bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-70ce-b733-e70008aec2fd" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0d-71c7-7e0d-998c-3bdb40ce0ade" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_019d9a0d-71c7-7e0d-998c-3bdb40ce0ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019d9a0d-71c7-7088-8828-80a8b2455b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_ifrs-full_OtherRevenue_019d9a0d-71c7-7088-8828-80a8b2455b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0d-71c7-7e6d-8853-da326ffa30b3" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019d9a0d-71c7-7e6d-8853-da326ffa30b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d9a0d-71c7-736b-b44d-10fadd209943" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_legn_CollaborationRevenue_019d9a0d-71c7-736b-b44d-10fadd209943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d9a0d-71c7-798d-a4f0-f1bf16b36599" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-79a3-931f-f7e4d9639129" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d9a0d-71c7-798d-a4f0-f1bf16b36599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUESummaryofRevenueDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-763a-9ab1-eaaea5e5e79f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-763a-9ab1-eaaea5e5e79f" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:to="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019d20ae-22c4-72bd-b930-417483a6e3b1" xlink:to="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019d20ae-22c4-72ba-9a80-717f2ab1b09a" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_country_US_019d20ae-22c4-72ba-9a80-717f2ab1b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019d20ae-22c4-7346-a082-4d5e27445f31" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_country_CN_019d20ae-22c4-7346-a082-4d5e27445f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OutsideTheUnitedStatesOfAmericaMember_019e0064-95f1-7a8a-814d-af28766f8a64" xlink:href="legn-20260331.xsd#legn_OutsideTheUnitedStatesOfAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019d20ae-22c4-72ba-8336-2ab62a09c790" xlink:to="loc_legn_OutsideTheUnitedStatesOfAmericaMember_019e0064-95f1-7a8a-814d-af28766f8a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019d20ae-22c4-79c4-bcaa-ad88f6894ea4" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019daea1-0aa3-7c74-a51e-3db03a8d3464" xlink:href="legn-20260331.xsd#legn_RevenueFromLicensingOfIntellectualPropertyAndOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualPropertyAndOther_019daea1-0aa3-7c74-a51e-3db03a8d3464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_019d20ae-22c4-7c4c-a300-8932c5208260" xlink:href="legn-20260331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_legn_CollaborationRevenue_019d20ae-22c4-7c4c-a300-8932c5208260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_019d20ae-22c4-76bb-a990-58d02b553474" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-720a-994d-65af76b36163" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_019d20ae-22c4-76bb-a990-58d02b553474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7769-bed4-a6b75ec3464c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_019d20ae-22c4-7769-bed4-a6b75ec3464c" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_019d20ae-22c4-7ffd-a890-f927447272a6" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_019d20ae-22c4-7f62-a16e-26e3dc8dd653" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_019d20ae-22c4-7f62-a16e-26e3dc8dd653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_019d20ae-22c4-7b32-af40-32338811df30" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_019d20ae-22c4-796c-b2b9-f5c9af74f0e5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_019d20ae-22c4-7b32-af40-32338811df30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019d20ae-22c4-7dea-9771-1273b4d6968a" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_019d20ae-22c4-78e7-910e-0e713d1fb1df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019d20ae-22c4-734c-a0cf-d976a53c8825" xlink:to="loc_ifrs-full_Revenue_019d20ae-22c4-78e7-910e-0e713d1fb1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#OTHEREXPENSEINCOMENETDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-7be0-ba7b-5158a63cc5a6" xlink:href="legn-20260331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_019d20ae-22c4-768e-a435-5206c1f06310" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-7be0-ba7b-5158a63cc5a6" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_019d20ae-22c4-768e-a435-5206c1f06310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense_019d20ae-22c4-7a40-ac02-615ccf804494" xlink:href="legn-20260331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-7be0-ba7b-5158a63cc5a6" xlink:to="loc_legn_OtherMiscellaneousIncomeExpense_019d20ae-22c4-7a40-ac02-615ccf804494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_019d20ae-22c4-7790-9a87-a20bd0df2636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_019d20ae-22c4-7be0-ba7b-5158a63cc5a6" xlink:to="loc_ifrs-full_OtherGainsLosses_019d20ae-22c4-7790-9a87-a20bd0df2636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_019d9a1d-bd56-7ce1-82cc-6e209b287aee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019d9a1d-bd56-703f-bc48-4cd2b9d23368" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_019d9a1d-bd56-7ce1-82cc-6e209b287aee" xlink:to="loc_ifrs-full_ProfitLoss_019d9a1d-bd56-703f-bc48-4cd2b9d23368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_019d9a1d-bd56-7b7b-855e-e4d3692e896d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_019d9a1d-bd56-7ce1-82cc-6e209b287aee" xlink:to="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_019d9a1d-bd56-7b7b-855e-e4d3692e896d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_019d9a1d-bd56-7cae-b0f7-33ff186c41e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_019d9a1d-bd56-7b7b-855e-e4d3692e896d" xlink:to="loc_ifrs-full_WeightedAverageShares_019d9a1d-bd56-7cae-b0f7-33ff186c41e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_019d9a1d-bd56-79b7-be54-02ea329bc0e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_019d9a1d-bd56-7b7b-855e-e4d3692e896d" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_019d9a1d-bd56-79b7-be54-02ea329bc0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_019d9a1d-bd56-7ec5-a8de-7622f154e190" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_019d9a1d-bd56-7ce1-82cc-6e209b287aee" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_019d9a1d-bd56-7ec5-a8de-7622f154e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_019d9a1d-bd56-7e99-a456-c5182ee27f64" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_019d9a1d-bd56-7ec5-a8de-7622f154e190" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_019d9a1d-bd56-7e99-a456-c5182ee27f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_019d9a1d-bd56-722d-8a34-3abc1c69927c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_019d9a1d-bd56-7ec5-a8de-7622f154e190" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_019d9a1d-bd56-722d-8a34-3abc1c69927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:href="legn-20260331.xsd#legn_LeasesTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_019e0548-240d-7161-8ca6-a329bf737e05" xlink:to="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019e0548-240d-728e-a7be-08bbe37f6c20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:to="loc_ifrs-full_BottomOfRangeMember_019e0548-240d-728e-a7be-08bbe37f6c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019e0548-240d-7d16-9a62-a96f1aebdb0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019e0548-240d-7423-9157-f281346cbb5f" xlink:to="loc_ifrs-full_TopOfRangeMember_019e0548-240d-7d16-9a62-a96f1aebdb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019e0548-240d-7c5b-8217-e0ee091d3458" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_019e0548-240d-7da8-9f0d-75b0c624fb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019e0548-240d-7d63-8e63-94a39ecc3c6f" xlink:to="loc_ifrs-full_LandMember_019e0548-240d-7da8-9f0d-75b0c624fb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019e0549-180f-73b8-bad4-0bfe90c5a8ac" xlink:to="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019e0549-180f-78d7-a97e-695ff31b8ad3" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019e0549-180f-7d85-bac1-944c85083b73" xlink:to="loc_legn_JanssenMember_019e0549-180f-78d7-a97e-695ff31b8ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:href="legn-20260331.xsd#legn_LeasesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_019e0548-240d-7045-a362-4cb9b8447d33" xlink:to="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm_019e0548-240d-768f-84c7-04975de5f6a1" xlink:href="legn-20260331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_LesseeLeasingArrangementsLeasesTerm_019e0548-240d-768f-84c7-04975de5f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease_019e0548-240d-7a4e-8471-d8e4f8755cc4" xlink:href="legn-20260331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_OngoingLeasePaymentsUnderTheLandLease_019e0548-240d-7a4e-8471-d8e4f8755cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_019e0549-180f-7ce0-8e78-01b588a5726a" xlink:href="legn-20260331.xsd#legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement_019e0549-180f-7ce0-8e78-01b588a5726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019e0549-180f-7016-a2d5-2509c4119ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_LeaseLiabilities_019e0549-180f-7016-a2d5-2509c4119ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables_019e0549-180f-78ed-8739-9cdc6bb0b73a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_FinanceLeaseReceivables_019e0549-180f-78ed-8739-9cdc6bb0b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019e0549-180f-7752-b9d9-65b6ffc6c29f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_019e0549-180f-7752-b9d9-65b6ffc6c29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinanceLeaseReceivables_019e0549-180f-7b8f-a0d6-fde298692dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentFinanceLeaseReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_CurrentFinanceLeaseReceivables_019e0549-180f-7b8f-a0d6-fde298692dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_019e0549-180f-7285-a98c-d7f7f4dba6dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_019e0548-240d-77db-8833-18305e5a5cbe" xlink:to="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_019e0549-180f-7285-a98c-d7f7f4dba6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:href="legn-20260331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019d20ae-22c4-71b8-b35c-ef1435b5eecb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:to="loc_ifrs-full_RightofuseAssets_019d20ae-22c4-71b8-b35c-ef1435b5eecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_019d20ae-22c4-7ee5-b271-dc2f7269bb73" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_019d20ae-22c4-7ee5-b271-dc2f7269bb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_019d20ae-22c4-786a-8ab2-141f3d4eb2a6" xlink:href="legn-20260331.xsd#legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:to="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_019d20ae-22c4-786a-8ab2-141f3d4eb2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_019d20ae-22c4-719f-854d-4245883a00ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_019d20ae-22c4-719f-854d-4245883a00ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019d20ae-22c4-7e5e-b046-90a5928312f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-75da-988c-9505a9a19179" xlink:to="loc_ifrs-full_RightofuseAssets_019d20ae-22c4-7e5e-b046-90a5928312f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_019d20ae-22c4-74f8-af66-77032a3f1ec0" xlink:href="legn-20260331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_019d20ae-22c4-74f8-af66-77032a3f1ec0" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_019d20ae-22c4-7f2b-8816-299cc056fc8a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_019d20ae-22c4-70ac-baec-c1d6f242f08c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_019d20ae-22c4-7b01-bdb3-91969f24bf91" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_019d20ae-22c4-70ac-baec-c1d6f242f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:to="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019dfb93-67d0-7ce6-a90e-169723625746" xlink:to="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019dfb93-ac42-7a9e-aec4-b9fbd84e13d9" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019dfb93-67d0-7588-879e-d10c20c4ee37" xlink:to="loc_legn_JanssenMember_019dfb93-ac42-7a9e-aec4-b9fbd84e13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:href="legn-20260331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_019d20ae-22c4-79b0-9943-61908ac010de" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-77c4-bba4-a8ba6fba4d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-77c4-bba4-a8ba6fba4d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities_019d20ae-22c4-739f-b801-855264d5fa12" xlink:href="legn-20260331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_legn_IncreaseInLeaseLiabilities_019d20ae-22c4-739f-b801-855264d5fa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance_019d20ae-22c4-7538-8dd6-b0ada65fe8b5" xlink:href="legn-20260331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_legn_IncreaseOfLeaseLiabilitiesBalance_019d20ae-22c4-7538-8dd6-b0ada65fe8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_019d20ae-22c4-74dc-9d8d-f0c51f1566b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_CashOutflowForLeases_019d20ae-22c4-74dc-9d8d-f0c51f1566b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_019d20ae-22c4-7604-8198-057b3998e05d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_019d20ae-22c4-7604-8198-057b3998e05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-726d-8189-69fa410be928" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-726d-8189-69fa410be928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_019d20ae-22c4-77e2-89e0-8871f7f6177f" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-743d-a432-193c1294a763" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019d20ae-22c4-743d-a432-193c1294a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-79f4-b2d4-e3cf6c1ce5ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019d20ae-22c4-79f4-b2d4-e3cf6c1ce5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-7501-9d2c-e1df528603c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_019d20ae-22c4-7749-a504-425108506573" xlink:to="loc_ifrs-full_LeaseLiabilities_019d20ae-22c4-7501-9d2c-e1df528603c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7949-901d-235752405aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_019d20ae-22c5-730b-8267-7cfb19337c1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7949-901d-235752405aea" xlink:to="loc_ifrs-full_RawMaterials_019d20ae-22c5-730b-8267-7cfb19337c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_019d20ae-22c5-77a1-b2d9-c3ab8d96ac16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7949-901d-235752405aea" xlink:to="loc_ifrs-full_WorkInProgress_019d20ae-22c5-77a1-b2d9-c3ab8d96ac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_019d20ae-22c5-79d7-a070-d76fbf93ce21" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7949-901d-235752405aea" xlink:to="loc_ifrs-full_FinishedGoods_019d20ae-22c5-79d7-a070-d76fbf93ce21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019d20ae-22c5-7978-b56e-1b08c3510fb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-7949-901d-235752405aea" xlink:to="loc_ifrs-full_Inventories_019d20ae-22c5-7978-b56e-1b08c3510fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINVENTORIESNETAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-79ec-a29b-3eab9dabb5b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InventoryReserve_019d20ae-22c5-733d-9574-699ed1d9ff0f" xlink:href="legn-20260331.xsd#legn_InventoryReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_019d20ae-22c5-79ec-a29b-3eab9dabb5b8" xlink:to="loc_legn_InventoryReserve_019d20ae-22c5-733d-9574-699ed1d9ff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-7384-8a3e-a3cf09931523" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_019d20ae-22c5-7384-8a3e-a3cf09931523" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_019d20ae-22c5-79cd-b89b-d0a5ee037250" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_019d20ae-22c5-7b6c-bc3e-057146932afd" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_019d20ae-22c5-7889-8e06-8fcf71de8276" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_019d20ae-22c5-7b6c-bc3e-057146932afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:href="legn-20260331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_019d20ae-22c5-78bf-995f-21fd419ee617" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_019d9a2e-8e96-7c04-b3f4-2f7770620ec1" xlink:href="legn-20260331.xsd#legn_OtherCollaborationReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_legn_OtherCollaborationReceivables_019d9a2e-8e96-7c04-b3f4-2f7770620ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_019d9a2e-8e96-7d46-88ed-ffd8517c4c76" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_019d9a2e-8e96-7d46-88ed-ffd8517c4c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_019d9a2e-8e96-7d31-948c-756c2b2f8fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Prepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_Prepayments_019d9a2e-8e96-7d31-948c-756c2b2f8fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_019d9a2e-8e96-72a7-992a-504ba35edcd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_ifrs-full_OtherCurrentAssets_019d9a2e-8e96-72a7-992a-504ba35edcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d9a2e-8e96-74bf-978c-8f817d615da2" xlink:href="legn-20260331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_019d20ae-22c5-752b-b680-f1b51932a926" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_019d9a2e-8e96-74bf-978c-8f817d615da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-733a-b438-86286e88904f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019d633c-0e2d-7094-9aab-b178a69bae8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-733a-b438-86286e88904f" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019d633c-0e2d-7094-9aab-b178a69bae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daea9-4b79-7cb3-894f-19f1c5063e74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-733a-b438-86286e88904f" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daea9-4b79-7cb3-894f-19f1c5063e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-76f2-9469-e34d2c0dba36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_019d20ae-22c5-76f2-9469-e34d2c0dba36" xlink:to="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:to="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019d9a4c-7181-76ab-8b1b-dc70f85ba04e" xlink:to="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_JanssenMember_019d9a4c-7181-7108-a1b8-2b31f9700c86" xlink:href="legn-20260331.xsd#legn_JanssenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019d9a4c-7181-7339-ae55-ba9736dd775c" xlink:to="loc_legn_JanssenMember_019d9a4c-7181-7108-a1b8-2b31f9700c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable_019d9a4c-7181-7172-abf9-57e7a528fe55" xlink:to="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvances_019d9a4c-7181-7415-9a48-3861be138c5c" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvances"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvances_019d9a4c-7181-7415-9a48-3861be138c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_019d9a4c-7181-78ee-8aec-09c4f7ba7622" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundedInterestsAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_019d9a4c-7181-78ee-8aec-09c4f7ba7622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019d9a4c-7181-7a0e-b45e-065203ff0469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_019d9a4c-7181-7a0e-b45e-065203ff0469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_019e0556-693f-7c3b-858d-220cd2b2165e" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease_019e0556-693f-7c3b-858d-220cd2b2165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_019e055a-ee99-7772-8d5b-df606db1f131" xlink:href="legn-20260331.xsd#legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable_019e055a-ee99-7772-8d5b-df606db1f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daeb2-a723-7231-8925-5eadd20cdafe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019daeb2-a723-7231-8925-5eadd20cdafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019d9a4c-7181-7cff-b60e-0c609207b3d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems_019d9a4c-7181-7e66-b10b-97bb5b7e6805" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019d9a4c-7181-7cff-b60e-0c609207b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-737f-8cc3-9d55b5fb07c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-737f-8cc3-9d55b5fb07c6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_019d20ae-22c5-7e2e-9b30-fbf9b765a4c5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_019d20ae-22c5-75a3-a271-9945bcbcd977" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_019d20ae-22c5-726e-a6ea-4542c24fd61b" xlink:to="loc_ifrs-full_OrdinarySharesMember_019d20ae-22c5-75a3-a271-9945bcbcd977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-78ec-8b05-3e4a09452623" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:href="legn-20260331.xsd#legn_AuthorisedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:to="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_019d20ae-22c5-7b80-a19b-90be6c2d6dce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_019d20ae-22c5-7b80-a19b-90be6c2d6dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-71a5-9a02-e6873d8d41e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-71a5-9a02-e6873d8d41e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital_019d20ae-22c5-77ed-a667-6730764e8a64" xlink:href="legn-20260331.xsd#legn_AuthorizedShareCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_019d20ae-22c5-7147-8a57-4895d3ca713a" xlink:to="loc_legn_AuthorizedShareCapital_019d20ae-22c5-77ed-a667-6730764e8a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-742a-bdf5-ab7342ffa649" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_019d20ae-22c5-70ce-81df-4c9b57c66df1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_019d20ae-22c5-70ce-81df-4c9b57c66df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-7659-8b34-8bf9a40536ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:to="loc_ifrs-full_ParValuePerShare_019d20ae-22c5-7659-8b34-8bf9a40536ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019d20ae-22c5-7ed9-91c3-ce278351bf34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_019d20ae-22c5-7bd1-94fa-41de5cf45b79" xlink:to="loc_ifrs-full_IssuedCapital_019d20ae-22c5-7ed9-91c3-ce278351bf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-7a95-8d5b-827ca7bfdd04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_019d20ae-22c5-7a95-8d5b-827ca7bfdd04" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019d20ae-22c5-7d18-9c38-525cd912a8d5" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c5-7f35-b9ce-e305167c682e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_ifrs-full_IssuedCapitalMember_019d20ae-22c5-7f35-b9ce-e305167c682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember_019d20ae-22c5-7d02-81ef-8d9ec102e47e" xlink:href="legn-20260331.xsd#legn_ShareCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_legn_ShareCapitalMember_019d20ae-22c5-7d02-81ef-8d9ec102e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_019d20ae-22c5-71cf-aa0a-2529dff0f4b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019d20ae-22c5-7c74-a193-21333464e6d3" xlink:to="loc_ifrs-full_SharePremiumMember_019d20ae-22c5-71cf-aa0a-2529dff0f4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019d20ae-22c5-7044-b108-68c13d5d7afe" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:href="legn-20260331.xsd#legn_ShareCapitalRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019d20ae-22c5-7bcd-812d-bd675c5ffe00" xlink:to="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7f46-ab21-f8ad8bce5244" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7f46-ab21-f8ad8bce5244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-79b5-83db-465f0c1d56ea" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-79b5-83db-465f0c1d56ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_019d20ae-22c5-7366-95a3-c894be849421" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_019d20ae-22c5-7366-95a3-c894be849421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption_019d20ae-22c5-7d77-a1f1-ca1d70ff7b97" xlink:href="legn-20260331.xsd#legn_ExerciseOfShareOption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ExerciseOfShareOption_019d20ae-22c5-7d77-a1f1-ca1d70ff7b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_019d20ae-22c5-7b71-8a00-e5852e4376ba" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_019d20ae-22c5-7b71-8a00-e5852e4376ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_019d20ae-22c5-7cef-8d14-0e76083fea0e" xlink:href="legn-20260331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_019d20ae-22c5-7cef-8d14-0e76083fea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7351-b415-65a0a4b6debe" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_019d20ae-22c5-7351-b415-65a0a4b6debe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-7515-aafc-052971527daf" xlink:href="legn-20260331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_019d20ae-22c5-7991-bdb4-d5ab2c2c326e" xlink:to="loc_legn_ShareCapitalAndSharePremium_019d20ae-22c5-7515-aafc-052971527daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="legn-20260331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_019df0be-d262-7634-94e6-d805e2bcdd1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_019df0be-d262-7634-94e6-d805e2bcdd1e" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_019df0be-6d6c-7cb3-a289-08de42b5a521" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueMilestonePaymentMember_019df0be-6d6c-772d-bf71-f558bfa58cf9" xlink:href="legn-20260331.xsd#legn_RevenueMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_019df0be-6d6c-7957-b3d4-3e8ee536531b" xlink:to="loc_legn_RevenueMilestonePaymentMember_019df0be-6d6c-772d-bf71-f558bfa58cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:to="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_019df898-558c-753b-a5e8-50be01018828" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019df898-677e-7361-b5de-d69b8227fc03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019df898-558c-78e0-8278-31c560a97b5c" xlink:to="loc_srt_ScenarioForecastMember_019df898-677e-7361-b5de-d69b8227fc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_019df0be-6d6c-7125-972d-494ac6a6ba08" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NumberOfCountriesToReceiveCommericalApproval_019e031f-c275-75ab-904b-e8c4151782ea" xlink:href="legn-20260331.xsd#legn_NumberOfCountriesToReceiveCommericalApproval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:to="loc_legn_NumberOfCountriesToReceiveCommericalApproval_019e031f-c275-75ab-904b-e8c4151782ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromMilestonePayments_019df60c-b78a-75b1-91ba-cf73ea9d7ec5" xlink:href="legn-20260331.xsd#legn_ProceedsFromMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_019df0be-6d6c-7d3b-b934-c2ccd03fffd3" xlink:to="loc_legn_ProceedsFromMilestonePayments_019df60c-b78a-75b1-91ba-cf73ea9d7ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>legendlogo.jpg
<TEXT>
begin 644 legendlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !8 -,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4F8*I).
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M6VJK"FJ6HE>$-GRI02LJ9[[75ES[45Y[33LSK3NKH^3_ -HGQEK7QN^,=O\
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M/B-:4H.2O]F2ZKMW]?5GH'_!1[_DW>/_ +#-K_Z!+7Q_^P-_R=#X7_ZX7O\
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M,#"G.=U>S_\ #T76O^A L/\ P8O_ /&ZJ;K<SY8JPHJG;WGJ?5&D:/J?A_\
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M89'4X(]_8C@CD5M0J*JDW\2,ZL73T6S/TU^&O_*.R\_[$_5O_0+BOAG]D/\
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M*NM0ZMXK\,VVLZC#;K:QW$TDBE8@S,%^5@,;G8_C7,?\,:_!C_H0['_O]/\
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MBBKHZS2_K8FI\)TWP7USX7MXKEMO!_B77M6U6>V8&#5;W4KB/RP58D"YR@/
MY'/4>M>X4445H\LK7"G+FC<X;XY>"+OXD?"'Q;X:L'6._P!1T^2*W+-M4RXR
MBD]@6 !/H:\]\&_M4>!]%\'Z=8>*KJX\+>*+"UCMKWP_>V,PNEF10K+$@0^8
MI(^4IG((Z=***NC%5$XLFI)P=T>I_#7Q;J/CKP;8ZYJ?AZZ\+SWFYTTV^?,\
M<>XA&<8&TLH#;>HR >:ZBBBN>6[-EL?/'Q2\ 67Q _:B\)6>JIJ T]/#%ZYE
ML+R>T8.+B+ ,D3*W0GY<X/IQ61\4O@MH?@3QI\)-0T-=:FG;Q?;1R_;=7O+U
E%C\F8D[99'5>0/FP#VSS116\9.\5?I_F9.*U9]/4445S&Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>q126pipeline001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 q126pipeline001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0?!54# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH **2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@ HHHH ***
M* "BBB@ HH/ R37SMXF\5ZAJ7B2^N;74+F*V,A6%8YF5=@X!P#WQG\:UI4G4
M=D85ZZHI-]3Z)HK&\*:N-=\,V-^6S(\>V7_?7AOU&?QK9K-IIV9M&2DDT%4?
M[9TO[7]D_M*S^T[]GD^>N_=TQC.<^U6O/A\WRO-3S/[FX9_*O"%_Y+#_ -Q@
M_P#HRM*5/GO?H8UZSIVMU9[W129&<9&:6LC<**0$'H0:1Y$B0O(ZHHZEC@4
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M&IN651\Q]^*UI4O:7UM8PKU_96TO<^B**\0O?"_C[1[62^^W7+I""[^1>L6
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MUW=,4RTU*QU#?]BO;:YV8W^3*K[<],X/'0UQ5[_R11?^P?%_[+6/\%NNM_\
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M2].] !12;E )+# ZG/2FQR1RIOCD5U]5.10 ^BHI;B"$@2S1QD]-[ 9J0$$
M@Y!Z$4 +12$@=2*9)/#$RK),B,W0,P!- $E%%("#T(- "T4A('4XH!!Z'- "
MT50UMFCT'471BK+:RD,#@@[37@>@Q^)/$E^UEI^IW)F6,R'S+IU& 0/7W%;4
MZ7.F[VL<];$>SDHVO<^BZ*\-U'1O'GABV.HR7]T88R-[Q79<+_O*3R/PKO?A
M[XSE\3V<UM?!1?VP!9E&!(I_BQV.>OU%$Z+4>9.Z%3Q*E+DDK,[(2QF0QAU+
M@9*YY ^E/KS#2_ &M6?C[^UY;^$VRW#3&42$R2 Y^4C'?.#S7IQ('4@5$XJ.
MSN:TYRDGS*PM%1R3PPX\V5$W=-S 9J3KWJ#0***B2X@E<I'-&[#JJL"10!([
MJB,[L%51DL3@ 54M=7TV^E,5GJ%I<2 ;BD,RN0/7 /O2:O\ \@6__P"O>3_T
M$UX]\(/^1NN/^O)__0TK6%-2@Y=C"I6<*D86W/:VEC5U1I%#M]U2>3]*?7F/
MB[P#K.M>,/[2M+Z%('V89Y"&@V@#@?AD8[FO31A5 +?B>]3**233N7"<I-IJ
MUOQ%HICRQQ)ODD5$_O,<"E1TD0.CAE/0J<@U!H.HHJ(7$!E\H3QF3^YN&?RH
M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDHI@+1244
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MD>#K*-UQ-./M$F?5N1^2[1^%>10RS^//'5D)U.)C&L@]$11O_/#'\:^@0 H
M   X %8UO<A&!TX;]Y5E5^2*.N_\B]J?_7I+_P"@&O$_AIJ]AHOB6:YU&Y6W
MA:U9 [ D;BRG''T->UZ[_P B]J?_ %Z2_P#H!KPCP+X<M/$^NR6-Y+-'&MNT
MH,) .0RCN#QS3H)>SE?8G%<WM8<NYZ5XJ^('AU_#=]:VEXMW<7,#PI&B-QN&
M,DD8XSFN;^#EC.VKW^H;2+=(/(W=BQ96Q^ 7]1726_PC\.Q2!Y)K^<#^!Y5
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ME1QT'TKU2DHJYSE.US*G2C3OR]3@?'_@2[\3W]K>Z=);QRI&8Y?.8KD Y7&
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M0YOQCX/MO%EBB-)Y%W#DPS8SC/52.X/Z5YY_PK7Q@(O[/&H0_8L_<^U/Y?\
MWSC^E>ST4X5IP5D34PU.H^9[G->#?!]OX3L9%$OGW<^#--C XZ*!Z#)^M<QX
M9^'FKZ-XRAU>YGLVMT>5BL;L6^96 X*@=QWKTRBE[66OF4\/#W=-MCS?QSX
MU;Q+X@%_936B1"!8\3.P;()]%/K7=7-E)-H,UBI7S7M6A!)XW%<?E5ZBDZDF
MDGT'&C&+<EU//? /@75/"^M7%Y?36CQR6YB A=B<EE/=1QP:I^,OAV-6UR2[
MT:[MH[V4>=-:2/M)YQO7'J1^?>O3J\[\5_#W4M2UQ]:TC53'<OC*2NRE,#'R
MLO0>WZUI"HW/F;L85:$8TN2,;HXOQ+X4UK2=#%]K^K>;('$5O;F9I2<]>3T
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MVDBF.=$D;++V(&W&0<?K7I5%$:DHIQ6S%.C&4E)[HXGQM\/HO$THOK.9+?4
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M9JWA6_O)+V6T>&XB"_N78D,#QU4<8)JGXY^'5YKFL-JNES0B255$T4K%>0,
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MR]E;ZM';6<A^<Q7+A6'KM Y.*M:7\,-8T?Q/:7\%U9RVMO<*X+NRNR@\\;2
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M$O(1@NQZG_/;%:E35GSS;+P]/V=-1*VIVSWFE7EK&5#S0/&I;IDJ0,_G7!^
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M":_]^G_^)H_X3CPY_P!!-?\ OT__ ,319A]8I?S+[T=%17._\)QX<_Z":_\
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M!-?^_3__ !-%F'UBE_,OO1T5%<[_ ,)QX<_Z":_]^G_^)H_X3CPY_P!!-?\
MOT__ ,319A]8I?S+[T=%17._\)QX<_Z":_\ ?I__ (FC_A./#G_037_OT_\
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M:_\ ?I__ (FC_A./#G_037_OT_\ \319A]8I?S+[T=%17._\)QX<_P"@FO\
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M":_]^G_^)H_X3CPY_P!!-?\ OT__ ,319A]8I?S+[T=%17._\)QX<_Z":_\
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M]57Q3>VJ^586D?A@ZJJ7L#;H)MP'[P+\V .H SQ1<.6/8]!_LS3_ /GQMO\
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M?6EUGQ_X9T&:*&_U,!Y81< 0Q/-B(]'.P'"^YHN'+'L;G]F:?_SXVW_?I?\
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MSS@U2TCXA>&-=U1--T_4Q+<R!C"&AD19@OWMC,H#XP>A/2BX<L>QN_V9I_\
MSXVW_?I?\*/[,T__ )\;;_OTO^%6:* Y8]BM_9FG_P#/C;?]^E_PH_LS3_\
MGQMO^_2_X59HH#ECV*W]F:?_ ,^-M_WZ7_"C^S-/_P"?&V_[]+_A5FB@.6/8
MK?V9I_\ SXVW_?I?\*/[,T__ )\;;_OTO^%6:* Y8]BM_9FG_P#/C;?]^E_P
MH_LS3_\ GQMO^_2_X59HH#ECV*W]F:?_ ,^-M_WZ7_"C^S-/_P"?&V_[]+_A
M7E</Q"\<7.E:]KUMI^@2:3H]Y/!+$[RI.ZQX)(.2OW2/UXKK)/BAX7M-/TZY
MO[YK=[VT2\$ A>5HHV .7V [1SC)HN'+'L=1_9FG_P#/C;?]^E_PH_LS3_\
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M+U6ZTSXC6<MN+6;6+V9K.5R,2(0=IR.0I/'XFL7_ (6OXN_Y\-$_\B_XT?\
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MW-EX<FT_X/SZ#;6<\5R=,N(TM99UE=9'5SL+@!3RV,X KB/^%K^+O^?#1/\
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MAHG_ )%_QH^KU>P<\>Y[917B?_"U_%W_ #X:)_Y%_P :4?%;Q<3_ ,>&B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCZ[/L'LD?/\ _P (OKO_ $"[G_OBC_A%]=_Z!=S_ -\5] 44?79]@]DCY_\
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MBOH"D)"@DD #DD]J/KL^P>R1X!_PB^N_] NY_P"^*N:=I?B?2FN&M-.N%-Q
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M=_Z!5S_WQ1_PBVN_] JY_P"^*ZQ_BCXAC@BG?3+-89L^6YC<!\<'!W<XI?\
MA:'B$V9N_P"S;+[.)!$9-CXW8SC[W7 I\]?L@M Y+_A%M=_Z!5S_ -\4?\(M
MKO\ T"KG_OBNG_X6UK7_ #Y:?_WR_P#\51_PMK6O^?+3_P#OE_\ XJCFK]D%
MH=SF/^$6UW_H%7/_ 'Q1_P (MKO_ $"[G_OBNG_X6UK7_/EI_P#WR_\ \531
M\5]95F/V*P^8Y^Z__P 51S5^R"T.YS7_  BVN_\ 0*N?^^*/^$6UW_H%7/\
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MG?\ X1;7?^@5<_\ ?%'_  BVN_\ 0*N?^^*^B**/KL^P>R1\[_\ "+:[_P!
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M_P (MKO_ $"KG_OBOHBBCZ[/L'LD?.__  BVN_\ 0*N?^^*/^$6UW_H%7/\
MWQ7T111]=GV#V2/G?_A%M=_Z!5S_ -\4?\(MKO\ T"KG_OBOHBBCZ[/L'LD?
M._\ PBVN_P#0*N?^^*/^$6UW_H%7/_?%?1%%'UV?8/9(^=_^$6UW_H%7/_?%
M'_"+:[_T"KG_ +XKZ(HH^NS[![)'SO\ \(MKO_0*N?\ OBC_ (1;7?\ H%7/
M_?%?1%%'UV?8/9(^=_\ A%M=_P"@5<_]\4?\(MKO_0*N?^^*^B**/KL^P>R1
M\[_\(MKO_0*N?^^*/^$6UW_H%7/_ 'Q7T111]=GV#V2/G?\ X1;7?^@5<_\
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MHI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Y4YXXI:1ONG/I0
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MH@;3&C)O/*(:,.C*3Y0!+;CD $;<#'7-9\NHV,/Q/@O99XFM5\G,JD,JGR5
M.1Z-_*NI_P"%2:3_ -!"]_\ '/\ "C_A4FD_]!"]_P#'/\*:K4M;R8<LNQS>
MF&XTV>./4M;M9@R73+$LZR;28B-V\'C<< +G\*D6?1[>S298],EF$.GKB54?
M&0PEX/?IGTXKH/\ A4FD_P#00O?_ !S_  H_X5)I/_00O?\ QS_"AUJ3UO\
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MU>98B.1E6!8>HY'/4"S<^,HO[7\.6EC"+B'5QYCREL>5&4+(<>K%3Q_LMZ4
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MQCGDG'XTV\T*XT_19KN[:2*YBO%MS%D$8:,N&R#ST'3UI_5(_P P>T?8]_\
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MYN%!+$XZ>YYQ7N_EK_SYK_X[1Y:_\^:_^.TUB8+3E_$7(^YXK#XXN!/97%U
MUS<6QE0R/-R\4@^Z<@\CL?PQ5VQ\166JS3V]^XALQY+1_:+@AP8V8\%(\$?,
M?EP/8UZ[Y:_\^:_^.T>6O_/FO_CM)XB#VC^(^1]SQN^\9P2:A*L=HTMFTEVK
MGS-K21S$=./E(P/6JL_BY)+<6T=@4@C-L(09<LJ0EC@G'))8\\8]*]N\M?\
MGS7_ ,=H\M?^?-?_ !VFL3!?9_$.1]SQG_A-H/)O@-+*2W1N=S), ")B3EOE
MRQ7.!R!CM69+XED/BQ-=AMPCIL_=,VX$*@0C.!U /YU[SY:_\^:_^.T>6O\
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M^EO+7_GS7_QVCRU_Y\U_\=H^O?W?Q#V7F?--%?2WEK_SYK_X[1Y:_P#/FO\
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MY'ZUN7VF?;YM,DEFQ]BN/M!55XD;RW0#KP 7W?\  15OS)?^>!_[Z%'F2_\
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M%% !2-C:<],4M(V-ISTQ0 #H,4M(.@I: "BBB@ HHHH **** "BBB@ HHHH
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M$L+1N(D\WS=F!E,*$W!E^K&:XT._LY_+BM;]]+:&PDO88Y'=I6#3"7'.2?\
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M@MXA=]QT'Q-\2W2S-#8:>ZPQF20B-_E7(&?O^I%0_P#"V->_Y]=._P"_;_\
MQ=6M1FTF&RNVAFL([B73)HI%@DB^9A*FT83"YV^G.!WQ7G573I4Y:\HG*2ZG
M=_\ "V->_P"?73O^_;__ !=(/BMKJLQ%KIWS')_=O_\ %UPM%7]7I?RBYY=S
MN_\ A;&O?\^NG?\ ?M__ (NE7XLZX'!>TT\KGD!'!(^NZN#HH^KTOY0YY=SZ
M+T'7K+Q#IJWEF_M)&3\T;>A_Q[UJ5X[\,])U:75_[1MY6M[!/EF8C(F_V ._
MU[5[%7F5Z:A.T6;P;:NPHHHK$H*1\;&STQS2TCXV-GIB@ 'W1BEI!]T?2EH
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M\:/JC[A_:*_E/IO>O]X?G1O7^\/SKYD_M/4/^?ZY_P"_K?XT?VGJ'_/]<_\
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M']HK^4^H_,3^^OYT>8G]]?SKY;_M/4/^?ZY_[^M_C1_:>H?\_P!<_P#?UO\
M&CZH^X?VBOY3ZD\Q/[Z_G7+>(/!&E>(]2%]=7=Q'((Q'MB=0,#/J#ZUX)_:>
MH?\ /]<_]_6_QH_M/4/^?ZY_[^M_C51PTX.\9">81>\3V;_A5.A?]!"^_P"_
MB?\ Q-'_  JG0O\ H(7W_?Q/_B:\9_M/4/\ G^N?^_K?XT?VGJ'_ #_7/_?U
MO\:TY*W\Y/UZ'\I[-_PJG0O^@A??]_$_^)H_X53H7_00OO\ OXG_ ,37C/\
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M_7/_ '];_&C^T]0_Y_KG_OZW^-'U1]P_M%?RGU&)$P/G7\Z7S$_OK^=?+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#+/;RO(C>8D<GEMN4'*'/0&NPS1[6?</J]+^5'"_\*GT#_GK=_\ ?P?X4?\
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MKO$%/+!"%<_@2 ?<T>UGW#ZO2_E1R/\ PJ?0/^>MW_W\'^%'_"I] _YZW?\
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M1GCCH>.M.7Q1HK"WQJ$6;B4PQ)SN9QC*[<9!&X'!'0YZ4>UGW#ZO2_E1S?\
MPJ?0/^>MW_W\'^%'_"I] _YZW?\ W\'^%=*OB;16^TXU*WQ; M*2V  #M)![
M_-QQGGCK4+>+M'^T:=!'<-*U_.UO$40G:ZJ20_=>F.>>1VYH]K/N'U>E_*C
M_P"%3Z!_SUN_^_@_PH_X5/H'_/6[_P"_@_PKH8?%.E&*S-Q>6\,MTBNB>9N
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MV\<8)Z?S1_<?_OFCS1_<?_OF@#DKSPE?2R2VT%Q;+927_P!M29BXF@+.'D4
M<,"=W)(P&Z'%0?\ "':I-JDEQ<WMM-'LNT4S&20.)L[0T1.Q0HP"%QN'<5VG
MFC^X_P#WS1YH_N/_ -\T <C;>%M5B2%VNH-T%]%<Q6[322JBJC(P\Q\OSN)
M/ Q@=:6X\%27>C6NFRW:JB"]61T!SBX60#'N/,_2NM\T?W'_ .^:/-']Q_\
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MEU<H 6A>"0 ]"0B'^E>[^>/^><G_ 'S6'J/A7P_JU])>WVD^=<28W2'>"<#
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M#$T=W9S2SQ,(=4N-0D !^;>LB1C_ ("CK^*UT/GC_GG)_P!\T>>/^><G_?-
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MT]+RU:._TR*POY65MZ[3(9&C'0[O-?@XP<'GI7;>>/\ GG)_WS1YX_YYR?\
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M@,W3'Z"B3X=^%I;6VMCIK+';S//&4N94;S'P&<L&#,Q  R2372>8_P#SQ?\
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M^8_QH DHJ/S'_P">+_F/\:/,?_GB_P"8_P : )**C\Q_^>+_ )C_ !H\Q_\
MGB_YC_&@"2BH_,?_ )XO^8_QH\Q_^>+_ )C_ !H DHJ/S'_YXO\ F/\ &CS'
M_P">+_F/\: )**C\Q_\ GB_YC_&CS'_YXO\ F/\ &@"2BH_,?_GB_P"8_P :
M/,?_ )XO^8_QH DHJ/S'_P">+_F/\:/,?_GB_P"8_P : )**C\Q_^>+_ )C_
M !H\Q_\ GB_YC_&@"2BH_,?_ )XO^8_QH\Q_^>+_ )C_ !H DJ2#.6].*K^8
M_P#SQ?\ ,?XU)#)("W[ER..X_P :3 M45%YK_P#/"3\U_P :/-?_ )X2?FO^
M-2!+7B?Q \-:YJ'C:]N[+3+J:%A'LDC0D'"*.#]17L_FO_SPD_-?\:JS:Q9V
MTIBGFABD'5'F12/P+5I2J.#ND8UZ4:L>63L>(7=AX_OEA%S;:M)Y#B2,[2"&
M'1LCJ?<\U%J6C^.-7$8O[#4IUCR45H^ 3U.!W]Z]P_M_3?\ G[MO_ B/_P"*
MH_M_3?\ G[MO_ B/_P"*K;ZQ)?9.9X2#WFSPV?1/&US#)#-I^HO'*(PZF+A@
M@PGY"K<5O\0X9I9HX-5$LJHKOY?+!<A>?;)KV?\ M_3?^?NV_P# B/\ ^*H_
MM_3?^?NV_P# B/\ ^*H^L2_E#ZI'^=G@4OA#Q3/,\TVCZA)(Y+,[QDEB>Y-,
M_P"$+\2_] 2]_P"_1KZ _M_3?^?NV_\  B/_ .*H_M_3?^?NV_\  B/_ .*J
MOK4^Q/U&G_,?/_\ PA?B7_H"7O\ WZ-'_"%^)?\ H"7O_?HU] ?V_IO_ #]V
MW_@1'_\ %4?V_IO_ #]VW_@1'_\ %4?6I]@^HTOYCY__ .$+\2_] 2]_[]&C
M_A"_$O\ T!+W_OT:^@/[?TW_ )^[;_P(C_\ BJ/[?TW_ )^[;_P(C_\ BJ/K
M4^P?4:7\Q\__ /"%^)?^@)>_]^C1_P (7XE_Z E[_P!^C7T!_;^F_P#/W;?^
M!$?_ ,51_;^F_P#/W;?^!$?_ ,51]:GV#ZC2_F/G_P#X0OQ+_P! 2]_[]&C_
M (0OQ+_T!+W_ +]&O?FU_3LKB\MNO/\ I$?H?]JG?V_IO_/W;?\ @1'_ /%4
M?6I]@^HTOYCY_P#^$+\2_P#0$O?^_1H_X0OQ+_T!+W_OT:^@/[?TW_G[MO\
MP(C_ /BJN1W/FQK)'$SHPRK*RD$>QS2^M370:P%-[2/G/_A"_$O_ $!+W_OT
M:/\ A"_$O_0$O?\ OT:^CO-?_GA)^:_XT>:__/"3\U_QH^MR[!_9\.[/G'_A
M"_$O_0$O?^_1KJ/!GPTO+Z^^TZ[;26UG"W^I<;6F/I[+ZG_(]F\U_P#GA)^:
M_P"-'FO_ ,\)/S7_ !J98J;5BX8&G%W;N/CC2&)8XT5(T 5548  Z "D0MOD
MSG&1C\J;YK_\\)/S7_&FK++N?,$F,\<CT^M<QVD]%1>:_P#SPD_-?\:/-?\
MYX2?FO\ C0!+147FO_SPD_-?\:/-?_GA)^:_XT 2T5%YK_\ /"3\U_QH\U_^
M>$GYK_C0!+2-G8V.N.*C\U_^>$GYK_C2-+)M.(),X]5_QH E'09I:A$LF!^X
MD_-?\:7S7_YX2?FO^- $M%1>:_\ SPD_-?\ &CS7_P">$GYK_C0!+147FO\
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M%0$5UW8DPVYOF!ZUTLI81.5SNQQBF^:__/"3\U_QILDLOEMM@D!QP<C_ !H
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M[O4[K[)>2:9(?)BD5 \[0*#LXX"X&=O;FBX'K\VHV-M:QW,]Y;Q6\I41RO(
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M?X@_Z"L_YC_"CZI+N']H0[,^E:*^:O\ A+_$'_05G_,?X4?\)?X@_P"@K/\
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M_OD4 2T5%]F@_P">,?\ WR*/LT'_ #QC_P"^10 Y,[Y,]-W'Y"GU EO"6?\
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M?\\8_P#OD4?9H/\ GC'_ -\B@"6F2Y,3A>N.,4W[-!_SQC_[Y%-EMX1$Y$2
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M#<W][:PSR6L4;RNKQL6"JX*Y) K&@\1:]<^$KN[O?$<MC]@U"XMG(LX_MLQ
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MIVY '//4TR36]3MO%<,,]Q> S:F;5;,VO[@VYC)5UDV\MD9^]_>&...K;2;
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M** "BBB@ HHHH **** "GP?ZQ_H/ZTRGP?ZQ_H/ZTF!/1112 *^??B=_R/\
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MMM.NYUA9%EN4:(1H60/T+ACPR]%/6H-)\66^J/9AK"]M([X-]DEN FR<J"2
M49L' )PV,@'TH V\2_WT_P"^#_C1B7^^G_?!_P :R-5\2PZ5+>!K:6=+*W6>
MX,9&5WMM10#@$G#'J, #U%.N-?:QT>ZU&_TJ^M%@QMA<Q/),2<*J!'8$DD
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M;P60B+W$TBK&1(,C!)Q3YO$&BV\<$D^KV$23J&A9[E ) > 5)/(^E %[$O\
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MT;9_^>D?_?L_XU+10!%MG_YZ1_\ ?L_XT;9_^>D?_?L_XU+10!%MG_YZ1_\
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M;9_^>D?_ '[/^-&V?_GI'_W[/^-5[S6=+T]7:]U*SM@C!&,TZIM8KN .3P<
MG'H,U:AFBN((YX)$EBD4,DB,&5@>001U% #=L_\ STC_ ._9_P :-L__ #TC
M_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\:EHH BVS_P#/2/\
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M2/\ []G_ !I'$X1CYD?3^X?\:FI'.$8XSQ0!57A1]*6@=!15 %%%% !1110
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MK(79LL 0'7GD-G.3GKFIH=+\0:;)=R:=!IBOJ$41?=*RI:3+&(SM4)\Z *I
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M:![03W>F6]I"T@W /&),[@5(V_..Q^GKT_G)Z/\ ]\'_  H\Y/1_^^#_ (4
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MBU:&739VL+.Q6:74&^WP.3+>,/- AE&U<<$N,EO]5V-:VE/JHA\ &\^R?9L
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MF*S=-TQ[*[FF9HMOV>&VC6)=H"1[R#CMRY&.>%'K@:= "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8J2#_ %C_ $']:93X/]8_T']:&!/1
M114@%>+>/_%>NZ9XSOK2RU.>"W01[8T(P,HI/ZFO::^??B=_R/\ J/\ NQ?^
MBUKIPJ3GKV./'2<:::?4I?\ "=>*/^@U=?F/\*/^$Z\4?]!JZ_,?X5SU%=W)
M'L>3[6?\S.A_X3KQ1_T&KK\Q_A1_PG7BC_H-77YC_"N>HHY(]@]K/^9G0_\
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M;CQ9J%M8RB[UT6D=M%?SQW4D<0DO/)G:.-,%=O09.T G*XQ0!Z;1573/M/\
M95G]M??=>0GG-@#<^T;C@<#G-6J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *9+_J7_W33Z9+_J7_ -TT /HHHH **** "BBB@ HHHH ****
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M\AK_ (4>RD'U69[%Y4>]G\M=S##' R1Z&EVKS\HY&#QVKQS_ (3CQ!_S^_\
MD-?\*/\ A./$'_/[_P"0U_PH]E(/JLSV#R(?+,?DQ^61@KM&#^%.V(65MJ[E
M& <<@5X[_P )QX@_Y_?_ "&O^%'_  G'B#_G]_\ (:_X4>RD'U69["D4:*%2
M-%53D *  :K6&FPZ>;EHVDDDN93-+)*VYF;  ^@   'M7D__  G'B#_G]_\
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M,]MK%U#PCH&JWKWE]ID4UQ)C=(Q.3@8'0^@%>6?\)UXB_P"?\_\ ?"_X4?\
M"=>(O^?\_P#?"_X4U2FMF3+!REH[,])_X0'PM_T!H/S;_&C_ (0'PM_T!H/S
M;_&O-O\ A.O$7_/^?^^%_P */^$Z\1?\_P"?^^%_PJN2KW)^H+LCTG_A ?"W
M_0&@_-O\:/\ A ?"W_0&@_-O\:\V_P"$Z\1?\_Y_[X7_  H_X3KQ%_S_ )_[
MX7_"CDJ]P^H+LCTG_A ?"W_0&@_-O\:/^$!\+?\ 0&@_-O\ &O-O^$Z\1?\
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M (3KQ%_S_G_OA?\ "C_A.O$7_/\ G_OA?\*/8R#ZK,]MHKQ+_A.O$7_/^?\
MOA?\*/\ A.O$7_/^?^^%_P */8R#ZK,]MHKQ+_A.O$7_ #_G_OA?\*/^$Z\1
M?\_Y_P"^%_PH]C(/JLSVVBO$O^$Z\1?\_P"?^^%_PH_X3KQ%_P _Y_[X7_"C
MV,@^JS/;:*\2_P"$Z\1?\_Y_[X7_  H_X3KQ%_S_ )_[X7_"CV,@^JS/;:*\
M2_X3KQ%_S_G_ +X7_"C_ (3KQ%_S_G_OA?\ "CV,@^JS/;:9+_J7_P!TUXK_
M ,)UXB_Y_P _]\+_ (4'QUXA(P;\D?[B_P"%'L9!]5F>VT5XE_PG7B+_ )_S
M_P!\+_A1_P )UXB_Y_S_ -\+_A1[&0?59GMM%>)?\)UXB_Y_S_WPO^%'_"=>
M(O\ G_/_ 'PO^%'L9!]5F>VT5XE_PG7B+_G_ #_WPO\ A1_PG7B+_G_/_?"_
MX4>QD'U69[;17B7_  G7B+_G_/\ WPO^%'_"=>(O^?\ /_?"_P"%'L9!]5F>
MVT5XE_PG7B+_ )_S_P!\+_A1_P )UXB_Y_S_ -\+_A1[&0?59GMM%>)?\)UX
MB_Y_S_WPO^%'_"=>(O\ G_/_ 'PO^%'L9!]5F>VTC?</TKQ/_A.O$7_/^?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M*.HI*4=10!]"YHS245QGCBYHS244 +FBDHH **** "BBB@ KCO$G@N77=6-Z
MEZD(**FTQYZ?C78U7O[ZVTO3[B_O)?*M;>-I99,$[5 R3@<GCTIIM:HJ$G!W
MB>?_ /"L9_\ H)Q_]^C_ (T?\*QG_P"@G'_WZ/\ C79:IXFTC1=,MM1O[HQV
MMTZ1PNL3N79@64!5!/(![51D\?>&(]-AOSJBM!-(\2!(9&D+(,N#&%W#:.3D
M<9&:?M)=S3ZQ4[G-_P#"L9_^@G'_ -^C_C1_PK&?_H)Q_P#?H_XUV-WXHT2Q
MTNSU.XU&);.]=$MI1EA*S_=  &>?_P!=,;Q;H::^-#:_4:@7$?E[&V[RNX)O
MQMW8YVYS[4_:2[A]8J=SD?\ A6,__03C_P"_1_QH_P"%8S_]!./_ +]'_&NO
MO/%>AV%[?6=SJ")<6%K]LND",QBB_O' /Y=>>E/T3Q-H_B(2_P!EWJSM#@R(
M4:-U!Z$JP!P>QQ@T>TEW#ZQ4[G&_\*QG_P"@G'_WZ/\ C1_PK&?_ *"<?_?H
M_P"->D44>TEW#ZQ4[GF__"L9_P#H)Q_]^C_C0?AE. 3_ &G'_P!^3_C7I%(W
MW3GTH]I+N'UBIW/./^%93D?\A./_ +]'_&C_ (5C/_T$X_\ OT?\:[O4-5L]
M*BB>[D<&5MD4<<32/(V"<*B@L> 3P.@JB_B[142V<7$TGVA9'016LLC 1L%<
ML%4E-K$ [L8-+VDNX?6*G<Y+_A6,_P#T$X_^_1_QH_X5C/\ ]!./_OT?\:[6
M3Q#I$<MC$=0@+WVTVRHV[S0W0C'8^O2A?$&F-JW]F"X;[3O,?^J?87"[B@?&
MTMMYVYSCM3]I+N'UBIW.*_X5C/\ ]!./_OT?\:/^%8S_ /03C_[]'_&O2*S]
M2UJQTIXH[IY3+*&9(H('F<A<9;:@)P,C)QCD>M'M)=P^L5.YP_\ PK&?_H)Q
M_P#?H_XT?\*QG_Z"<?\ WZ/^-=9+XOT.%T#7K,CVZ7/FQP2/&L3DA79U4J@.
MUN6(Z&IKWQ)INGW AN3=KET02+8S-&6<@*!($*G)8#KU.*/:2[A]8J=SC?\
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M0Y4D'@@9&1P>AZCBCVDNX?6*G<\[_P"%8S_]!./_ +]'_&C_ (5C/_T$X_\
MOT?\:](HH]I+N'UBIW/-_P#A6,__ $$X_P#OT?\ &C_A6,__ $$X_P#OT?\
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MX?6*G<XG_A6,_P#T$X_^_1_QH_X5C/\ ]!./_OT?\:](HH]I+N'UBIW/-_\
MA6,__03C_P"_1_QH_P"%8S_]!./_ +]'_&O2**/:2[A]8J=SS?\ X5C/_P!!
M./\ []'_ !H_X5C/_P!!./\ []'_ !KTBBCVDNX?6*G<\W_X5C/_ -!./_OT
M?\:/^%8S_P#03C_[]'_&O2**/:2[A]8J=SS?_A6,_P#T$X_^_1_QH_X5C/\
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MWZ/^-'_"J[K_ *"<7_?H_P"->GT4>UGW#ZQ4[GF'_"J[K_H)Q?\ ?H_XT?\
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M_C0?A;<J-QU.+CG_ %1_QKT^D? 1LC(QTH]K/N'UBIW*@.12T#H**1B%%%%
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M&A:3(0D*&("8[[R:DU#P[JLVHZS=A[E[.75K>=M/4QA+J%8H58[L;@0RDXW
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M ,]4_P"^A1Y\/_/5/^^A0!)14?GP_P#/5/\ OH4>?#_SU3_OH4 245'Y\/\
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M[RZ\N>/&Y?)9L9&1R!CH:W:\5\?_ /(Z7WTC_P#0%K2G%2=F;4::G*S/0_\
MA/?#'_/\?_ =_P#XFC_A/?#'_/\ '_P'?_XFO%J*V]C$Z?JL/,]I_P"$]\,?
M\_Q_\!W_ /B:/^$]\,?\_P ?_ =__B:\6HH]C$/JL/,]I_X3WPQ_S_'_ ,!W
M_P#B:/\ A/?#'_/\?_ =_P#XFO%J*/8Q#ZK#S/:?^$]\,?\ /\?_  '?_P")
MH_X3WPQ_S_'_ ,!W_P#B:\6HH]C$/JL/,]I_X3WPQ_S_ !_\!W_^)H_X3WPQ
M_P _Q_\  =__ (FO%J*/8Q#ZK#S/:?\ A/?#'_/\?_ =_P#XFC_A/?#'_/\
M'_P'?_XFO%J*/8Q#ZK#S/:#X]\,Y7_3<\_\ /!^./]VE_P"$]\,?\_Q_\!W_
M /B:\6HH]C$/JL/,]I_X3WPQ_P _Q_\  =__ (FMVPOK/4[-+NSD26%^C ?H
M1V-?/-;WA?Q'>:!J"F%6F@E8"2W'\?N/]JIE15M"9X56]W<]QVK_ '1^5&U?
M[H_*DC?S(U?:R[@#M88(]C3JYSB$VK_='Y4;5_NC\J6B@!-J_P!T?E3$"EY!
ML7@^G7@5)3$.7D& ,$?CP* ';5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E2T4
M)M7^Z/RHVK_='Y4M% ";5_NC\J:RJ$8[1T]*?2.<(QZ\4 (%7:/E'Y4NU?[H
M_*@?='TI: $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O\ ='Y4;5_N
MC\J6B@"-@HD0;%YSVI^U?[H_*FL<2(,#G//IQ3Z $VK_ '1^5&U?[H_*EHH
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MZ 4 )/XVTA;*>>TDDN9(X?.CC\IXQ,I8(&5F4 J691N&1Z9Q5K1-;FU>WO\
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M.SS-V IZ'CD$CO5R7PS):7SW&@S6FGK-;"VFC:VWJ &9@R $ -\[=00<CTY
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MY''/<R#C_9]ZE/A:]N]2BU'4;^W>Y66 LL$!2/RX?,9% +$Y\R3<3GL!CO0
MZT\9VC1R37IBMX5>094N[D?:6@A(4*<[RI/!R/3N+C>+]$2UAN#=2;96D4(+
M:4R+Y9Q(63;N0*>I8 #(SUK*T_P,UDU@9+]9?LPM!)^ZQYGD+(?7C,DF_P##
M'O61K?A[6; 3Q:1OGO;^"[A>9K;=&#/,TF=V\;"N[DD$$ 8R1B@#T*UNH;VS
M@N[=]\$\:R1M@C<K#(.#ST-35%;P):VL5O$,1Q($4>@ P*EH **** "BBB@
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ME&8X'E42./92<GI0!-O;_GD_Z?XT;V_YY/\ I_C4,.I6%Q>S64-[;2W4(S+
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M]/\ &GNZQHSNP5%&68G  ]:ALKVVU&TCN[.9)K>0921#D,,XR* '[V_YY/\
MI_C1O;_GD_Z?XU)29&[;D9QG% #-[?\ /)_T_P :-[?\\G_3_&I** (][?\
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MR?\ 3_&I** (][?\\G_3_&I8)7!8>2YZ=,?XTE2VY.7'88I,!WFO_P \)/\
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M $%9OR7_  KN/!?C?^T2FFZI(!=](ICP)?8_[7\_KU4J4DKD3P\HJYVWFO\
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M?^._XT>:_P#SPD_\=_QJ6B@"!IG#H/)DYS_=_P :=YK_ //"3_QW_&G,Q$B
M=#G-/H B\U_^>$G_ ([_ (T>:_\ SPD_\=_QJ6B@"+S7_P">$G_CO^-'FO\
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MGG1M]TGV?$S+);^4_E@*%\L?P'=G.[*YYQ6_X)MYK<:GYT,D>Y[;;O4C.+2
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M Z'T%73DHN[-:-10E=G@U%>X?\(1X<_Z!<?_ 'V_^-'_  A'AS_H%Q_]]O\
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M%% !1110 4444 %,E)6)RO4#BGTR4D1.5Z@<4 /HHHH **** "BBB@ HHHH
M**** "BBB@ I')",1U I:1R0C$=<4 4QTHH'2BK$%%%% !1110 4444 %%%%
M !36C1CEE!/N*=6-XMU"XTGP?K&HVC!+FULY9HF*@@,JDC@]: -;R8_[B_E1
MY,?]Q?RKA_%_B+5=.\*^';JRN7AN=0O+:":2*V$S[7C8MM3')R!@"LBW\4>(
MKOPE=:A/K5MI\>GWMQ!/<26>+F0*!Y2>2<A79CRO7&W'6D!Z?Y,?]Q?RH\F/
M^XOY5Y?XD^(.KZ3I&B6K-:6NM/';3ZH)",0H[JA4*?XB23_LA3[5:;Q=K1\1
M-=1W<)TM?$":*+(0@[E:,'S?,ZYW-TZ8H ]&\F/^XOY4>3'_ '%_*O/_  -X
MXN_$.J*=26XMTU*.2;38#;*L1CC;!Q)N+,V""<A1Z5Z'3 9Y,?\ <7\J/)C_
M +B_E3Z*+ ,\F/\ N+^5(T,>T_(O3TJ2D;[I^E%@&+#'M'R+T]*7R8_[B_E6
M+K%W>'5-*TFSN3:&[6622X5%9E2,+PH8$9)<<D'@'CTSGDU]M;L-(?6$B<VM
MU,T\$"-YNR6)8]P8<';(=P7'/0BD!U?DQ_W%_*CR8_[B_E7(IKVKW-AH%^LM
MM%'<W:VMU$L))=@SJQ5BWRKE,@8)YZU$WB.^A\51VTUV09-2-H-/,''DF,E9
M0^,Y)&<YVXR,9&: .S\F/^XOY4>3'_<7\JQ]1\0G3]=M-)-E))/>X^S,K?*X
M!_>Y/\.Q<-[Y '-1ZC<7]YXD31[.]:QC2T-U)-'&KNY+[54;@0!PQ/&>G(I@
M;GDQ_P!Q?RH\F/\ N+^5<>UWXBFU.[MO[4MX9['2X+DK%"KPRRLTP8G(W!3Y
M2\ C&3R:635]6N?[(O[:\6/^T3;/;Z:L2MNA8*TS2,1N&U6;!! &%!R6Q2 Z
M_P F/^XOY4>3'_<7\JY'2-9U.?4-,N+BZ\RVU.:ZB%MY:@0",L4*D#).$P<D
MY)XQTK9UZ[FCDTNPMY&B?4+L0M(O5$6-Y&Q[D1E<]MV>U &KY,?]Q?RH\F/^
MXOY5S.EW.M:J!JL6H11P&^EA^Q/&H3R4E:(G=C=YAV[NN,\8[U7TGQ:U]XNO
MK$W5L]I)YL=DB,/,5X"%DW=_F)8CVC)[T ==Y,?]Q?RH\F/^XOY5Y_X5\77=
MT-.EN]0GNHI=-6[OQ-8F+[.[;0AC(0;U8[QP&^[G/KT+>+K5;LVS0N'$^PY.
M,0^3YWG=,[=O'^]Q0!O^3'_<7\J/)C_N+^5<GX-U34)G^RZPUT;RYMQ>0O*T
M922+=C*A0"A^9,H<XR,$\U);1:K/XIU+3)M>NVM;>U@F 6*%6)E:92-P3(QY
M8P1SUH ZCR8_[B_E1Y,?]Q?RK-\.7\^HZ'%-<D-<QR2V\S 8#/%(T;-CMDH3
MCWK5IV B6*/+?(O7T]J=Y,?]Q?RK'\4ZA<:5X5U:_M7V3P0LZ-MW8( YQWKG
MH/&3Z<=1>>YEO[.*2"WAFNX/LCBX?<6C?*KA538V[;T;^*D!W/DQ_P!Q?RH\
MF/\ N+^5<7#XT>YNUNT0"V2QN'D@,R!#(DT:!A(V!MPQ(/H>F>*LVOC66_\
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MLC^I_E3Z (OLT/\ SR7\J/LT/_/)?RJ6B@"+[-#_ ,\E_*C[-#_SR7\JEHH
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MB/=)'<%VDMTN&$19U*LVW.,D$^V><9YJUINDVFE>=]E1E\XH7W,3G;&L8_\
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M2Q>;.S^4D<BR(BY/ W*N>YP,DX%8'_"S$_Z!K?\ ?S_ZU'_"S$_Z!K?]_/\
MZU',@_LG&?R?BO\ ,ZMM!L&D=S&Q+W@O3\Y_UH4*#], <5!I/A?3]%N4GM6N
M2T=O]FB66=G6.+((10>@&![US?\ PLQ/^@:W_?S_ .M1_P +,3_H&M_W\_\
MK4<R#^R<9_)^*_S.^HK@?^%F)_T#6_[^?_6H_P"%F)_T#6_[^?\ UJ.9!_9.
M,_D_%?YG?45P/_"S$_Z!K?\ ?S_ZU'_"S$_Z!K?]_/\ ZU',@_LG&?R?BO\
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M##ZICO\ GW^*_P SD/\ A#_$/_0*N/R%'_"'^(?^@5<?D*Z__A::_P#0,/\
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M 2,'/4$BL[_A::_] P_]_*/^%IK_ - P_P#?RBZ#^RL9_)^*_P ST555$"J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*.HI*4=10!] 44E%
M;GYJ+1244 +1244 +1244P%HI** %KS?QMHNI7_B$S6MG)+'Y2C<O3/->CT5
M+5SJP>+EA:GM(*[VU/%?^$8UO_H'3?D*/^$8UO\ Z!TWY"O:J*GD/4_M^O\
MRK\?\SQ7_A&-;_Z!TWY"C_A&-;_Z!TWY"O:J*.0/[?K_ ,J_'_,\5_X1C6_^
M@=-^0H_X1C6_^@=-^0KVJBCD#^WZ_P#*OQ_S/%?^$8UO_H'3?D*/^$8UO_H'
M3?D*]JHHY _M^O\ RK\?\SQ7_A&-;_Z!TWY"C_A&-:_Z!TWY"O:J0_=/THY
M_M^O_*OQ_P SQR?0_$5TL2SV=S(L*".,-CY5'85#_P (QK?_ $#IOR%>U#H*
M*.02SZLE907X_P"9XK_PC&M_] Z;\A1_PC&M_P#0.F_(5[511R#_ +?K_P J
M_'_,\5_X1C6_^@=-^0H_X1C6_P#H'3?D*]JHHY _M^O_ "K\?\SQ7_A&-;_Z
M!TWY"C_A&-;_ .@=-^0KVJBCD#^WZ_\ *OQ_S/%?^$8UO_H'3?D*/^$8UO\
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M@;/^0KW>F( 'D(.22,CTX%'*']OU_P"5?C_F>%_\(MKG_0,G_*C_ (1;7/\
MH&3_ )5[O11RA_;]?^5?C_F>$?\ "+:Y_P! R?\ *C_A%M<_Z!D_Y5[O11RA
M_;]?^5?C_F>$?\(MKG_0,G_*C_A%M<_Z!D_Y5[O11RA_;]?^5?C_ )GA'_"+
M:Y_T#)_RH_X1;7/^@;/^0KW>D;E&R<#%'*']OU_Y5^/^9X3_ ,(MKG_0-G_(
M4?\ "+:Y_P! R?\ *O=A]T4M'*']OU_Y5^/^9X1_PBVN?] R?\J/^$6US_H&
M3_E7N]%'*']OU_Y5^/\ F>$?\(MKG_0,G_*C_A%M<_Z!D_Y5[O11RA_;]?\
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M1_PBVN?] R?\J]WHHY0_M^O_ "K\?\SPC_A%M<_Z!D_Y4?\ "+:Y_P! R?\
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MZ!D_Y4?\(MKG_0,G_*O=Z*.4/[?K_P J_'_,\(_X1;7/^@9/^5'_  BVN?\
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M!42>,=>-O?7H,("Q7):"5HO]&*.%#!5;S"%&2^X?3:.*]':W@>2.1H8V>/\
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MZ6.VMX45(H(D5&W*JH  ?4>_)_.H+#38M/:ZD62666ZE\V664@LQP% X
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MB_5XM'%[%J$$UU<6-Q<26OE*?L#IC ..< G80W4],=*](\F+:J^6FU3E1M&
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M!_S?@_\ (\RHKTW_ (57;?\ 05E_[\C_ !H_X57;?]!67_OR/\:+,/[9P?\
M-^#_ ,CS*BO3?^%5VW_05E_[\C_&C_A5=M_T%9?^_(_QHLP_MG!_S?@_\CS*
MBO3?^%5VW_05E_[\C_&C_A5=M_T%9?\ OR/\:+,/[9P?\WX/_(\RHKTW_A5=
MM_T%9?\ OR/\:/\ A5=M_P!!67_OR/\ &BS#^V<'_-^#_P CS*BO3#\+;8$
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MM@T@DO+F!9HN%18@""P)R3SSC%2VOC:PDMK9Y4N&#0V\DUQ' 1%'YR@H3DY
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M]Y)U/\1]*?Y _P">DO\ WV:<W^LC^I_E3Z (O('_ #TE_P"^S1Y _P">DO\
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M/=999[+[&4  VKN+;E/4-SP>V!563PQ<EIF@UNY@>[A2*]>.-=TK*NWS%/\
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M4;Y?^>/_ (^* ):*BWR_\\?_ !\4;Y?^>/\ X^* ):*BWR_\\?\ Q\4;Y?\
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MPB621-R #AE88)]JS- M;_P_)97EYIEY)$UE);@0IYDJ-Y[NI=03\SJREB.
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M6V5+A=)CN+M4C$,MQMW%#$0J2(V /,VG)"D]!P0 >AZAJ5II5K]IO9A%%O5
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M;_A/_$G_ #_+_P!^$_PH_P"$_P#$G_/\O_?A/\*YFBBX?4L-_P ^X_<CIO\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %,E_U+_P"Z:?3)?]2_^Z:
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MW_[_ +?XUL^4G]Q?RH\I/[B_E1RA]?Q/_/Q_>S&_X5_X;_Y]W_[_ +?XT?\
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MM,VE?[/M<%0A'E+]T!0!^2K_ -\CTH_LK3)+?R18VK0]-@B7;PI3I],CZ<4
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ML$>UMPV1@8.",\=\$_F:FHH I'1-**%#IED5+[R/(7!;UZ=>3S4PL+-2Q%I
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MYI(+"R(9(F7>R%AC<O4?2LG1$G9[MY[VXF\NX>)%DVXV@\'@#FM>@ #.!C-
MS(\174UI:VIAF,0DN51V#!?E(;N00.@YJ]IS^;8QMYOFYS\^\/G\0 #5AE5Q
MAU##T(S0JA%"J H'8<4"ZF/J5T4U06\]\;*V$'F)("HWOD@C)!' P<>]:EJ_
MF6D,GF&3<@.\KMW<=<=J>Z+(,.H8=>1FG4 <Y>:EJ4=OKAA0,MNQ$4F_!3]V
MIX&.>2:Z-3E%)ZD4FU2",#!Z\=:6@$+1244#%HI** %HI** #%&*7:W]T_E1
MM;^Z?RHN F*,4NUO[I_*C:W]T_E1<!,48I=K?W3^5&UO[I_*BX"8IDL,<\31
M31I)&W574$'\#4FUO[I_*C:W]T_E1<#B+?3XUT/31!&+:5]48-+%&H8 2R8[
M>GK2M?WZ>8#>;9(8;N-;F6($@)<HBDD*<?+U.,=R#BNVVM_=/Y4;6_NG\J0'
M,VVI3OX1U2[CN7DEMTF\N8LKC*ID%6  < ]\=L'I5 :C>3.T-EJ\UQ [VBM<
MJ$+1N[L)$!"X^Z%.".,^]=A<VJ7=K-;3(6BF0QNO(RI&"*D6/8@55( &!0!Q
M\>HZK_;TL!O8T\J9T\B1]SM$$.&$83)).&W;L=1[53CUO41I[A+_ ,[$L GN
M?-7RXU8/N(<)\A)500R_+N'KD=[M;^Z?RHVM_=/Y4 <.]]J[V%S+_:;9M]/E
MN8GM]KK(RN^S)*#=P #@ 'K3WO9+&36 =0E22348@=\BHL2-"A!+%3L4D%=V
M#TP.<FNUVM_=/Y4;6_NG\J //TO;JXBAO+B]<RMIM^B*=I25D? X*C<=HST&
M<9P!D5H+J=X+Q4^V.ET+F".&Q"KB2!@F]\8R>"YW X&W'KGL-K?W3^5&UO[I
M_*@#E]!N;][G33<WDTZWEE+-(LBJ KJ\8&, 8X<U5U*_N;>YU#;>I:QB_*DD
MK$7'V>(@"0J5SDGANN,9XQ79;6_NG\J-K?W3^5 '-ZR)-0\,:>YDG1I;BS9B
M4"N<RIG<N" ><X[$55_M*\74=@OI#=_:Y(GL2JX6 !MKXQD<!6W9P2<>U==M
M;^Z?RHVM_=/Y4 <PTETOP_:ZFN)+BZELUF9I44_,R@D;0,8]L5"LVIRW4974
M9U^TW]U:!=B;8T5)2C#Y<Y!1>2:ZW:W]T_E1M;^Z?RH XJ76=6FT^.\9OLL,
MERMO*781B()&V\[BK;<R_)DC& .F<TV35M0A^P-/J:L612$MR-TN92 R[D E
MRNW(4KCD@<BNWVM_=/Y4;6_NG\J .)M;E[13;S:M-!;G4+I;BX9D#1D,3&I)
M&%# [N>O&.M:&A7.HW^I(UW<S".*RBD$>Q5$I9YEWL,9!*JAP,=>E=-M;^Z?
MRHVM_=/Y4 <IJ5WJ<+:W<6]S+BWEABCCPH2-&$9=_NDY +')R!Z&J O[Q'2\
MDN5N?)M[PPRVS"8A<0D?-M56(.[MC &<X-=UM;^Z?RHVM_=/Y4 <$E_/=A3-
MJ9-O;:E!B>*977:R<Y?8H(W>W4XJ7^TKF.W<37[6**ER\!CC0>=*)Y %P5Y(
M 7Y1RVX]:[C:W]T_E1M;^Z?RH Y&"]U1KH7,]S,A&H16[6H5=@5HD+#IG[S'
MG/:I_#&HW%W=30SWS7;")79EP45B3VVJT;?[#9QCKUKI]K?W3^5&UO[I_*@#
MBEU6]>[=+;4I)[O[7=0M9@(1'$HDVM@#(P509)YSBD;7+F_\F.SU$X:*R622
M$*2CO*5DZ@@-CJ#T]*["VLX[1'2&,JKR/*PY.68EB?S)J;:W]T_E0!QT>I7*
M:P\":I+-<1Z@+<6;;#NAV*68@+GC).[.,C'M4,.KW[V@:/4V:Y>R>2\5XP19
M2@K@85<KR6&#GA<\X.>Q@LX[9IFBC*F:0ROU.6( S^0%3;6_NG\J .$?6KYK
M:!4OMEL9Y4>[DN$5,A4*JLP0JP.YN2H)*X[<VH]4OTU6PCNM0#22+ K008&2
MR_,VQE!9"3G<#\N.G!SV.UO[I_*C:W]T_E0!S>OW\UM>M&VH/8Q+:&2!D53Y
MTV3\O(.2!M^4<G<?2JT%YJCW0N9KF9"-0BMVM=J[ K1(6'3/#,><]JZW:W]T
M_E1M;^Z?RH XC1+G488]%TU'<175O#,K;1^[2,?O5Z=_W8]?G/I789N?M>WR
MH?LVW[_F'?N]-NW&/?/X4BV,:WS7FQS.4\L%F)"KU( Z#.!G'7 ]*L;6_NG\
MJ //-0BN;*RUNYB622VN[V2*>,<^6^X;) /0_=/_  $]C6NE_=S:HL'V^473
MWDL,MFH7]U -^V0<9' 1MQX);'L.LVM_=/Y4;6_NG\J ..B5I?A1(HN9'D&F
M,';<"P8(<H>.Q!4CK^-.N[VZLKJ6W2_E2> P)9VI5?\ 2E.W<2-N3R6!QC;M
MSQ77[6_NG\J-K?W3^5 &/H37,UE<W-S<RRN]Q.JJX4"-4E=5 P!V ZYKE[76
M;^;2K>2VU>6YEFLH9+E]J$V\K21C PN 2&?@Y^[GZ^@%"1@J?RJ*UM([*TAM
M8(RL,*+'&O)PH& ,GVH Y>YOKRUU"6W_ +1F^TPW$$5M:L%/VF(A-[GC)ZOD
MC 7;]<Y=U?WDK?:([Z635(K>^)M@JG[.X4[ %QD=!C.=W7FO0=K?W3^5&UO[
MI_*@#D+G7FN;^7[-J073?,@62ZB*D1*RR%CN((&65%)/3/:IM.<MXDM)&U2:
MXCELY!$SJ$$NV3L,<G&#D=>O0UU.UO[I_*C:W]T_E0!R,NJ7 UZYACU)S/'J
M,,,=B N&A9(RYQC=P&=LYXQ4=O>W:Z?I4FH:O/;P7<<DLURVQ=L@V[(P2N "
M"Q]25Z\UUD-G';R7$D495KB3S)#R<MM"Y]N%'Y5-M;^Z?RH X<7VLW%E+<O>
MW%O-%%:$(L: $NV&)4J3R.<=JLR7MU;7TUE=ZI-!8Q7;1F\?8& \F-U4L5P
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MW]T_E1<!,44NUO[I_*BBX%ZBBBLQA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Legend Biotech Corporation<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001801198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther', window );">License and other revenue - total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">298.4<span></span>
</td>
<td class="nump">185.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305.1<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(175.4)<span></span>
</td>
<td class="num">(69.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CostOfLicenseAndOtherRevenue', window );">Cost of license and other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(85.7)<span></span>
</td>
<td class="num">(101.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrativeExpense', window );">Administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40.0)<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_SellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50.1)<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49.8)<span></span>
</td>
<td class="num">(51.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(54.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(53.1)<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (54.3)<span></span>
</td>
<td class="num">$ (101.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 60.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (53.8)<span></span>
</td>
<td class="num">$ (40.3)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified to present loss on asset impairment into the other operating expenses line for comparative purposes.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CostOfLicenseAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of License And Other Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CostOfLicenseAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from licensing of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualPropertyAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_SellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_SellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 121.4<span></span>
</td>
<td class="nump">$ 116.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">331.1<span></span>
</td>
<td class="nump">285.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationPrepaidLeases', window );">Collaboration prepaid leases</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">514.0<span></span>
</td>
<td class="nump">486.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Collaboration inventories, net</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepayments, other receivables and other assets</a></td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">253.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_TimeDeposits', window );">Time deposits</a></td>
<td class="nump">188.2<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">646.4<span></span>
</td>
<td class="nump">901.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,082.7<span></span>
</td>
<td class="nump">1,247.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,596.7<span></span>
</td>
<td class="nump">1,733.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Tax payable</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherPayablesAndAccrualsCurrent', window );">Other payables and accruals</a></td>
<td class="nump">130.2<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Collaboration interest-bearing advanced funding</a></td>
<td class="nump">266.0<span></span>
</td>
<td class="nump">319.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">509.1<span></span>
</td>
<td class="nump">636.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities long term</a></td>
<td class="nump">112.1<span></span>
</td>
<td class="nump">87.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">119.9<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">629.0<span></span>
</td>
<td class="nump">731.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">967.6<span></span>
</td>
<td class="nump">1,002.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">967.7<span></span>
</td>
<td class="nump">1,002.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY</a></td>
<td class="nump">$ 1,596.7<span></span>
</td>
<td class="nump">$ 1,733.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationPrepaidLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Prepaid Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationPrepaidLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherPayablesAndAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables and accruals, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherPayablesAndAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_TimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Times deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_TimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Share-based compensation reserves</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Retained accumulated losses</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,040.6<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td colspan="2" class="nump">$ 2,696.0<span></span>
</td>
<td colspan="2" class="nump">$ 74.4<span></span>
</td>
<td colspan="2" class="num">$ (68.2)<span></span>
</td>
<td colspan="2" class="num">$ (1,661.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(101.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(101.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="nump">60.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">60.7<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="num">(40.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">60.7<span></span>
</td>
<td colspan="2" class="num">(101.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">2.4<span></span>
</td>
<td colspan="2" class="num">(0.9)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity', window );">Reclassification of vested restricted share units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">14.5<span></span>
</td>
<td colspan="2" class="num">(14.5)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation expense</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">15.9<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">1,017.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td colspan="2" class="nump">2,712.9<span></span>
</td>
<td colspan="2" class="nump">74.9<span></span>
</td>
<td colspan="2" class="num">(7.5)<span></span>
</td>
<td colspan="2" class="num">(1,762.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,017.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,002.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">1,002.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td colspan="2" class="nump">2,750.3<span></span>
</td>
<td colspan="2" class="nump">88.0<span></span>
</td>
<td colspan="2" class="nump">122.2<span></span>
</td>
<td colspan="2" class="num">(1,958.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(54.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(54.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">0.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="num">(53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">0.5<span></span>
</td>
<td colspan="2" class="num">(54.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">0.2<span></span>
</td>
<td colspan="2" class="num">(0.1)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity', window );">Reclassification of vested restricted share units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">30.4<span></span>
</td>
<td colspan="2" class="num">(30.4)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation expense</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">19.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">967.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td colspan="2" class="nump">$ 2,780.9<span></span>
</td>
<td colspan="2" class="nump">$ 76.8<span></span>
</td>
<td colspan="2" class="nump">$ 122.7<span></span>
</td>
<td colspan="2" class="num">$ (2,012.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">$ 967.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These reserve accounts comprise the consolidated reserves of $967.6 million and $1,017.6 million in the consolidated statements of financial position as at March&#160;31, 2026 and 2025, respectively</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through reclassification of vested restricted stock, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (99.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(12.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForInventoryReserveProvision', window );">Provision for inventory reserve</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForDepreciationOfRightOfUseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13.2<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign currency exchange loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows provided by (used in) operations before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17.4)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease in trade receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets', window );">Increase/(decrease) in prepayments, other receivables and other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(48.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Increase/(decrease) in collaboration inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease)/increase in trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8.1)<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Decrease in other payables and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(65.2)<span></span>
</td>
<td class="num">(39.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Decrease in contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Interest income received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(85.1)<span></span>
</td>
<td class="num">(103.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets', window );">Prepayment to collaborator for collaboration assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18.4)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdditionInTimeDeposits', window );">Addition in time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(327.0)<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DecreaseInTimeDeposits', window );">Decrease in time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184.9<span></span>
</td>
<td class="nump">374.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(168.0)<span></span>
</td>
<td class="nump">256.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal portion of lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(255.5)<span></span>
</td>
<td class="nump">155.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">901.9<span></span>
</td>
<td class="nump">286.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">646.4<span></span>
</td>
<td class="nump">441.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash and bank balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">834.6<span></span>
</td>
<td class="nump">1,005.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Less: Pledged deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_TimesDepositsCurrentAndNoncurrent', window );">Time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188.2<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition', window );">Cash and cash equivalents as stated in the statement of financial position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">646.4<span></span>
</td>
<td class="nump">441.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding', window );">Non-cash repayment of collaboration interest-bearing advanced funding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 57.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts including loss on impairment, loss on disposal of PPE, amortization of intangible assets, and deferred government grant have been grouped into the other, net line item for comparative purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified between increase in (decrease)/trade payables and decrease in other payables and accruals for comparative purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts including interest on lease payments have been grouped into decrease in other payables and accruals.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts including decrease/(increase) in other non-current assets, government grant received, increase/(decrease) in other non-current liabilities, and increase in pledged deposits, net have been grouped into the other assets and liabilities, net line item for comparative purposes.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdditionInTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition in time deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdditionInTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in prepayments other receivable other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForDepreciationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForDepreciationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Increase (Decrease) In Other Assets and liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForInventoryReserveProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Inventory Reserve Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForInventoryReserveProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents as stated in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DecreaseInTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in time deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DecreaseInTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Repayment Of Collaboration Interest-Bearing Advanced Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment To Collaborator For Collaboration Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_TimesDepositsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Times deposits current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_TimesDepositsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">CORPORATE INFORMATION</a></td>
<td class="text">CORPORATE INFORMATION <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Legend Biotech Corporation ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Legend is an investment holding company. The Company's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PREPARATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_BasisOfPreparationAbstract', window );"><strong>Basis of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">BASIS OF PREPARATION</a></td>
<td class="text">BASIS OF PREPARATION <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#8220;Company&#8221;) for the three months ended March&#160;31, 2026 have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS34&#8221;) issued by the International Accounting Standards Board (the &#8220;IASB&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2025. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#8217;s annual consolidated financial statements as at December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of Preparation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</a></td>
<td class="text">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no new International Financial Reporting Standards (&#8220;IFRS&#8221;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2026 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.</span></div>The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 180<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_180_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 180<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_180_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Related party sublicense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue - total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">298.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total license and other revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">216.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">298.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeExpenseNetTextBlock', window );">OTHER (EXPENSE)/INCOME, NET</a></td>
<td class="text">OTHER (EXPENSE)/INCOME, NET <div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange loss, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(55.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense)/income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Foreign currency exchange loss is primarily remeasurement losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeExpenseNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeExpenseNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS PER SHARE <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2026 and 2025, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(101.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">370.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">367.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">370.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">367.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company as a lessee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between 3 and 29 years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 50 years, and no ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#8217;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Right-of-use assets</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2026 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">285.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">331.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lease liabilities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of a lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2026 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           The Company has a lease that commenced in February 2026, with Janssen located in Raritan, New Jersey. The Company expects to receive 50% of the future lease payments from Janssen from profit sharing under the Janssen Agreement. The Company recognizes the full lease liability of approximately $30.6 million, rather than its share because the Company has the primary responsibility for making the lease payments. A finance sublease receivable of approximately $15.3&#160;million is subsequently recognized when the related right-of-use asset is subleased to the collaboration. The total sublease receivable of $15.3&#160;million has been classified in prepayments, other receivables and other assets of $1.8&#160;million, and other non-current assets of $13.5&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">COLLABORATION INVENTORIES, NET</a></td>
<td class="text">COLLABORATION INVENTORIES, NET<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $12.5&#160;million and $18.7 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively. The Company&#8217;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock', window );">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</a></td>
<td class="text">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">227.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">253.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2026 and December&#160;31, 2025 is insignificant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">COLLABORATION INTEREST-BEARING ADVANCED FUNDING</a></td>
<td class="text">COLLABORATION INTEREST-BEARING ADVANCED FUNDING <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">266.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the Janssen Agreement, the Company received advances from Janssen over time ("Funding Advances"). These Funding Advances are accounted for as interest-bearing borrowings funded by Janssen, constituted by a principal amounting to $250.0&#160;million and applicable interests accrued amounting to $73.3&#160;million upon such principal as of March&#160;31, 2026. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding Funding Advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%.  <br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">There is no specific maturity date for the Funding Advances. However, pursuant to the terms of the Janssen Agreement, Janssen may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#8217;s share of pre-tax profits starting from the first calendar quarter following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the quarter ended March&#160;31, 2026, the Company reduced its collaboration advanced funding principal balance by $57.3&#160;million by offsetting it with the pre-tax profit receivable for the quarter, which resulted in an outstanding principal balance of $192.7&#160;million and outstanding accrued interest balance of $73.3&#160;million, in each case as of March&#160;31, 2026. As of March&#160;31, 2026, the Company estimated that the entire balance of $266.0&#160;million (inclusive of both principal and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">interest) would be recouped by Janssen within the next 12 months, and therefore such amount was classified as a current liability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interest for the Funding Advances was $4.2&#160;million and $4.6&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively. These amounts are included in Finance Costs on the consolidated statement of profit or loss and other comprehensive income/(loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">SHARE CAPITAL AND SHARE PREMIUM</a></td>
<td class="text">SHARE CAPITAL AND SHARE PREMIUM <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000,000,000 ordinary shares of $0.0001 each</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025 and January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">369,886,369</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,750.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,750.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">271,380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,321,834</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">371,479,583</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,780.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,781.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory', window );">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the authorisation of financial statements for issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENT<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2026, milestones payable to Legend were triggered due to the successful completion of milestones related to the receipt of commercialization approvals in three major European countries. The milestone payments of $55.0&#160;million attributable to these milestones will be recognized as License and other revenue in the three months ended June 30, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Analysis of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Related party sublicense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and other revenue - total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">298.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Revenue by Geographic Area</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total license and other revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">216.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">298.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock', window );">Summary of Disclosure of Timing of transfer of Goods or Services</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Timing Of Transfer Of Goods Or Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock', window );">Schedule of Total Other (Expense) / Income</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange loss, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(55.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense)/income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other expenses, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Foreign currency exchange loss is primarily remeasurement losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Calculations of Basic and Diluted Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(101.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">370.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">367.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">370.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">367.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Carrying Amounts of The Right-of-use Assets and Movements</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2026 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">285.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">331.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeaseLiabilitiesTextBlock', window );">Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term</a></td>
<td class="text">The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2026 are as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LesseeLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee lease liabilities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LesseeLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock', window );">Summary of Prepayments, Other Receivables and Other Assets</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">227.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">253.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Summary of Interest-Bearing Loans and Borrowings</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">266.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Summary of Shares</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,000,000,000 ordinary shares of $0.0001 each</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock', window );">Summary of Movements in the Company's Share Capital and Share Premium</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025 and January 1, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">369,886,369</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,750.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,750.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">271,380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,321,834</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">371,479,583</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,780.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,781.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in the company's share capital and share premium explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Summary of Analysis of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther', window );">License and other revenue - total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">298.4<span></span>
</td>
<td class="nump">185.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305.1<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_NovartisMember', window );">Novartis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualProperty', window );">License and other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_RelatedPartySublicenseMember', window );">Related Party Sublicense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualProperty', window );">License and other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Licensing Of Intellectual Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from licensing of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualPropertyAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_RelatedPartySublicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_RelatedPartySublicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Summary of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther', window );">License and other revenue - total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">298.4<span></span>
</td>
<td class="nump">185.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305.1<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther', window );">License and other revenue - total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216.4<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther', window );">License and other revenue - total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=legn_OutsideTheUnitedStatesOfAmericaMember', window );">Outside the United States of America</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 82.0<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualPropertyAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from licensing of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualPropertyAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=legn_OutsideTheUnitedStatesOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=legn_OutsideTheUnitedStatesOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Analysis of Timing of Transfer of Goods or Services (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">$ 305.1<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Revenue at a point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Revenue over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign currency exchange loss, net</a></td>
<td class="num">$ (5.9)<span></span>
</td>
<td class="num">$ (55.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherMiscellaneousIncomeExpense', window );">Other (expense)/income, net</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Total other expenses, net</a></td>
<td class="num">$ (5.1)<span></span>
</td>
<td class="num">$ (54.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 218<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_218_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherMiscellaneousIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherMiscellaneousIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (54.3)<span></span>
</td>
<td class="num">$ (101.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic (in shares)</a></td>
<td class="nump">370.2<span></span>
</td>
<td class="nump">367.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted (in shares)</a></td>
<td class="nump">370.2<span></span>
</td>
<td class="nump">367.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepayments, other receivables and other assets</a></td>
<td class="nump">$ 209,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement', window );">Lease commitment, percentage of future lease payments expected under profit Sharing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceLeaseReceivables', window );">Finance lease receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepayments, other receivables and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinanceLeaseReceivables', window );">Current finance lease receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinanceLeaseReceivables', window );">Non-current finance lease receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Freehold land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OngoingLeasePaymentsUnderTheLandLease', window );">Ongoing lease payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">29 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinanceLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current finance lease receivables. [Refer: Finance lease receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinanceLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinanceLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current finance lease receivables. [Refer: Finance lease receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinanceLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LesseeLeasingArrangementsLeasesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements leases term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LesseeLeasingArrangementsLeasesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OngoingLeasePaymentsUnderTheLandLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ongoing lease payments under the land lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OngoingLeasePaymentsUnderTheLandLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Beginning balance</a></td>
<td class="nump">$ 285.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">62.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate', window );">Exchange realignment</a></td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="num">(13.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Ending balance</a></td>
<td class="nump">$ 331.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of exchange realignment in foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Analyzed into:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion</a></td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current portion</a></td>
<td class="nump">112.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Analyzed into:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying amount at March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying amount at January 1, 2026</a></td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseInLeaseLiabilities', window );">Additions</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseOfLeaseLiabilitiesBalance', window );">Accretion of interest recognized during the period</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payments</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange realignment</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying amount at March 31, 2026</a></td>
<td class="nump">123.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Analyzed into:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current portion</a></td>
<td class="nump">112.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying amount at March 31, 2026</a></td>
<td class="nump">$ 123.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseOfLeaseLiabilitiesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase of lease liabilities balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseOfLeaseLiabilitiesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET - Summary of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 24.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work-in-process</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total collaboration inventories, net</a></td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="nump">$ 32.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details) - Prepayments Other Receivable and Other Assets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherCollaborationReceivables', window );">Other collaboration receivables</a></td>
<td class="nump">$ 174.0<span></span>
</td>
<td class="nump">$ 227.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxReceivables', window );">VAT recoverable</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PrepaymentsOtherReceivablesAndOtherAssets', window );">Total</a></td>
<td class="nump">$ 209.3<span></span>
</td>
<td class="nump">$ 253.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherCollaborationReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Collaboration Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherCollaborationReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PrepaymentsOtherReceivablesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PrepaymentsOtherReceivablesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=legn_PrepaymentsOtherReceivablesAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=legn_PrepaymentsOtherReceivablesAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Effective interest rate (%)</a></td>
<td class="nump">6.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Collaboration Interest-bearing Advanced Funding</a></td>
<td class="nump">$ 266.0<span></span>
</td>
<td class="nump">$ 319.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems', window );"><strong>Disclosure of continuing involvement in derecognised financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease', window );">Advanced funding principal balance increase (decrease)</a></td>
<td class="num">$ (57.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable', window );">Outstanding principal balance</a></td>
<td class="nump">192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Collaboration interest-bearing advanced funding</a></td>
<td class="nump">266.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems', window );"><strong>Disclosure of continuing involvement in derecognised financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestBearingBorrowingsFundingAdvances', window );">Interest bearing borrowings, funding advances</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestBearingBorrowingsFundedInterestsAccrued', window );">Interest accrued on funding advances</a></td>
<td class="nump">$ 73.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Interest rate margin percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestBearingBorrowingsFundedInterestsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest bearing borrowings funded interests accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestBearingBorrowingsFundedInterestsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestBearingBorrowingsFundingAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Bearing Borrowings, Funding Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestBearingBorrowingsFundingAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Bearing Borrowings, Funding Advances, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issued and fully paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AuthorisedAbstract', window );"><strong>Authorized:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Authorized (in shares)</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Authorized, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AuthorizedShareCapital', window );">2,000,000,000 ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issued and fully paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and fully paid (in shares)</a></td>
<td class="nump">371,479,583<span></span>
</td>
<td class="nump">369,886,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issued and fully paid, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AuthorisedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AuthorisedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">$ 2,750.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">30.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">$ 2,781.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Number of shares in issue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">369,886,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOptionNumberOfSharesInIssue', window );">Exercise of share option (in shares) | shares</a></td>
<td class="nump">271,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue', window );">Reclassification of vesting of restricted share units (in shares) | shares</a></td>
<td class="nump">1,321,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">371,479,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">2,750.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">30.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">$ 2,780.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ExerciseOfShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ExerciseOfShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ExerciseOfShareOptionNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share option number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ExerciseOfShareOptionNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of vested restricted stock units, number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of vested restricted stock units, share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalAndSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalAndSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital and share premium, number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details) - Revenue Milestone Payment<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2026 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_NumberOfCountriesToReceiveCommericalApproval', window );">Number of countries to receive commerical approval | country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=legn_RevenueMilestonePaymentMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ProceedsFromMilestonePayments', window );">Milestone payments recognized as revenue | $</a></td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_NumberOfCountriesToReceiveCommericalApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries To Receive Commerical Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_NumberOfCountriesToReceiveCommericalApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ProceedsFromMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ProceedsFromMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=legn_RevenueMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=legn_RevenueMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>68</ContextCount>
  <ElementCount>168</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Disclosure - CORPORATE INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CORPORATEINFORMATION</Role>
      <ShortName>CORPORATE INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - BASIS OF PREPARATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/BASISOFPREPARATION</Role>
      <ShortName>BASIS OF PREPARATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY</Role>
      <ShortName>NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENET</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - COLLABORATION INVENTORIES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET</Role>
      <ShortName>COLLABORATION INVENTORIES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS</Role>
      <ShortName>APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/REVENUE</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHEREXPENSEINCOMENET</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/LOSSPERSHARE</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/LEASES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables</Role>
      <ShortName>COLLABORATION INVENTORIES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails</Role>
      <ShortName>REVENUE - Summary of Analysis of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - REVENUE - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUESummaryofRevenueDetails</Role>
      <ShortName>REVENUE - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails</Role>
      <ShortName>REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails</Role>
      <ShortName>LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails</Role>
      <ShortName>LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails</Role>
      <ShortName>LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails</Role>
      <ShortName>COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails</Role>
      <ShortName>COLLABORATION INVENTORIES, NET - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="legn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - SUBSEQUENT EVENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SUBSEQUENTEVENTDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="legn-20260331.htm">legn-20260331.htm</File>
    <File>legn-20260331.xsd</File>
    <File>legn-20260331_cal.xml</File>
    <File>legn-20260331_def.xml</File>
    <File>legn-20260331_lab.xml</File>
    <File>legn-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="276">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "legn-20260331.htm": {
   "nsprefix": "legn",
   "nsuri": "http://legendbiotech.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "legn-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "legn-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "legn-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "legn-20260331_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "legn-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "legn-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 117,
   "keyCustom": 51,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 7,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 68,
   "entityCount": 1,
   "segmentCount": 22,
   "elementCount": 267,
   "unitCount": 5,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 276,
    "http://xbrl.sec.gov/dei/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://legendbiotech.com/role/COVER",
     "longName": "0000001 - Document - COVER",
     "shortName": "COVER",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS",
     "longName": "9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:RevenueFromLicensingOfIntellectualPropertyAndOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "longName": "9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://legendbiotech.com/role/CORPORATEINFORMATION",
     "longName": "9952155 - Disclosure - CORPORATE INFORMATION",
     "shortName": "CORPORATE INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://legendbiotech.com/role/BASISOFPREPARATION",
     "longName": "9952156 - Disclosure - BASIS OF PREPARATION",
     "shortName": "BASIS OF PREPARATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY",
     "longName": "9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
     "shortName": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://legendbiotech.com/role/REVENUE",
     "longName": "9952158 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENET",
     "longName": "9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET",
     "shortName": "OTHER (EXPENSE)/INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfOtherIncomeExpenseNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfOtherIncomeExpenseNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://legendbiotech.com/role/LOSSPERSHARE",
     "longName": "9952160 - Disclosure - LOSS PER SHARE",
     "shortName": "LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://legendbiotech.com/role/LEASES",
     "longName": "9952161 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET",
     "longName": "9952162 - Disclosure - COLLABORATION INVENTORIES, NET",
     "shortName": "COLLABORATION INVENTORIES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS",
     "longName": "9952163 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING",
     "longName": "9952164 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM",
     "longName": "9952165 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS",
     "longName": "9952166 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
     "shortName": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://legendbiotech.com/role/SUBSEQUENTEVENT",
     "longName": "9952167 - Disclosure - SUBSEQUENT EVENT",
     "shortName": "SUBSEQUENT EVENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://legendbiotech.com/role/REVENUETables",
     "longName": "9955511 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables",
     "longName": "9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)",
     "shortName": "OTHER (EXPENSE)/INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://legendbiotech.com/role/LOSSPERSHARETables",
     "longName": "9955513 - Disclosure - LOSS PER SHARE (Tables)",
     "shortName": "LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://legendbiotech.com/role/LEASESTables",
     "longName": "9955514 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables",
     "longName": "9955515 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)",
     "shortName": "COLLABORATION INVENTORIES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables",
     "longName": "9955516 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables",
     "longName": "9955517 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables",
     "longName": "9955518 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
     "longName": "9955519 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)",
     "shortName": "REVENUE - Summary of Analysis of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
     "longName": "9955520 - Disclosure - REVENUE - Summary of Revenue (Details)",
     "shortName": "REVENUE - Summary of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:RevenueFromLicensingOfIntellectualPropertyAndOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "legn:RevenueFromLicensingOfIntellectualPropertyAndOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
     "longName": "9955521 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)",
     "shortName": "REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails",
     "longName": "9955522 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)",
     "shortName": "OTHER (EXPENSE)/INCOME, NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails",
     "longName": "9955523 - Disclosure - LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details)",
     "shortName": "LOSS PER SHARE - Summary of Calculations of Basic and Diluted Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
     "longName": "9955524 - Disclosure - LEASES - Additional Information (Details)",
     "shortName": "LEASES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-55",
      "name": "legn:LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails",
     "longName": "9955525 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)",
     "shortName": "LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
     "longName": "9955526 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)",
     "shortName": "LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "legn:IncreaseInLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails",
     "longName": "9955527 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)",
     "shortName": "COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails",
     "longName": "9955528 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)",
     "shortName": "COLLABORATION INVENTORIES, NET - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "legn:InventoryReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "legn:InventoryReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails",
     "longName": "9955529 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-56",
      "name": "legn:OtherCollaborationReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "legn:OtherCollaborationReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails",
     "longName": "9955530 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
     "longName": "9955531 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails",
     "longName": "9955532 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ifrs-full:NumberOfSharesAuthorised",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
     "longName": "9955533 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "legn:ShareCapitalAndSharePremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "legn:ShareCapitalAndSharePremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails",
     "longName": "9955534 - Disclosure - SUBSEQUENT EVENT (Details)",
     "shortName": "SUBSEQUENT EVENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "legn:NumberOfCountriesToReceiveCommericalApproval",
      "unitRef": "country",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "legn:NumberOfCountriesToReceiveCommericalApproval",
      "unitRef": "country",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "legn_AdditionInTimeDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AdditionInTimeDeposits",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Addition in time deposits",
        "label": "Addition In Time Deposits",
        "documentation": "Addition in time deposits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in collaboration inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in prepayments, other receivables and other assets",
        "label": "Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets",
        "documentation": "Adjustments for decrease increase in prepayments other receivable other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of property, plant and equipment",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "legn_AdjustmentsForDepreciationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AdjustmentsForDepreciationOfRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of right-of-use assets",
        "label": "Adjustments For Depreciation Of Right Of Use Assets",
        "documentation": "Adjustments for depreciation of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance costs",
        "label": "Adjustments for finance costs"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance income",
        "label": "Adjustments for finance income"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in contract liabilities",
        "label": "Adjustments for increase (decrease) in contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets and liabilities, net",
        "label": "Adjustments for Increase (Decrease) In Other Assets and liabilities, Net",
        "documentation": "Adjustments for Increase (Decrease) In Other Assets and liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in other payables and accruals",
        "label": "Adjustments for increase (decrease) in other operating payables"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease)/increase in trade payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "legn_AdjustmentsForInventoryReserveProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AdjustmentsForInventoryReserveProvision",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for inventory reserve",
        "label": "Adjustments For Inventory Reserve Provision",
        "documentation": "Adjustments For Inventory Reserve Provision"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized foreign currency exchange loss",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r177"
     ]
    },
    "ifrs-full_AdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Administrative expenses",
        "label": "Administrative expenses"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r146",
      "r167"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r69",
      "r72",
      "r110",
      "r111",
      "r129"
     ]
    },
    "legn_AuthorisedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AuthorisedAbstract",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized:",
        "label": "Authorised [Abstract]",
        "documentation": "Authorised."
       }
      }
     },
     "auth_ref": []
    },
    "legn_AuthorizedShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "AuthorizedShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2,000,000,000 ordinary shares of $0.0001 each",
        "label": "Authorized Share Capital",
        "documentation": "Authorized share capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15"
     ]
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share [abstract]",
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_BasisOfPreparationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "BasisOfPreparationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation [Abstract]",
        "documentation": "Basis of Preparation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsAdjustmentToInterestRateBasis",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate margin percentage",
        "label": "Borrowings, adjustment to interest rate basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate (%)",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of Range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r44",
      "r57",
      "r58",
      "r92",
      "r156",
      "r157",
      "r183"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and bank balances",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r39",
      "r93",
      "r127"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS",
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_Cash",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents as stated in the statement of financial position",
        "label": "Cash And Cash Equivalents As Stated In Statement Of Financial Position",
        "documentation": "Cash and cash equivalents as stated in statement of financial position."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r26"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r26"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r26"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) operations before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r179"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r80"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r63",
      "r108",
      "r109"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [domain]",
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r63",
      "r108",
      "r109"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of current inventories [abstract]",
        "label": "Classes of current inventories [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r100"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r100"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r115",
      "r137"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [domain]",
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r115",
      "r137"
     ]
    },
    "legn_CollaborationPrepaidLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "CollaborationPrepaidLeases",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration prepaid leases",
        "label": "Collaboration Prepaid Leases",
        "documentation": "Collaboration Prepaid Leases"
       }
      }
     },
     "auth_ref": []
    },
    "legn_CollaborationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "CollaborationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_RevenueFromContractsWithCustomers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Collaboration Revenue",
        "documentation": "Collaboration Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL COMPREHENSIVE LOSS",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31",
      "r36",
      "r104",
      "r107",
      "r119",
      "r141",
      "r155"
     ]
    },
    "legn_CostOfLicenseAndOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "CostOfLicenseAndOtherRevenue",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of license and other revenue",
        "label": "Cost Of License And Other Revenue",
        "documentation": "Cost Of License And Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of collaboration revenue",
        "label": "Cost of sales"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r146"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [domain]",
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r130",
      "r155"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration interest-bearing advanced funding",
        "verboseLabel": "Collaboration Interest-bearing Advanced Funding",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_CurrentFinanceLeaseReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentFinanceLeaseReceivables",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current finance lease receivables",
        "label": "Current finance lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current finance lease receivables. [Refer: Finance lease receivables]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current portion",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r131",
      "r155"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments, other receivables and other assets",
        "label": "Current prepayments and other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax payable",
        "label": "Current tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r169",
      "r170"
     ]
    },
    "legn_DecreaseInTimeDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DecreaseInTimeDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in time deposits",
        "label": "Decrease In Time Deposits",
        "documentation": "Decrease in time deposits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of right-of-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      }
     },
     "auth_ref": [
      "r50",
      "r79"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r94"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15"
     ]
    },
    "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
        "label": "Disclosure of authorisation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the authorisation of financial statements for issue."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/BASISOFPREPARATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PREPARATION",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
        "label": "Disclosure of borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL AND SHARE PREMIUM",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r115",
      "r137"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r115",
      "r137"
     ]
    },
    "ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsLineItems",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of continuing involvement in derecognised financial assets [line items]",
        "label": "Disclosure of continuing involvement in derecognised financial assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfContinuingInvolvementInDerecognisedFinancialAssetsTable",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of continuing involvement in derecognised financial assets [table]",
        "label": "Disclosure of continuing involvement in derecognised financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to continuing involvement in derecognised financial assets."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest-Bearing Loans and Borrowings",
        "label": "Disclosure of detailed information about borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inventories",
        "label": "Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]",
        "documentation": "The disclosure of detailed information about inventories."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]",
        "label": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]",
        "documentation": "Disclosure of detailed information about lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "documentation": "Disclosure of detailed information about lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Other (Expense) / Income",
        "label": "Disclosure Of Detailed Information About Other Income (Expense) [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepayments, Other Receivables and Other Assets",
        "label": "Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [abstract]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Revenue",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENT",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue by Geographic Area",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATION INVENTORIES, NET",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in the Company's Share Capital and Share Premium",
        "label": "Disclosure Of Movements In Company Share Capital And Share Premium Explanatory [Table Text Block]",
        "documentation": "Disclosure of movements in the company's share capital and share premium explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]",
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r95"
     ]
    },
    "legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/CORPORATEINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CORPORATE INFORMATION",
        "label": "Disclosure of notes and other explanatory information [text block]",
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "legn_DisclosureOfOtherIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfOtherIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Other Income and Expense [Abstract]",
        "documentation": "Disclosure of Other Income and Gains"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfOtherIncomeExpenseNetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfOtherIncomeExpenseNetTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER (EXPENSE)/INCOME, NET",
        "label": "Disclosure of Other Income (Expense), Net [Text Block]",
        "documentation": "Disclosure of Other Income (Expense), Net"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Carrying Amounts of The Right-of-use Assets and Movements",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r83"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Shares",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r116",
      "r138"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Disclosure of Timing of transfer of Goods or Services",
        "label": "Disclosure Of Timing Of Transfer Of Goods Or Services [Table Text Block]",
        "documentation": "Disclosure Of Timing Of Transfer Of Goods Or Services"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "verboseLabel": "Loss per share",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Calculations of Basic and Diluted Loss per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rate changes, net",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30",
      "r41",
      "r42",
      "r43",
      "r103",
      "r106",
      "r110",
      "r111",
      "r117",
      "r129",
      "r133"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_ExchangeDifferencesOnTranslationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExchangeDifferencesOnTranslationAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE LOSS",
        "label": "Exchange differences on translation [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_ExerciseOfShareOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ExerciseOfShareOption",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Exercise Of Share Option",
        "documentation": "Exercise of share option."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ExerciseOfShareOptionNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ExerciseOfShareOptionNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share option (in shares)",
        "label": "Exercise Of Share Option Number Of Shares In Issue",
        "documentation": "Exercise of share option number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Finance costs",
        "label": "Finance costs"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income received",
        "label": "Finance income received, classified as operating activities"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_FinanceLeaseReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceLeaseReceivables",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease receivables",
        "label": "Finance lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to finance leases."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r174"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency exchange loss, net",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r101",
      "r124"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue at a point in time",
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r162"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue over time",
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r162"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r13",
      "r40",
      "r68",
      "r96",
      "r97",
      "r98",
      "r144"
     ]
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax paid",
        "label": "Income taxes paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r93"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange realignment",
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r90"
     ]
    },
    "legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange realignment",
        "label": "Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate",
        "documentation": "Increase (decrease) through effect of exchange realignment in foreign exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vested restricted share units",
        "label": "Increase Decrease Through Reclassification Of Vested Restricted Stock Equity",
        "documentation": "Increase (decrease) through reclassification of vested restricted stock, equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based compensation expense",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "legn_IncreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "IncreaseInLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase In Lease Liabilities",
        "documentation": "Increase in lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_IncreaseOfLeaseLiabilitiesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "IncreaseOfLeaseLiabilitiesBalance",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of interest recognized during the period",
        "label": "Increase Of Lease Liabilities Balance",
        "documentation": "Increase of lease liabilities balance."
       }
      }
     },
     "auth_ref": []
    },
    "legn_InterestBearingBorrowingsFundedInterestsAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "InterestBearingBorrowingsFundedInterestsAccrued",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued on funding advances",
        "label": "Interest Bearing Borrowings Funded Interests Accrued",
        "documentation": "Interest bearing borrowings funded interests accrued."
       }
      }
     },
     "auth_ref": []
    },
    "legn_InterestBearingBorrowingsFundingAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "InterestBearingBorrowingsFundingAdvances",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest bearing borrowings, funding advances",
        "label": "Interest Bearing Borrowings, Funding Advances",
        "documentation": "Interest Bearing Borrowings, Funding Advances"
       }
      }
     },
     "auth_ref": []
    },
    "legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "InterestBearingBorrowingsFundingAdvancesIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced funding principal balance increase (decrease)",
        "label": "Interest Bearing Borrowings, Funding Advances, Increase (Decrease)",
        "documentation": "Interest Bearing Borrowings, Funding Advances, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable",
        "documentation": "Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense on borrowings",
        "label": "Interest expense on borrowings"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration inventories, net",
        "totalLabel": "Total collaboration inventories, net",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r89",
      "r126",
      "r169"
     ]
    },
    "legn_InventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "InventoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory reserve",
        "documentation": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r172"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "Number of shares in issue",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "legn_JanssenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "JanssenMember",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen",
        "label": "Janssen [Member]",
        "documentation": "Janssen"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LandMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freehold land",
        "label": "Land [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "legn_LeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LeaseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease [Abstract]",
        "documentation": "Lease abstract."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease commitment, percentage of future lease payments expected under profit Sharing agreement",
        "label": "Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement",
        "documentation": "Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "periodStartLabel": "Carrying amount at January 1, 2026",
        "periodEndLabel": "Carrying amount at March 31, 2026",
        "totalLabel": "Carrying amount at March 31, 2026",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analyzed into:",
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r154"
     ]
    },
    "legn_LeasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LeasesLineItems",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "documentation": "Leases line items."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LeasesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LeasesTable",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Table]",
        "label": "Leases [Table]",
        "documentation": "Leases table."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LesseeLeaseLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LesseeLeaseLiabilitiesTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term",
        "label": "Lessee Lease Liabilities [Text Block]",
        "documentation": "Lessee lease liabilities text block."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LesseeLeasingArrangementsLeasesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "LesseeLeasingArrangementsLeasesTerm",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, lease terms",
        "label": "Lessee Leasing Arrangements Leases Term",
        "documentation": "Lessee leasing arrangements leases term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r69",
      "r73",
      "r110",
      "r111",
      "r129"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r152"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [domain]",
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r152"
     ]
    },
    "legn_NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash repayment of collaboration interest-bearing advanced funding",
        "label": "Non-Cash Repayment Of Collaboration Interest-Bearing Advanced Funding",
        "documentation": "Non-Cash Repayment Of Collaboration Interest-Bearing Advanced Funding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r95"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [domain]",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r95"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r130",
      "r155"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentFinanceLeaseReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinanceLeaseReceivables",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current finance lease receivables",
        "label": "Non-current finance lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities long term",
        "verboseLabel": "Non-current portion",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r131",
      "r155"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "NovartisMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis"
       }
      }
     },
     "auth_ref": []
    },
    "legn_NumberOfCountriesToReceiveCommericalApproval": {
     "xbrltype": "integerItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "NumberOfCountriesToReceiveCommericalApproval",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of countries to receive commerical approval",
        "label": "Number Of Countries To Receive Commerical Approval",
        "documentation": "Number Of Countries To Receive Commerical Approval"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized (in shares)",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r134"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAbstract",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and fully paid:",
        "label": "Number of shares issued [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and fully paid (in shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r113",
      "r135"
     ]
    },
    "legn_OngoingLeasePaymentsUnderTheLandLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "OngoingLeasePaymentsUnderTheLandLease",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ongoing lease payments",
        "label": "Ongoing Lease Payments Under The Land Lease",
        "documentation": "Ongoing lease payments under the land lease."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "legn_OtherCollaborationReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "OtherCollaborationReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other collaboration receivables",
        "label": "Other Collaboration Receivables",
        "documentation": "Other Collaboration Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income, net of tax",
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r121",
      "r140",
      "r145"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign operations",
        "verboseLabel": "Exchange differences on translation of foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r145"
     ]
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_OtherExpenseByFunction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherExpenseByFunction",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other operating expenses",
        "label": "Other expense, by function"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r146",
      "r167"
     ]
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 4.0
      },
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "totalLabel": "Total other expenses, net",
        "label": "Other gains (losses)"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186"
     ]
    },
    "legn_OtherMiscellaneousIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "OtherMiscellaneousIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense)/income, net",
        "label": "Other Miscellaneous Income (Expense)",
        "documentation": "Other Miscellaneous Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "legn_OtherPayablesAndAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "OtherPayablesAndAccrualsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables and accruals",
        "label": "Other Payables And Accruals Current",
        "documentation": "Other payables and accruals, current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r172"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": {
       "parentTag": "legn_RevenueFromLicensingOfIntellectualPropertyAndOther",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Other revenue"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "legn_OutsideTheUnitedStatesOfAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "OutsideTheUnitedStatesOfAmericaMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside the United States of America",
        "label": "Outside the United States of America [Member]",
        "documentation": "Outside the United States of America"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Authorized, price per share (in dollars per share)",
        "verboseLabel": "Issued and fully paid, price per share (in dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r114",
      "r136"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal portion of lease payments",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "PrepaymentToCollaboratorForCollaborationRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepayment to collaborator for collaboration assets",
        "label": "Prepayment To Collaborator For Collaboration Right Of Use Assets",
        "documentation": "Prepayment To Collaborator For Collaboration Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r170"
     ]
    },
    "legn_PrepaymentsOtherReceivablesAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "PrepaymentsOtherReceivablesAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Prepayments Other Receivables And Other Assets",
        "documentation": "Prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_PrepaymentsOtherReceivablesAndOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "PrepaymentsOtherReceivablesAndOtherAssetsMember",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments Other Receivable and Other Assets",
        "label": "Prepayments Other Receivables And Other Assets [Member]",
        "documentation": "Prepayments other receivables and other assets.,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of share options",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "legn_ProceedsFromMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ProceedsFromMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments recognized as revenue",
        "label": "Proceeds from Milestone Payments",
        "documentation": "Milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Loss for the period",
        "verboseLabel": "Net loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31",
      "r69",
      "r71",
      "r104",
      "r107",
      "r120",
      "r139",
      "r155",
      "r159"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before tax",
        "terseLabel": "Loss before tax",
        "label": "Profit (loss) before tax"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r160",
      "r161",
      "r166",
      "r167"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r193"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r99",
      "r125"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r44",
      "r57",
      "r58",
      "r92",
      "r156",
      "r157",
      "r183"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [domain]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r44",
      "r57",
      "r58",
      "r92",
      "r156",
      "r157",
      "r183"
     ]
    },
    "ifrs-full_RawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Current raw materials"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r174"
     ]
    },
    "legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vesting of restricted share units (in shares)",
        "label": "Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue",
        "documentation": "Reclassification of vested restricted stock units, number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vesting of restricted share units",
        "label": "Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium",
        "documentation": "Reclassification of vested restricted stock units, share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "legn_RelatedPartySublicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "RelatedPartySublicenseMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Sublicense",
        "label": "Related Party Sublicense [Member]",
        "documentation": "Related Party Sublicense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r105"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r102",
      "r168"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation reserves",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained accumulated losses",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r168"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Revenue",
        "label": "Revenue"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r59",
      "r67",
      "r70",
      "r74",
      "r75",
      "r77",
      "r142",
      "r155",
      "r166",
      "r167"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue",
        "terseLabel": "Total revenue",
        "label": "Revenue from contracts with customers"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r78"
     ]
    },
    "legn_RevenueFromLicensingOfIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "RevenueFromLicensingOfIntellectualProperty",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": {
       "parentTag": "legn_RevenueFromLicensingOfIntellectualPropertyAndOther",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and other revenue",
        "label": "Revenue From Licensing Of Intellectual Property",
        "documentation": "Revenue From Licensing Of Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "legn_RevenueFromLicensingOfIntellectualPropertyAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "RevenueFromLicensingOfIntellectualPropertyAndOther",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_RevenueFromContractsWithCustomers",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and other revenue - total",
        "totalLabel": "License and other revenue - total",
        "label": "Revenue From Licensing Of Intellectual Property and Other",
        "documentation": "Revenue from licensing of intellectual property."
       }
      }
     },
     "auth_ref": []
    },
    "legn_RevenueMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "RevenueMilestonePaymentMember",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Milestone Payment",
        "label": "Revenue Milestone Payment [Member]",
        "documentation": "Revenue Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r82"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_SellingAndDistributionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "SellingAndDistributionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Selling and distribution expenses",
        "label": "Selling And Distribution Expenses",
        "documentation": "Selling and distribution expenses."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalAndSharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ShareCapitalAndSharePremium",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Share Capital And Share Premium",
        "documentation": "Share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ShareCapitalAndSharePremiumNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share Capital And Share Premium Number Of Shares In Issue",
        "documentation": "Share capital and share premium, number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ShareCapitalMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Share Capital [Member]",
        "documentation": "Share capital."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "ShareCapitalRollForward",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital [Roll Forward]",
        "label": "Share Capital [Roll Forward]",
        "documentation": "Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_Cash",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Pledged deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://legendbiotech.com/role/SUBSEQUENTEVENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION",
        "label": "Supplemental Cash Flow Information [Abstract]",
        "documentation": "Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "legn_TimeDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "TimeDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Time Deposits",
        "documentation": "Times deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_TimesDepositsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20260331",
     "localname": "TimesDepositsCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_Cash",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Times Deposits Current And Noncurrent",
        "documentation": "Times deposits current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [axis]",
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r162"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [domain]",
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r162"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of Range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r44",
      "r57",
      "r58",
      "r92",
      "r156",
      "r157",
      "r183"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT recoverable",
        "label": "Value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHARESummaryofCalculationsofBasicandDilutedLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding",
        "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r174"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42G&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "164",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "180",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "190",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_c&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001801198-26-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001801198-26-000014-xbrl.zip
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MIY^RE;*2G_HZ&&V@<^,.P:F!F-YTAYB!U\&C66LWM;G<Y4]JN: 4#QNJ@$L
M;)JJ$Q8<=+Y2G@Z'P.J>"+&H.;N1SZ:#]3JVJ'CLV];(3[?!0!>*A,-8#;6]
MQ.,%1U=;8")46R =S 0BT)D+C _X*TTK#K*_0++%*XZGMKI82<&Z%9T-V=.
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MJA:\PZ\P)+HE5HW'0['X"Z\>T6\(/%)"5$CB@C334_  *&MJ  !6O^^ 3@(
ML& 7()@61 J5 W.T-Z&?@K?R)-:ZMYC 1)PO),Y5'70RQ](;4=L;"+$4J?.+
M\A(X2Z*;SRB9G>6-;)#:G'I,/[\\-]@FF0U$!NP]<QSI3/89VU*>E(C#A<2A
M _Z_J#Q#XX9\B*D5I"T*QBG%87UA]%04+Q PS:-"GT?%DE 6,HIZ''N:5Y7,
MXF+4J\6S,@?;VB#<ETV 8\1LL9(JPKSYLBP9.<H=&(MQGA]#I@,;*,L. Z3)
M;V#_1.W6S P&V37; B!%$+\VP9%HA]!IA]9LLXKE7,Q&+D*QI\C)M%F^,K?J
MM2"#!?50[]@7/]RYE,9,<5KL89*[=V2V63BY+V7%?($<B#TP?H@LUMJ23->A
M!2R)WKBPWL!T3@/X^5*A,;Y?Z HA_(6\DCN*P:9BXXD86*:\U3W<\P-T1[ZX
M<15L.4#V3/ !#+%J!8  1D#-8=K6U#!7JPVI.6 "<N8L3$F$R3;'[7B <$M?
M2 K[\.ASFQ;A ^[K$[L%;=8W,#4//R=*+%%B<5-B"\GI1N#_7" PF0)B+J@U
M-7-H7+^LUL"Y7WF%6(0OG5:_J<4=D@G;E5 JT4)GT4*[]Q<)]<;K/UA/HX[[
MR]M\Z?YANB^$/% P>(_,I=Q8E/(0=5\0\"\5H8C"]R$NF6.)J[])":0'A,T$
M:H&IQXEA;/XL)^ZWM* N*8MY9C*$CDBM"^)J!8$["KE_>XJ,Q8XI\L2!C>$*
M1^< .P=\/WYN^\*HK6*C#X-.@DJ$ &,"QSTVUZ?)6MZ,,"UE@&=P=R;B=^BZ
M8\E+@MG$'VX^X:88VU%D(\6>WT8"E+&XCGD0UTD#O=(+VYH4$EUDKR_MK_8L
MSUTNJ;H\L.L7L?_ E)6H!<NE8'S"1F/#FC!,;"W-@$OI,40!!$('I*2&92[M
M:/,WJ C!I&0,)&:R_8R+W45%(PC<]>L2WV_7T-)A\87-A'</H"AK7DU=N6,1
M[@"K)VVLV'U<;:>[BQ# &+@(OE)5(PT/ML:9%H1,81(> )JQ,6[[%Y_[-M6
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MK$N.[S=XYM0"+VUY\K$VK[J7ICRWO8#"GXG#A:"R'^"<B59!P8#24MOS+T/
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M*=+Z2+ZT6Q_K70)&OM'J[+1$=8&9W'QM5K\^U@'Z%'EL-1K5=H?4F^1SO=$
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M*UQ(G?_J4D!8$+S#G^")E<.SWVP,^8_YU#?/<7E_<AP.7#Z3>X4!L\B ?W\
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MI/61/%0[G\C'1NN/\$U"8/WF:[/Z];$.@/_RME"Y)X^M1J/:[I!ZDWRN-QJ
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M!X#9ZBA<*CJ88$O@; $%O>4L/X$RO*',=N)3_-I[^R#/BH+N(@Z0([P19X
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MR,J[L&6V&VF[GQZ[E&BN2P]JJKA*Z2>ITM2K::O9;^'WFOT?+JTP&$:1&58
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M/1!J_3[ML;('?=N!&Q:A[[V!9KU0XF@>)?[O?L$,_J7Z"R'0 YT$/JR;_5H
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M=H[]#<N6#[!LK PB12_[9A82L6)D<G,R8KWQ,)^6;[W8,%4VO>=@'W\ R3J
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MM#SX]+$(PU1.2I65?)X;!^1V6;$KS$<;.H0LFP9.:X>2"AA?-';<L69Y87N
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M+NC 08A:A CQW] )5M<#-A*FX9=*[(8/:LMLN]YK2=*#*D2$Q=\B6LDQ&"X
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M<9(,,_0T&AJ%K%1V8(=SFB-+/R>Q0Z]H&D_<K0#B#\YZXMK.+$L"R2=A$?,
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M'EOIF^NH0V);JF 2TR'&X4$_^JYD"FKDJ$4MRI*F"&3K/L%)9;2&!AG1ZRO
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M GGVA,F8D@&=*,=4+*D#27DV9<&C?%/^O86$K=AGQV6)@1WW8ZT+L8UO9I[
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M;"$-'P1P%Y$<POTZW&]KIH8*,>"PS/ FZS,M4[Y35;9M"H@FN!TR.^FDR]!
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M&<R#"AH"91$&C')-!.6&*9$QM*R!^LJQ[1ND4!LV2TBD0W=3#(MZU,CZU:\
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M7%(*$HP1I,9[BV#W7*H'_C4RJP6UK?*,Q.#9-(S:V:'*)J/)S1K^.Y8 P;T
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MQM3"VE)JQ3:HRE-XYAXKP&B5 "6T8CZ\LQWV=>LY):1[1V,DQ<3.3CR9F*S
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MIZ3E;KE'Y=I#D3?<YLVP(IZPURX0:R)8#W\N7K3*W=_^\O]02P,$%     @
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M6#;T8W[;C5@!] ,48(2HZWJAY"3ODJ5[CE=R^2I9<,D 5Z(5=TK=D E/]RF
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M'L8X$,H>2TG5[ =V:H"HT@-$>T7>@;A2!:!:%XF9)0RJ@ _1 96<@]FC5*L
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M)R:(NLY/<6P8(#> E+K(#!WJF'8L>8UJMAM4#^N'Q36X7BT^K*Y7#ZOE_8A
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M'&B%ODUBR[2P)TYNV2Y#\_IEO3,,8_?_LZ9Q;!K^3^//[%],0!'N[N\@#)A
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M!VTGM$S+=VP/(SGO)2I:LU>K\V @8T+!EDF5/E,4A5#XV% #,'(SO=2 ?9-
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MK9K^<_15_W0UUO-03>\!^+?%/SNI'KY/1W=?YC]AB/GSQY[_.OTS1,IAJ#W
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M$$A"(4"*.8^]YUSEJ^RJ273IHV*'P&M57Z4#"K>C>W_J'Y*WL$$XDM$T1]$
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MMC^_=,53+IRT(-U>.'3UY+61VRU-](HA! 8*@AS41KA\)<3U:"Y=(Y75,>M
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M4,WGU?UE6#"QVN/DA0F<;N.%\0!*8SR)SI7%^0Y76PCL!7":*'S3Q3U2^KV
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MV'L!G(^CB9[8Y1MR[:T??4U>Y 8CTCL@!5% 66>Y,3">$_(U!-U!9)G)GAW
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M&@!2 5D&.?$B^U#+@[DHG6]<!+I95-YB05A!7Z3C/,+&2V?W, KD&;;S;O"
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MBGLY\]JY]+KJD#'\W>5E?>O=S?N!^<P8Z 7:GU_QX;<'/YGYR\D:,RLRM"$
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M83< R''+_]\@P\!_29]H!^MW"<$)@[N%L_U!A==Y-,H3<:[#^6WW<Y@N: W
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M#S#??K@IO!K*W:3_+U!+ 0(4 Q0    ( ,HXK%S?4+40U"D  )(Y @ =
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M,S,Q7V-A;"YX;6Q02P$"% ,4    " #*.*Q<BF&=[+<=  !>9 $ %0
M        @ '#[0  ;&5G;BTR,#(V,#,S,5]D968N>&UL4$L! A0#%     @
MRCBL7*JKVMC<<0  +\4$ !4              ( !K0L! &QE9VXM,C R-C S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,HXK%Q0/E8_W$   (5( P 5
M      "  ;Q] 0!L96=N+3(P,C8P,S,Q7W!R92YX;6Q02P$"% ,4    " #*
M.*Q<:R5*KS %  #P"P  $               @ '+O@$ <3$R-G!I<&5L:6YE
:+FAT;5!+!08     "  ( !,"   IQ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>legn-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:legn="http://legendbiotech.com/20260331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="legn-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:RelatedPartySublicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:RelatedPartySublicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">legn:OutsideTheUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">legn:OutsideTheUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">legn:RevenueMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">legn:RevenueMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="country">
        <measure>legn:country</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-3">0001801198</dei:EntityCentralIndexKey>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-5">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-8">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">Legend Biotech Corporation</dei:EntityRegistrantName>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-1" decimals="-5" id="f-9" unitRef="usd">6700000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-2" decimals="-5" id="f-10" unitRef="usd">9400000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-5" id="f-11" unitRef="usd">298400000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-5" id="f-12" unitRef="usd">185600000</legn:CollaborationRevenue>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-13" unitRef="usd">305100000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-2" decimals="-5" id="f-14" unitRef="usd">195000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-5" id="f-15" unitRef="usd">175400000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2" decimals="-5" id="f-16" unitRef="usd">69500000</ifrs-full:CostOfSales>
    <legn:CostOfLicenseAndOtherRevenue contextRef="c-1" decimals="-5" id="f-17" unitRef="usd">500000</legn:CostOfLicenseAndOtherRevenue>
    <legn:CostOfLicenseAndOtherRevenue contextRef="c-2" decimals="-5" id="f-18" unitRef="usd">1800000</legn:CostOfLicenseAndOtherRevenue>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-19" unitRef="usd">85700000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2" decimals="-5" id="f-20" unitRef="usd">101900000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:AdministrativeExpense contextRef="c-1" decimals="-5" id="f-21" unitRef="usd">40000000.0</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense contextRef="c-2" decimals="-5" id="f-22" unitRef="usd">31500000</ifrs-full:AdministrativeExpense>
    <legn:SellingAndDistributionExpenses contextRef="c-1" decimals="-5" id="f-23" unitRef="usd">50100000</legn:SellingAndDistributionExpenses>
    <legn:SellingAndDistributionExpenses contextRef="c-2" decimals="-5" id="f-24" unitRef="usd">41000000.0</legn:SellingAndDistributionExpenses>
    <ifrs-full:OtherExpenseByFunction contextRef="c-1" decimals="-5" id="f-25" unitRef="usd">3200000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="c-2" decimals="-5" id="f-26" unitRef="usd">1000000.0</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-5" id="f-27" unitRef="usd">-49800000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-2" decimals="-5" id="f-28" unitRef="usd">-51700000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-5" id="f-29" unitRef="usd">5500000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">5100000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-5" id="f-31" unitRef="usd">7300000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-2" decimals="-5" id="f-32" unitRef="usd">12100000</ifrs-full:FinanceIncome>
    <ifrs-full:OtherGainsLosses contextRef="c-1" decimals="-5" id="f-33" unitRef="usd">-5100000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-2" decimals="-5" id="f-34" unitRef="usd">-54500000</ifrs-full:OtherGainsLosses>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-5" id="f-35" unitRef="usd">-53100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-5" id="f-36" unitRef="usd">-99200000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-5" id="f-37" unitRef="usd">1200000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-2" decimals="-5" id="f-38" unitRef="usd">1800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-39" unitRef="usd">-54300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-5" id="f-40" unitRef="usd">-101000000.0</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-41"
      unitRef="usdPerShare">-0.15</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-42"
      unitRef="usdPerShare">-0.27</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-43"
      unitRef="usdPerShare">-0.15</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-44"
      unitRef="usdPerShare">-0.27</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-5" id="f-45" unitRef="usd">500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-2" decimals="-5" id="f-46" unitRef="usd">60700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-5" id="f-47" unitRef="usd">500000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-2" decimals="-5" id="f-48" unitRef="usd">60700000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-5" id="f-49" unitRef="usd">-53800000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-2" decimals="-5" id="f-50" unitRef="usd">-40300000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-5" id="f-51" unitRef="usd">121400000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-52" unitRef="usd">116300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-5" id="f-53" unitRef="usd">331100000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-5" id="f-54" unitRef="usd">285200000</ifrs-full:RightofuseAssets>
    <legn:CollaborationPrepaidLeases contextRef="c-3" decimals="-5" id="f-55" unitRef="usd">35000000.0</legn:CollaborationPrepaidLeases>
    <legn:CollaborationPrepaidLeases contextRef="c-4" decimals="-5" id="f-56" unitRef="usd">72700000</legn:CollaborationPrepaidLeases>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-3" decimals="-5" id="f-57" unitRef="usd">26500000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-4" decimals="-5" id="f-58" unitRef="usd">12400000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-5" id="f-59" unitRef="usd">514000000.0</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-4" decimals="-5" id="f-60" unitRef="usd">486600000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-3" decimals="-5" id="f-61" unitRef="usd">37100000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-4" decimals="-5" id="f-62" unitRef="usd">32000000.0</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-5" id="f-63" unitRef="usd">1700000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-4" decimals="-5" id="f-64" unitRef="usd">13100000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c-3" decimals="-5" id="f-65" unitRef="usd">209300000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c-4" decimals="-5" id="f-66" unitRef="usd">253400000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <legn:TimeDeposits contextRef="c-3" decimals="-5" id="f-67" unitRef="usd">188200000</legn:TimeDeposits>
    <legn:TimeDeposits contextRef="c-4" decimals="-5" id="f-68" unitRef="usd">46700000</legn:TimeDeposits>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-5" id="f-69" unitRef="usd">646400000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-5" id="f-70" unitRef="usd">901900000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-5" id="f-71" unitRef="usd">1082700000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-4" decimals="-5" id="f-72" unitRef="usd">1247100000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-3" decimals="-5" id="f-73" unitRef="usd">1596700000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-4" decimals="-5" id="f-74" unitRef="usd">1733700000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c-3" decimals="-5" id="f-75" unitRef="usd">74300000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c-4" decimals="-5" id="f-76" unitRef="usd">83000000.0</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:CurrentTaxLiabilities contextRef="c-3" decimals="-5" id="f-77" unitRef="usd">20300000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities contextRef="c-4" decimals="-5" id="f-78" unitRef="usd">19200000</ifrs-full:CurrentTaxLiabilities>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-3" decimals="-5" id="f-79" unitRef="usd">130200000</legn:OtherPayablesAndAccrualsCurrent>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-4" decimals="-5" id="f-80" unitRef="usd">195400000</legn:OtherPayablesAndAccrualsCurrent>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-5" id="f-81" unitRef="usd">11200000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-5" id="f-82" unitRef="usd">7400000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-3" decimals="-5" id="f-83" unitRef="usd">6000000.0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-4" decimals="-5" id="f-84" unitRef="usd">11300000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-5" id="f-85" unitRef="usd">266000000.0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-4" decimals="-5" id="f-86" unitRef="usd">319100000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-3" decimals="-5" id="f-87" unitRef="usd">1100000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-4" decimals="-5" id="f-88" unitRef="usd">1000000.0</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-5" id="f-89" unitRef="usd">509100000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-4" decimals="-5" id="f-90" unitRef="usd">636400000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-5" id="f-91" unitRef="usd">112100000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-4" decimals="-5" id="f-92" unitRef="usd">87200000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-3" decimals="-5" id="f-93" unitRef="usd">7800000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-4" decimals="-5" id="f-94" unitRef="usd">8000000.0</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-5" id="f-95" unitRef="usd">119900000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-4" decimals="-5" id="f-96" unitRef="usd">95200000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-3" decimals="-5" id="f-97" unitRef="usd">629000000.0</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-4" decimals="-5" id="f-98" unitRef="usd">731600000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-5" id="f-99" unitRef="usd">100000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-4" decimals="-5" id="f-100" unitRef="usd">100000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-5" id="f-101" unitRef="usd">967600000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-4" decimals="-5" id="f-102" unitRef="usd">1002000000</ifrs-full:OtherReserves>
    <ifrs-full:Equity contextRef="c-3" decimals="-5" id="f-103" unitRef="usd">967700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-5" id="f-104" unitRef="usd">1002100000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-5" id="f-105" unitRef="usd">1596700000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-4" decimals="-5" id="f-106" unitRef="usd">1733700000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity contextRef="c-5" decimals="-5" id="f-107" unitRef="usd">100000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-5" id="f-108" unitRef="usd">2696000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-5" id="f-109" unitRef="usd">74400000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-5" id="f-110" unitRef="usd">-68200000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-5" id="f-111" unitRef="usd">-1661700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-5" id="f-112" unitRef="usd">1040600000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-11" decimals="-5" id="f-113" unitRef="usd">-101000000.0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-5" id="f-114" unitRef="usd">-101000000.0</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-12" decimals="-5" id="f-115" unitRef="usd">60700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-2" decimals="-5" id="f-116" unitRef="usd">60700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-5" id="f-117" unitRef="usd">60700000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-11" decimals="-5" id="f-118" unitRef="usd">-101000000.0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-2" decimals="-5" id="f-119" unitRef="usd">-40300000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-13" decimals="-5" id="f-120" unitRef="usd">2400000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-14" decimals="-5" id="f-121" unitRef="usd">-900000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-2" decimals="-5" id="f-122" unitRef="usd">1500000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-13" decimals="-5" id="f-123" unitRef="usd">14500000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-14" decimals="-5" id="f-124" unitRef="usd">-14500000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-2" decimals="-5" id="f-125" unitRef="usd">0</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-14" decimals="-5" id="f-126" unitRef="usd">15900000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-2" decimals="-5" id="f-127" unitRef="usd">15900000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-15" decimals="-5" id="f-128" unitRef="usd">100000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-16" decimals="-5" id="f-129" unitRef="usd">2712900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-5" id="f-130" unitRef="usd">74900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-5" id="f-131" unitRef="usd">-7500000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-5" id="f-132" unitRef="usd">-1762700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-5" id="f-133" unitRef="usd">1017700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-5" id="f-134" unitRef="usd">100000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-5" id="f-135" unitRef="usd">2750300000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-5" id="f-136" unitRef="usd">88000000.0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-5" id="f-137" unitRef="usd">122200000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-5" id="f-138" unitRef="usd">-1958500000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-5" id="f-139" unitRef="usd">1002100000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-26" decimals="-5" id="f-140" unitRef="usd">-54300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">-54300000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-27" decimals="-5" id="f-142" unitRef="usd">500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-5" id="f-143" unitRef="usd">500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-27" decimals="-5" id="f-144" unitRef="usd">500000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-26" decimals="-5" id="f-145" unitRef="usd">-54300000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-5" id="f-146" unitRef="usd">-53800000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-28" decimals="-5" id="f-147" unitRef="usd">200000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-29" decimals="-5" id="f-148" unitRef="usd">-100000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-5" id="f-149" unitRef="usd">100000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-28" decimals="-5" id="f-150" unitRef="usd">30400000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-29" decimals="-5" id="f-151" unitRef="usd">-30400000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-1" decimals="-5" id="f-152" unitRef="usd">0</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-29" decimals="-5" id="f-153" unitRef="usd">19300000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-5" id="f-154" unitRef="usd">19300000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-30" decimals="-5" id="f-155" unitRef="usd">100000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-5" id="f-156" unitRef="usd">2780900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-5" id="f-157" unitRef="usd">76800000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-5" id="f-158" unitRef="usd">122700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-5" id="f-159" unitRef="usd">-2012800000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-5" id="f-160" unitRef="usd">967700000</ifrs-full:Equity>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-5" id="f-161" unitRef="usd">967600000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-20" decimals="-5" id="f-162" unitRef="usd">1017600000</ifrs-full:OtherReserves>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-5" id="f-163" unitRef="usd">-53100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-5" id="f-164" unitRef="usd">-99200000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-1" decimals="-5" id="f-165" unitRef="usd">7300000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-2" decimals="-5" id="f-166" unitRef="usd">12100000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-1" decimals="-5" id="f-167" unitRef="usd">5500000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-2" decimals="-5" id="f-168" unitRef="usd">5100000</ifrs-full:AdjustmentsForFinanceCosts>
    <legn:AdjustmentsForInventoryReserveProvision contextRef="c-1" decimals="-5" id="f-169" unitRef="usd">-6100000</legn:AdjustmentsForInventoryReserveProvision>
    <legn:AdjustmentsForInventoryReserveProvision contextRef="c-2" decimals="-5" id="f-170" unitRef="usd">-3800000</legn:AdjustmentsForInventoryReserveProvision>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c-1" decimals="-5" id="f-171" unitRef="usd">2400000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c-2" decimals="-5" id="f-172" unitRef="usd">2300000</ifrs-full:AdjustmentsForDepreciationExpense>
    <legn:AdjustmentsForDepreciationOfRightOfUseAssets contextRef="c-1" decimals="-5" id="f-173" unitRef="usd">13200000</legn:AdjustmentsForDepreciationOfRightOfUseAssets>
    <legn:AdjustmentsForDepreciationOfRightOfUseAssets contextRef="c-2" decimals="-5" id="f-174" unitRef="usd">2800000</legn:AdjustmentsForDepreciationOfRightOfUseAssets>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-5" id="f-175" unitRef="usd">5900000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-2" decimals="-5" id="f-176" unitRef="usd">55200000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-5" id="f-177" unitRef="usd">19300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-2" decimals="-5" id="f-178" unitRef="usd">15900000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-1" decimals="-5" id="f-179" unitRef="usd">2800000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-2" decimals="-5" id="f-180" unitRef="usd">1100000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-5" id="f-181" unitRef="usd">-17400000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-2" decimals="-5" id="f-182" unitRef="usd">-32700000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-5" id="f-183" unitRef="usd">11400000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-2" decimals="-5" id="f-184" unitRef="usd">5900000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets contextRef="c-1" decimals="-5" id="f-185" unitRef="usd">-7000000.0</legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets>
    <legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets contextRef="c-2" decimals="-5" id="f-186" unitRef="usd">-48600000</legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-5" id="f-187" unitRef="usd">700000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-2" decimals="-5" id="f-188" unitRef="usd">-3200000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-5" id="f-189" unitRef="usd">-8100000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-2" decimals="-5" id="f-190" unitRef="usd">19500000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-1" decimals="-5" id="f-191" unitRef="usd">-65200000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-2" decimals="-5" id="f-192" unitRef="usd">-39100000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-1" decimals="-5" id="f-193" unitRef="usd">-5100000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-2" decimals="-5" id="f-194" unitRef="usd">-9000000.0</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet contextRef="c-1" decimals="-5" id="f-195" unitRef="usd">-2000000.0</legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet>
    <legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet contextRef="c-2" decimals="-5" id="f-196" unitRef="usd">500000</legn:AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-197" unitRef="usd">7800000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="c-2" decimals="-5" id="f-198" unitRef="usd">15000000.0</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-199" unitRef="usd">200000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-2" decimals="-5" id="f-200" unitRef="usd">11900000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-201" unitRef="usd">-85100000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-2" decimals="-5" id="f-202" unitRef="usd">-103600000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-203" unitRef="usd">7500000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-2" decimals="-5" id="f-204" unitRef="usd">2000000.0</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets contextRef="c-1" decimals="-5" id="f-205" unitRef="usd">18400000</legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets>
    <legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets contextRef="c-2" decimals="-5" id="f-206" unitRef="usd">15400000</legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets>
    <legn:AdditionInTimeDeposits contextRef="c-1" decimals="-5" id="f-207" unitRef="usd">327000000.0</legn:AdditionInTimeDeposits>
    <legn:AdditionInTimeDeposits contextRef="c-2" decimals="-5" id="f-208" unitRef="usd">100000000.0</legn:AdditionInTimeDeposits>
    <legn:DecreaseInTimeDeposits contextRef="c-1" decimals="-5" id="f-209" unitRef="usd">184900000</legn:DecreaseInTimeDeposits>
    <legn:DecreaseInTimeDeposits contextRef="c-2" decimals="-5" id="f-210" unitRef="usd">374000000.0</legn:DecreaseInTimeDeposits>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-211" unitRef="usd">-168000000.0</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-2" decimals="-5" id="f-212" unitRef="usd">256600000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-1" decimals="-5" id="f-213" unitRef="usd">100000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-2" decimals="-5" id="f-214" unitRef="usd">1400000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-215" unitRef="usd">1300000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-2" decimals="-5" id="f-216" unitRef="usd">800000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-217" unitRef="usd">-1200000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-2" decimals="-5" id="f-218" unitRef="usd">600000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-219" unitRef="usd">-1200000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-2" decimals="-5" id="f-220" unitRef="usd">1400000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-221" unitRef="usd">-255500000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-2" decimals="-5" id="f-222" unitRef="usd">155000000.0</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-5" id="f-223" unitRef="usd">901900000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-10" decimals="-5" id="f-224" unitRef="usd">286700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-5" id="f-225" unitRef="usd">646400000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-20" decimals="-5" id="f-226" unitRef="usd">441700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Cash contextRef="c-3" decimals="-5" id="f-227" unitRef="usd">834600000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-20" decimals="-5" id="f-228" unitRef="usd">1005500000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-3" decimals="-5" id="f-229" unitRef="usd">0</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-20" decimals="-5" id="f-230" unitRef="usd">100000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <legn:TimesDepositsCurrentAndNoncurrent contextRef="c-3" decimals="-5" id="f-231" unitRef="usd">188200000</legn:TimesDepositsCurrentAndNoncurrent>
    <legn:TimesDepositsCurrentAndNoncurrent contextRef="c-20" decimals="-5" id="f-232" unitRef="usd">563700000</legn:TimesDepositsCurrentAndNoncurrent>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition contextRef="c-3" decimals="-5" id="f-233" unitRef="usd">646400000</legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition contextRef="c-20" decimals="-5" id="f-234" unitRef="usd">441700000</legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition>
    <legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">57300000</legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding>
    <legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding contextRef="c-2" decimals="-5" id="f-236" unitRef="usd">0</legn:NonCashRepaymentOfCollaborationInterestBearingAdvancedFunding>
    <legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory contextRef="c-1" id="f-237">CORPORATE INFORMATION &lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legend Biotech Corporation ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Legend is an investment holding company. The Company's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-238">BASIS OF PREPARATION &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#x201c;Company&#x201d;) for the three months ended March&#160;31, 2026 have been prepared in accordance with International Accounting Standard (&#x201c;IAS&#x201d;) 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Interim Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x201c;IAS34&#x201d;) issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2025. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#x2019;s annual consolidated financial statements as at December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-239">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new International Financial Reporting Standards (&#x201c;IFRS&#x201d;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2026 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-240">REVENUE&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Novartis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Related party sublicense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and other revenue - total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total license and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the timing of transfer of goods or services is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue over time*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-241">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Novartis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Related party sublicense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and other revenue - total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-35" decimals="-5" id="f-242" unitRef="usd">5100000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-36" decimals="-5" id="f-243" unitRef="usd">9300000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-37" decimals="-5" id="f-244" unitRef="usd">1600000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-38" decimals="-5" id="f-245" unitRef="usd">0</legn:RevenueFromLicensingOfIntellectualProperty>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-5" id="f-246" unitRef="usd">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2" decimals="-5" id="f-247" unitRef="usd">100000</ifrs-full:OtherRevenue>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-1" decimals="-5" id="f-248" unitRef="usd">6700000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-2" decimals="-5" id="f-249" unitRef="usd">9400000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-5" id="f-250" unitRef="usd">298400000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-5" id="f-251" unitRef="usd">185600000</legn:CollaborationRevenue>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-252" unitRef="usd">305100000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-2" decimals="-5" id="f-253" unitRef="usd">195000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-254">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total license and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-39" decimals="-5" id="f-255" unitRef="usd">5100000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-40" decimals="-5" id="f-256" unitRef="usd">9300000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-41" decimals="-5" id="f-257" unitRef="usd">1600000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-42" decimals="-5" id="f-258" unitRef="usd">100000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">6700000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:RevenueFromLicensingOfIntellectualPropertyAndOther contextRef="c-2" decimals="-5" id="f-260" unitRef="usd">9400000</legn:RevenueFromLicensingOfIntellectualPropertyAndOther>
    <legn:CollaborationRevenue contextRef="c-39" decimals="-5" id="f-261" unitRef="usd">216400000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-40" decimals="-5" id="f-262" unitRef="usd">158900000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-43" decimals="-5" id="f-263" unitRef="usd">82000000.0</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-44" decimals="-5" id="f-264" unitRef="usd">26700000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">298400000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-5" id="f-266" unitRef="usd">185600000</legn:CollaborationRevenue>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">305100000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-2" decimals="-5" id="f-268" unitRef="usd">195000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock contextRef="c-1" id="f-269">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the timing of transfer of goods or services is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue over time*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock>
    <ifrs-full:Revenue contextRef="c-45" decimals="-5" id="f-270" unitRef="usd">300000000.0</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-46" decimals="-5" id="f-271" unitRef="usd">185700000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-47" decimals="-5" id="f-272" unitRef="usd">5100000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-48" decimals="-5" id="f-273" unitRef="usd">9300000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-5" id="f-274" unitRef="usd">305100000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-5" id="f-275" unitRef="usd">195000000.0</ifrs-full:Revenue>
    <legn:DisclosureOfOtherIncomeExpenseNetTextBlock contextRef="c-1" id="f-276">OTHER (EXPENSE)/INCOME, NET &lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total other (expense)/income, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange loss, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense)/income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Foreign currency exchange loss is primarily remeasurement losses.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfOtherIncomeExpenseNetTextBlock>
    <legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock contextRef="c-1" id="f-277">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total other (expense)/income, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange loss, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense)/income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Foreign currency exchange loss is primarily remeasurement losses.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-1" decimals="-5" id="f-278" unitRef="usd">-5900000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-2" decimals="-5" id="f-279" unitRef="usd">-55200000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <legn:OtherMiscellaneousIncomeExpense contextRef="c-1" decimals="-5" id="f-280" unitRef="usd">800000</legn:OtherMiscellaneousIncomeExpense>
    <legn:OtherMiscellaneousIncomeExpense contextRef="c-2" decimals="-5" id="f-281" unitRef="usd">700000</legn:OtherMiscellaneousIncomeExpense>
    <ifrs-full:OtherGainsLosses contextRef="c-1" decimals="-5" id="f-282" unitRef="usd">-5100000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-2" decimals="-5" id="f-283" unitRef="usd">-54500000</ifrs-full:OtherGainsLosses>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-284">LOSS PER SHARE &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2026 and 2025, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted loss per share are based on: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(101.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;370.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;370.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-285">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted loss per share are based on: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(101.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;370.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;370.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-286" unitRef="usd">-54300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-5" id="f-287" unitRef="usd">-101000000.0</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-288" unitRef="shares">370200000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-2" decimals="-5" id="f-289" unitRef="shares">367500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-290" unitRef="shares">370200000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-2" decimals="-5" id="f-291" unitRef="shares">367500000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-292"
      unitRef="usdPerShare">-0.15</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-293"
      unitRef="usdPerShare">-0.27</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-294"
      unitRef="usdPerShare">-0.15</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-295"
      unitRef="usdPerShare">-0.27</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-296">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company as a lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between 3 and 29 years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 50 years, and no ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#x2019;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp;amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s right-of-use assets and the movements for the three months ended March&#160;31, 2026 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the commencement date of a lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The balance of the Company&#x2019;s lease liabilities and the movements for the three months ended March&#160;31, 2026 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accretion of interest recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Analyzed into:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;           The Company has a lease that commenced in February 2026, with Janssen located in Raritan, New Jersey. The Company expects to receive 50% of the future lease payments from Janssen from profit sharing under the Janssen Agreement. The Company recognizes the full lease liability of approximately $30.6 million, rather than its share because the Company has the primary responsibility for making the lease payments. A finance sublease receivable of approximately $15.3&#160;million is subsequently recognized when the related right-of-use asset is subleased to the collaboration. The total sublease receivable of $15.3&#160;million has been classified in prepayments, other receivables and other assets of $1.8&#160;million, and other non-current assets of $13.5&#160;million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-49" id="f-297">P3Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-50" id="f-298">P29Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-51" id="f-299">P50Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:OngoingLeasePaymentsUnderTheLandLease contextRef="c-51" decimals="INF" id="f-300" unitRef="usd">0</legn:OngoingLeasePaymentsUnderTheLandLease>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-301">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s right-of-use assets and the movements for the three months ended March&#160;31, 2026 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-5" id="f-302" unitRef="usd">285200000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-5" id="f-303" unitRef="usd">62800000</ifrs-full:AdditionsToRightofuseAssets>
    <legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate contextRef="c-1" decimals="-5" id="f-304" unitRef="usd">-3700000</legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-5" id="f-305" unitRef="usd">13200000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-5" id="f-306" unitRef="usd">331100000</ifrs-full:RightofuseAssets>
    <legn:LesseeLeaseLiabilitiesTextBlock contextRef="c-1" id="f-307">The balance of the Company&#x2019;s lease liabilities and the movements for the three months ended March&#160;31, 2026 are as follows:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accretion of interest recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Analyzed into:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:LesseeLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-52" decimals="-5" id="f-308" unitRef="usd">94600000</ifrs-full:LeaseLiabilities>
    <legn:IncreaseInLeaseLiabilities contextRef="c-53" decimals="-5" id="f-309" unitRef="usd">30700000</legn:IncreaseInLeaseLiabilities>
    <legn:IncreaseOfLeaseLiabilitiesBalance contextRef="c-53" decimals="-5" id="f-310" unitRef="usd">900000</legn:IncreaseOfLeaseLiabilitiesBalance>
    <ifrs-full:CashOutflowForLeases contextRef="c-53" decimals="-5" id="f-311" unitRef="usd">2300000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-53" decimals="-5" id="f-312" unitRef="usd">-600000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LeaseLiabilities contextRef="c-54" decimals="-5" id="f-313" unitRef="usd">123300000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-54" decimals="-5" id="f-314" unitRef="usd">11200000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-54" decimals="-5" id="f-315" unitRef="usd">112100000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-54" decimals="-5" id="f-316" unitRef="usd">123300000</ifrs-full:LeaseLiabilities>
    <legn:LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement contextRef="c-55" decimals="2" id="f-317" unitRef="number">0.50</legn:LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement>
    <ifrs-full:LeaseLiabilities contextRef="c-55" decimals="-5" id="f-318" unitRef="usd">30600000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinanceLeaseReceivables contextRef="c-55" decimals="-5" id="f-319" unitRef="usd">15300000</ifrs-full:FinanceLeaseReceivables>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c-55" decimals="-5" id="f-320" unitRef="usd">15300000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentFinanceLeaseReceivables contextRef="c-55" decimals="-5" id="f-321" unitRef="usd">1800000</ifrs-full:CurrentFinanceLeaseReceivables>
    <ifrs-full:NoncurrentFinanceLeaseReceivables contextRef="c-55" decimals="-5" id="f-322" unitRef="usd">13500000</ifrs-full:NoncurrentFinanceLeaseReceivables>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c-1" id="f-323">COLLABORATION INVENTORIES, NET&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reserve for inventory was $12.5&#160;million and $18.7 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively. The Company&#x2019;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock>
    <ifrs-full:RawMaterials contextRef="c-3" decimals="-5" id="f-325" unitRef="usd">22400000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-4" decimals="-5" id="f-326" unitRef="usd">24100000</ifrs-full:RawMaterials>
    <ifrs-full:WorkInProgress contextRef="c-3" decimals="-5" id="f-327" unitRef="usd">5200000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-4" decimals="-5" id="f-328" unitRef="usd">1100000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods contextRef="c-3" decimals="-5" id="f-329" unitRef="usd">9500000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-4" decimals="-5" id="f-330" unitRef="usd">6800000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c-3" decimals="-5" id="f-331" unitRef="usd">37100000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-4" decimals="-5" id="f-332" unitRef="usd">32000000.0</ifrs-full:Inventories>
    <legn:InventoryReserve contextRef="c-3" decimals="-5" id="f-333" unitRef="usd">12500000</legn:InventoryReserve>
    <legn:InventoryReserve contextRef="c-4" decimals="-5" id="f-334" unitRef="usd">18700000</legn:InventoryReserve>
    <legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock contextRef="c-1" id="f-335">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other collaboration receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2026 and December&#160;31, 2025 is insignificant.</legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock>
    <legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other collaboration receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock>
    <legn:OtherCollaborationReceivables contextRef="c-56" decimals="-5" id="f-337" unitRef="usd">174000000.0</legn:OtherCollaborationReceivables>
    <legn:OtherCollaborationReceivables contextRef="c-57" decimals="-5" id="f-338" unitRef="usd">227800000</legn:OtherCollaborationReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c-56" decimals="-5" id="f-339" unitRef="usd">10900000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c-57" decimals="-5" id="f-340" unitRef="usd">8100000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:Prepayments contextRef="c-56" decimals="-5" id="f-341" unitRef="usd">19400000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="c-57" decimals="-5" id="f-342" unitRef="usd">14600000</ifrs-full:Prepayments>
    <ifrs-full:OtherCurrentAssets contextRef="c-56" decimals="-5" id="f-343" unitRef="usd">5000000.0</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-57" decimals="-5" id="f-344" unitRef="usd">2900000</ifrs-full:OtherCurrentAssets>
    <legn:PrepaymentsOtherReceivablesAndOtherAssets contextRef="c-56" decimals="-5" id="f-345" unitRef="usd">209300000</legn:PrepaymentsOtherReceivablesAndOtherAssets>
    <legn:PrepaymentsOtherReceivablesAndOtherAssets contextRef="c-57" decimals="-5" id="f-346" unitRef="usd">253400000</legn:PrepaymentsOtherReceivablesAndOtherAssets>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="c-1" id="f-347">COLLABORATION INTEREST-BEARING ADVANCED FUNDING &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Interest-bearing Advanced Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Pursuant to the Janssen Agreement, the Company received advances from Janssen over time ("Funding Advances"). These Funding Advances are accounted for as interest-bearing borrowings funded by Janssen, constituted by a principal amounting to $250.0&#160;million and applicable interests accrued amounting to $73.3&#160;million upon such principal as of March&#160;31, 2026. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding Funding Advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%.  &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There is no specific maturity date for the Funding Advances. However, pursuant to the terms of the Janssen Agreement, Janssen may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#x2019;s share of pre-tax profits starting from the first calendar quarter following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the quarter ended March&#160;31, 2026, the Company reduced its collaboration advanced funding principal balance by $57.3&#160;million by offsetting it with the pre-tax profit receivable for the quarter, which resulted in an outstanding principal balance of $192.7&#160;million and outstanding accrued interest balance of $73.3&#160;million, in each case as of March&#160;31, 2026. As of March&#160;31, 2026, the Company estimated that the entire balance of $266.0&#160;million (inclusive of both principal and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest) would be recouped by Janssen within the next 12 months, and therefore such amount was classified as a current liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest for the Funding Advances was $4.2&#160;million and $4.6&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively. These amounts are included in Finance Costs on the consolidated statement of profit or loss and other comprehensive income/(loss).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="c-1" id="f-348">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Interest-bearing Advanced Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:BorrowingsInterestRate contextRef="c-3" decimals="4" id="f-349" unitRef="number">0.0684</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-5" id="f-350" unitRef="usd">266000000.0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <legn:InterestBearingBorrowingsFundingAdvances contextRef="c-58" decimals="-5" id="f-351" unitRef="usd">250000000.0</legn:InterestBearingBorrowingsFundingAdvances>
    <legn:InterestBearingBorrowingsFundedInterestsAccrued contextRef="c-59" decimals="-5" id="f-352" unitRef="usd">73300000</legn:InterestBearingBorrowingsFundedInterestsAccrued>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis contextRef="c-58" decimals="3" id="f-353" unitRef="number">0.025</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease contextRef="c-1" decimals="-5" id="f-354" unitRef="usd">-57300000</legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease>
    <legn:InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable contextRef="c-3" decimals="-5" id="f-355" unitRef="usd">192700000</legn:InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable>
    <legn:InterestBearingBorrowingsFundedInterestsAccrued contextRef="c-59" decimals="-5" id="f-356" unitRef="usd">73300000</legn:InterestBearingBorrowingsFundedInterestsAccrued>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-5" id="f-357" unitRef="usd">266000000.0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-59" decimals="-5" id="f-358" unitRef="usd">4200000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-60" decimals="-5" id="f-359" unitRef="usd">4600000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-360">SHARE CAPITAL AND SHARE PREMIUM &lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000,000,000 ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued and fully paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of movements in the Company&#x2019;s share capital and share premium is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2025 and January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,886,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,750.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,750.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification of vesting of restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,321,834&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;371,479,583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,780.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,781.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-361">&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000,000,000 ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued and fully paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;371,479,583 and (2025: 369,886,369) ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c-61"
      decimals="INF"
      id="f-362"
      unitRef="shares">2000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c-62"
      decimals="INF"
      id="f-363"
      unitRef="shares">2000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="c-61"
      decimals="INF"
      id="f-364"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-62"
      decimals="INF"
      id="f-365"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <legn:AuthorizedShareCapital contextRef="c-62" decimals="-5" id="f-366" unitRef="usd">200000</legn:AuthorizedShareCapital>
    <legn:AuthorizedShareCapital contextRef="c-61" decimals="-5" id="f-367" unitRef="usd">200000</legn:AuthorizedShareCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-62"
      decimals="INF"
      id="f-368"
      unitRef="shares">371479583</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-61"
      decimals="INF"
      id="f-369"
      unitRef="shares">369886369</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="c-61"
      decimals="INF"
      id="f-370"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-62"
      decimals="INF"
      id="f-371"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:IssuedCapital contextRef="c-62" decimals="-5" id="f-372" unitRef="usd">100000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-61" decimals="-5" id="f-373" unitRef="usd">100000</ifrs-full:IssuedCapital>
    <legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock contextRef="c-1" id="f-374">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of movements in the Company&#x2019;s share capital and share premium is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in millions, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2025 and January 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,886,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,750.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,750.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification of vesting of restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,321,834&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;371,479,583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,780.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,781.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock>
    <legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue
      contextRef="c-21"
      decimals="INF"
      id="f-375"
      unitRef="shares">369886369</legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue>
    <legn:ShareCapitalAndSharePremium contextRef="c-63" decimals="-5" id="f-376" unitRef="usd">100000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-22" decimals="-5" id="f-377" unitRef="usd">2750300000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-4" decimals="-5" id="f-378" unitRef="usd">2750400000</legn:ShareCapitalAndSharePremium>
    <legn:ExerciseOfShareOptionNumberOfSharesInIssue
      contextRef="c-64"
      decimals="INF"
      id="f-379"
      unitRef="shares">271380</legn:ExerciseOfShareOptionNumberOfSharesInIssue>
    <legn:ExerciseOfShareOption contextRef="c-65" decimals="-5" id="f-380" unitRef="usd">0</legn:ExerciseOfShareOption>
    <legn:ExerciseOfShareOption contextRef="c-28" decimals="-5" id="f-381" unitRef="usd">200000</legn:ExerciseOfShareOption>
    <legn:ExerciseOfShareOption contextRef="c-1" decimals="-5" id="f-382" unitRef="usd">200000</legn:ExerciseOfShareOption>
    <legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue
      contextRef="c-64"
      decimals="INF"
      id="f-383"
      unitRef="shares">1321834</legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-65" decimals="-5" id="f-384" unitRef="usd">0</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-28" decimals="-5" id="f-385" unitRef="usd">30400000</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-1" decimals="-5" id="f-386" unitRef="usd">30400000</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue
      contextRef="c-30"
      decimals="INF"
      id="f-387"
      unitRef="shares">371479583</legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue>
    <legn:ShareCapitalAndSharePremium contextRef="c-66" decimals="-5" id="f-388" unitRef="usd">100000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-31" decimals="-5" id="f-389" unitRef="usd">2780900000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-3" decimals="-5" id="f-390" unitRef="usd">2781000000</legn:ShareCapitalAndSharePremium>
    <ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory contextRef="c-1" id="f-391">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2026.</ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-392">SUBSEQUENT EVENT&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2026, milestones payable to Legend were triggered due to the successful completion of milestones related to the receipt of commercialization approvals in three major European countries. The milestone payments of $55.0&#160;million attributable to these milestones will be recognized as License and other revenue in the three months ended June 30, 2026.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <legn:NumberOfCountriesToReceiveCommericalApproval
      contextRef="c-67"
      decimals="INF"
      id="f-393"
      unitRef="country">3</legn:NumberOfCountriesToReceiveCommericalApproval>
    <legn:ProceedsFromMilestonePayments contextRef="c-68" decimals="-5" id="f-394" unitRef="usd">55000000.0</legn:ProceedsFromMilestonePayments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-9" xlink:label="f-9" xlink:type="locator"/>
        <link:loc xlink:href="#f-10" xlink:label="f-10" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts included within other revenue have been combined into the license and other revenue line for comparative purposes. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-9"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-10"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc xlink:href="#f-26" xlink:label="f-26" xlink:type="locator"/>
        <link:loc xlink:href="#f-25" xlink:label="f-25" xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts have been reclassified to present loss on asset impairment into the other operating expenses line for comparative purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-26"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-25"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-144"
          xlink:label="f-144"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-129"
          xlink:label="f-129"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-123"
          xlink:label="f-123"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-142"
          xlink:label="f-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-118"
          xlink:label="f-118"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-132"
          xlink:label="f-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-153"
          xlink:label="f-153"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-110"
          xlink:label="f-110"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-124"
          xlink:label="f-124"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-148"
          xlink:label="f-148"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-140"
          xlink:label="f-140"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-135"
          xlink:label="f-135"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-111"
          xlink:label="f-111"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-131"
          xlink:label="f-131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-157"
          xlink:label="f-157"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-108"
          xlink:label="f-108"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-137"
          xlink:label="f-137"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-147"
          xlink:label="f-147"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-126"
          xlink:label="f-126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-158"
          xlink:label="f-158"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-151"
          xlink:label="f-151"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-113"
          xlink:label="f-113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-159"
          xlink:label="f-159"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-130"
          xlink:label="f-130"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-121"
          xlink:label="f-121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-117"
          xlink:label="f-117"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-145"
          xlink:label="f-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-156"
          xlink:label="f-156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-109"
          xlink:label="f-109"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-120"
          xlink:label="f-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-138"
          xlink:label="f-138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-136"
          xlink:label="f-136"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-115"
          xlink:label="f-115"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-150"
          xlink:label="f-150"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These reserve accounts comprise the consolidated reserves of $967.6 million and $1,017.6 million in the consolidated statements of financial position as at March&#160;31, 2026 and 2025, respectively</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-144"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-129"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-123"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-142"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-118"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-132"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-153"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-110"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-124"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-148"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-140"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-135"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-111"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-131"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-157"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-108"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-137"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-147"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-126"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-158"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-151"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-113"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-159"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-130"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-121"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-117"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-145"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-156"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-109"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-120"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-138"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-136"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-115"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-150"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-192"
          xlink:label="f-192"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-191"
          xlink:label="f-191"
          xlink:type="locator"/>
        <link:footnote id="fn-4" xlink:label="fn-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts have been reclassified between increase in (decrease)/trade payables and decrease in other payables and accruals for comparative purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-192"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-191"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-179"
          xlink:label="f-179"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-180"
          xlink:label="f-180"
          xlink:type="locator"/>
        <link:footnote id="fn-5" xlink:label="fn-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts including loss on impairment, loss on disposal of PPE, amortization of intangible assets, and deferred government grant have been grouped into the other, net line item for comparative purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-179"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-180"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnote id="fn-6" xlink:label="fn-6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts including interest on lease payments have been grouped into decrease in other payables and accruals.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-192"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-191"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-196"
          xlink:label="f-196"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-195"
          xlink:label="f-195"
          xlink:type="locator"/>
        <link:footnote id="fn-7" xlink:label="fn-7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts including decrease/(increase) in other non-current assets, government grant received, increase/(decrease) in other non-current liabilities, and increase in pledged deposits, net have been grouped into the other assets and liabilities, net line item for comparative purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-196"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-195"
          xlink:to="fn-7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
